var title_f29_19_30000="Bipolar sterilization B";
var content_f29_19_30000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Bipolar electrodesiccation at laproscopic sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 352px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFgAckDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiioLy7gsoVlupVijaSOEM3Qu7hEH1LMo/GgCeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmyIsiFZFDKeoIzTqKAPHPiT8Mntdai8d/D+3SLxVYfvDZ9Ib5ejKwyMNtJxgjPFdl8LvHlj4/8ADa6haIbe9hbyb2yf79tKOqn244//AF12FeH/ABS0a7+Hfiv/AIWZ4Utnmic+Xrunx5CzxH/lqMdGB5J9efWgD3Gis/QNXstf0ez1XSp1nsrqMSxSKeoPr7joR61oUAFFHSigAooooAKKKKACiiigArL8RwWNxp8SapMYbcXlq6sDjMq3EbRL+MgQfjWpXNfEL/kA2v8A2FtM/wDS+CgDpaKKO9ABSUtFACZOfal/CkpaAG/KqkkAAcmvC/gVA2ofFD4geILf7OdOlmW2j2DlWXr+HFex+I706Z4e1O+EZkNvbyS7B/FhScV4/wDs13Gl6X8NNT8S3Ev2SHUL+WacSthUIOMD86APcNihcbRt9MU4ADgAYqK2njuraK4gbdDIodT6g1L2oAijtoY3LJCik85A61438Q9SeTxpOzQJEtlAQs57+3617NNIsMMkhyQiliBXzf4jvUvIb+O4d5Yr+5KxA9YznHNAHcfCC0g0nwhrWueVGZJmeTkddoPH0NXP2f8AS/s3hG61OWKNLjVLuS4bZ0xnAH86j8dRtofwZ+wlxFLIqQ5j4J3Nn+Vd54P09NL8LaXZRgqsNugwe3GT/OgDY4AopOnSigBaKQnH0paACijmk69aAFopODS9aACiikz6UALRRRQAUUgOaU9aACik59aWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKZNFHPC8UqK8TqVdGGQQeCDT6OtAHhvg2SX4VfEyTwhdkjwrrbGfR36iCYn5oiewOD+le5VyHxS8Kx+K/Cs8C4S/tj9otJ8fNHIvIwffGKf8ADPxG/iXwnb3NwR9vgJtrtc/8tU4J/HrQB1hpOopaKAAe1FFBoAKKKKACiiigArL8R31vp+nwzXduLiNry1gCEA4eS4jjRuf7rMrf8B45rUrA8b2093o1tHbRPLIup6fKVQZIRLyF2b6BVJPsDQBv0UUUAFFFFABQaKKAOE+OGrXOi/C7XryxdFuVgKpuGc54xXnclhBcfBHwNpEsDW8mpzQvJbIMNIxJLZ/MH8qv/tT3dvN4d0TQZpmjl1W+SNCOnDL19q6bWrGKT4leEtPclY9PtDLHx8pYcDA/4CKAPRbaFLa2igiULHGgRVHYAYAqT+dGetFAGJ401H+yfDV9cpII5QmIye7HpXi00DanPo1i0CjUJmEs6LxlS3WvUPivNa/8I6ltewvKs8qqoXqG7VyfgWytr7xPHNcs0WrWm1AmM5jGDQBZ+KFs+p+LPB3h2J2+yCYTToOpVfU/hXq4AHAGAK8y0VpdX+NerzyAC30y2EcfcEsAPz616aKAFIoNIc9qKAAg7valpBSmgBOe3PNLSfXrQORQAtFFFABRRQaAD+VJjJpSaKAExg0UtFAB0ooooATvS0EUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUHmgAooooAK8qMf8AwgfxRDxgroXiIhZMnCw3HY+nPP516rXF/Fvw8fEXgy6hhZku7ci4gdTgh16c0Adp3orm/h34gHifwhp+pNxO6bJ17rIvDA/z/GukoAKD1oooAKKO9FAB04ooooAKxvFuoT6ZpUE9qVEj39lbncMjZLdRRv8Ajtdq2ayfE+mSatpsNvC6IyXtpdEvnG2G5jlYcdyEIHuRQBrUA5OKKTv7UALQaKO9AAaaThgKdSDoOaAPD/jJNp2ufFvwB4YuYWnlNwbpinWML83Pp92u605mvfijqTSwiSG0tVSGUchG4yPrya898MxPqv7Ueuajbyx3FlpunGCZmPMLs3AH4Z/A13vwyjeS68Q6ilx51pd3n7vP3gy5DZ/OgDugRSg0HqB2pOF+lAHlnxH1GOTxpp1n9o8v7In2iRG6MBzUnw08l49U8RSPunMbOVI/gGcYP/ATXM+LdQBk8WanPAt5CQtlZzL95JGBG38wK3tZvF8I/CO8kZopIpUW3tZoero6DBY/77MKAL/wPhkn0fVdYmbc2oXjsueoVSR/jXpI6cc1heBdO/snwfpNphQ6wKz7e7t8x/Umt71x1oAOtJj8qMen40tABRRjjFIPegAOaXAo4x7UhyOgzQAtFFFAAaKKKADAooooAM0UCg0AFFFFABRSEUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQOlFFABQeeo60UHpQB5x4JA8N+Pda8OqhSzu/8AT7YngbjwygdOgB49K9Hrzr4vwyadFpXim2cpJo1wJJVX/lpExAZT+Ga9AtJ0urWG4iJMcqLIufQjI/nQBKaTv9aM8+1LQAUUHnvRQAUUUUAFc549keLQ7Vo3ZGOq6apKnBwb6AEfQgkV0dZfiOCxuNPiTVJjDbi8tXVgcZlW4jaJfxkCD8aANSgUVV1TULTSrCa91G4jtrWFdzyyHAA/x7AdzQBaqpqep2OlW5uNTvLaztx1luJVjUfixArm0m8Q+J/mtTJ4e0dvuyyRhr6dfUIwKwg/7QZvZTWhpXhHRdNuRdpZi51Dve3jG4uD/wBtHJIHsMD2oA+f9A/aavUITxBoMEy95LOUxkf8BbOfzFe+eCPFdv4u0hdRtNP1KygbGBfQeUX915IYe44rD8KfCPwh4bv5b6201bq9eVpUlu8SeVkkgIMbVxng4z711viWWWHQL+W3lSKVIWZZHOFUgdTQB4f8BY21TxD8TfFmnI3k3d19jhtzyTJGuSfzcfnXrHw50N9C8Mxw3KFLqeVp5lP8LMeg/SvLPgYl/pP7PMereHLJrjxBqU09xIGGfNl850DY6Y2ote4aQ10+k2L6koS9aCNp1HQSbRuH55oAudW6/hVXU7j7Lp13OSoEcbMNxwOlWiOR61x/xX1C00/wTfHUDKtvOyW5ePqhd1UH8yKAPHi81wmjvptvMLnzLrxDNp+CTNLa7HijH/XQucf7pxXdfESyg/tLwR4YsbcfZJ7zzHtCc/u0O9vywTXK+F7eHVvHdvp011Put7iKyt7iMYcNo7gS7/8AZm+0AfQHrxXSaIv9v/tDatdvO09r4f08QRKPuxXEjsGB9Ts/nQB66AAAAOBS03GMAntil7mgBaTORS0CgA7Ug70p6UCgAoo5o70AFFFAoAKBRRQAUUd6KACiiigAooooADntRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUE4xRQAUUVheMtbuPD+lw31vYS3qC4jjnSIZZIyfmf8KALviDS7fWdGu9PvIxJDPGyFT7iuY+Durzav4EszesPt1pLNZzR9GQRyuiAjjqgQ++a1vB3i/R/F1j9p0e5Dsv+shYFZIzkjBB+lcz4WR9H+MnjCwnQKmtQQapZ7B8uyGOOCXPod7KffOaAPRuopaKKACigUd/agAoooFABXNfEL/kA2v8A2FtM/wDS+CulrL8R31vp+nwzXduLiNry1gCEA4eS4jjRuf7rMrf8B45oA02YIpZyFUDJJOABXHaDAfFl/H4i1FS2lxNu0i1b7pXkfamHdm/gz91SD1Y4ufENnfw2bCJmV9TuIdPJU4ISWRVkI9xGXP1FdHFGkMSRRIqRooVVUYCgdAKAH0UUUAFebftF6zBo3we8QtcF83cBso9g/jk4GfbrmvSa8U/abuY7608HeEZl/d+IdaggkkHVEV0Bx7/vBQB2Xw/uYvDXgjwNompotvqNzZx2scKDhpEh3v8AorE+9dweMmuC1Ce3v/jHomizxPu0jS5NXt5QcZd2a2Kt6jaxP1rvetAB3rzX4p6/pen65o0OsXUUenaesmq6lDLystvtMEfH8RE8kJwcdPwr0nA/M5rxPxnDp/ifxZrFj4jtoG0iW7j0lr3lDHYi3+0O4fOABexxxlzkA/Jw1AGv8DrMhtXuxIGkRILHUELZI1WLeL6THT52MRLD7xXJ6Ck/ZvE994I1HxHdSRyS+IdWudQBUfMqBhEFY98GIn/gVU9Y1S+8IfAs6lp+nyW3ivXgjvCkZSQ6ld4DMFPRgxJCn+6Aa9L8HaLa+HfC+maVYQLb29rCqiMcYY8sfqWJP40Aa6jAx6d6XNKKKACk+lLRQAHpQKKDwOaACkzS0c44oAKKKKACiiigAooooAKDRRQAUUUUAB6UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABA70UUUAFB5B70UUAeeeP/Alxdf8TzwPNHpPiu2PmRSKMRXQ7xSr0IOMZ7E1xGn/ABCk1P4peErm502axvxBNoWr2kinNlczMssS5PUOLdmUjI2988V71Xi/7QGhy6RY2fjjQraM3OlapbanqcKgA3ccSmNWJ6kqrkf7rN6CgD2gdBmiorSYXFrDMuMSIH4OeozUtABQOlFA96ACijofrRQAVgeN7ae70a2jtonlkXU9PlKoMkIl5C7N9Aqkn2BrfrG8W6hPpmlQT2pUSPf2VudwyNkt1FG/47XagDTubaC5Ef2iJJPKcSJuGdrDow9CM9alPtS0d896AAHik70tJigAGe9eF/EJBqf7TXgLTr0tdWENjLdx2+44guEErrLgd8rH+Qr3Tvivn34dX8esftD+PvEBikh0/T4DZySXJBMTxAJJjrgZUnjsaAPTvDEj3vxH8ZS3kSmTT3t7O0l24IgeCOVl9x5jMcn6dq7U1xnwusri00Gea8uhfTXd1NOLsnJmRpGKZPspA/CuzoAzPEeqR6H4f1PV543mi060lumjT7zhELED3IGK+db/AEix1yGDRLZrtpLi6Gj3ZIwYoNQYaoJR15Qr5XPXBPHAr1z4u61ZWVlpml3pmX7fOLqRlXKfZ7Mrczq2Ou6ONkA6HdzxXJ+DUOqfFCzlt5hKLC2nneYgkT291KJ7ZR/1yiZUHp0HFAG/8Q70ap8TvAvhTYstt50msXZUEPE1uA9uc9MFwwIxk8e+fTeCDXknge5/4SP43+MdXjTy4NKjj0cBhks8ZYswP1c/lXrSjAwaAHDpRSDP4Uo6mgAoooPTigAJo780hHIOaWgAxRRQKACiiigANFFBoAKKKDx1oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArP8QaTb67oeoaVe7vs17A8Em04IDDGRWhQaAPIf2ePEVzNot/4O1osdd8M3D2c7HP72MMQjgnqDzz6AHvXr1eMfFvXYvhx8QNA8XzafIdHvFaw1Se3X5gcExsw/ix83vhfoK9f0+9ttRsbe9sZ47i0uEEkUsbZV1IyCD9KALFHvRRQAd6KOc+1B6cUAFZPifTJNW02G3hdEZL20uiXzjbDcxysOO5CED3IrWFc549keLQ7Vo3ZGOq6apKnBwb6AEfQgkUAdHRRQPSgAHNIRnFH8qWgCvdu6Wtw0TKsixsVLdAcHBPtXzT8CbqaXwN8QvG16hum1e8m3WcXrIw3Ejt/rPyFe0/GXWRoHwu8S36y+VMLOSOJh18xhtUfma8q+Gemz6T8AvDVrYMsF9q12LiRGHMyF+R642haAPavAenx6b4S0y3hctEIg65/hzzj8M1v4NRWUQhs4YgoQKgG0duKm70AeX+NL28ufHQtrWS0mgtbaExQuFO5vNJvUJ9TbFcA+oxzWH8M9Ys9N0rxn4vnRk0K1dmtAFO5YYwRsH0wqiqmt6miab4j1mS1EDyTt5EqMC1vclRGwJ9GRUFQ/Eh5vD37Oy2VnbRDUNYaO2MQ43tIcufxAP50AdH+zLY3Mfw0i1TUWEl5q1xJevL3YMRjP5V6z6Z61g+BNGi0DwfpemQLsjt4Au3071vD1oAM0tAoFABRRRQAUmcHpR1welLQAg6nn8KWiigAooooAKD0oooAOaOo5oooAToBS0UUAFFFFABRRmigAooooAKKKKACiiigAooooAKKKKACiiigDFXxBB/wksmiyxvHOEEiO33XB9K2q4z4i2s0K2GuW25m02Xe8aj7yEjNdXp91FfWcN1AcxyqGFAFiiiigAoNFGM9aAM/X9F07xDpFzpetWkV5YXC7ZYZBwR9RyD6EcjtXlXwvEvw78Y3Pw9vLiWfTJVN5o0sp5EZJLRk9yCT+VeyfzrhPi54buNY0OLU9H3JrmkP9ptWTgsB95PfI/WgDvKKwPBHiO38U+HLTUrZ13uoE0Y6xv3Ujsa36ADrRRQKACsvxHBY3GnxJqkxhtxeWrqwOMyrcRtEv4yBB+Nalc18Qv+QDa/8AYW0z/wBL4KAOlBzSHj3oNJ1GOMUAKT29aKM0UAeH/te300Hwwh0+3RWbUb6KHGeSQdwA+pFdDbaJPFc+BdHe3kMOm2SMb1R8ocJgr/46PzrgP2xrPUxp3h3VraKWbTbC58yfbysbZ4J9M9M17j4E1uz8R+D9K1TTpPMtp7dCCRgggYII7HIoA3u9ZniS4jt9CvpJt/l+UykocEZGM5/GtL3rlPiPMv8AYDQec0fmHLbf7o65oA8k8a/Z7i10fR9OikttQ1W5D31lJklhxiQf41tfElP7R+K/gHwrHEJtPslN3NtOWQjCru9sD9a1/AOgJ4l1Ww8W6jci4mslMFoV4wo9awPhrLD4o/aA8a66hlQ6aiWCqeAwA25/8doA90PvRQefrRjJBoAXHGKDSUtAATiig0dKACijtRQAHmjFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFfUPJ+xTi6IFuUIkJ7LjmvOfh9rkOh69P4RvrpGDs0umSM3+uj64HvXprqrqVcBlIwQRkGvEPjT4OkWKDUNFjK6hZyfaLNweVI6oPY4H50Ae4UVzHw58Uw+LvC1rqCkLdBQlzEeGjkHUEdq6egAFFFFAARQaDRQB5DqtrefDPxjPr2lwxzeENUkH9p26HD2cx6SoM4KnnIAr1q3mjubeKaFg0Uih1YdwRkGuU8V+BLHxFftdzXV1BK8XlOsbnaw7ZFeOy6r4o+AeqxQ6xLNr3w/u5SkNwcmWyYnOCee2eO+DjBGCAfSPQUg55qvp17balYW19YTpcWlzGssMsZyrowyCPqKsfhQAtZ+v6YNY0ieyM8ts0m1o54sb4nVgyOMjGQyg8+lX+MeorF8SeJtG8Mx2suvanb6fHcSeTEJT/AKx/QDrQAzwpfarPFcWXiCzMOo2ZCNcRqRBdKc7ZIz2zjlOqn1BBO6cY56UiurRq6sCjAEHsRXm/xW+L2heALeOFs6nrU/EGn2zAsT0BY87Rnj1PYGgD0S7uYLOBp7qVIYl6s5wBUdpqFpeWoubW5hltz0kRwR+deLWngXxP4t1CDxN8Qtajso5lBt/D0bbIogRwrydS3OSMHnvV7R/g7o/hnU7q+m8RalHpt38o0/zcRIT2Vuvf0FAHq19a6frulXVjdpBe2NyjRTRnDKykYINfNMup6v8As4eK1sZvM1XwDqbvJbLuIktWPVRnPI4z2Yc8HIrK8YeFfFfwu+JGk23w71y71GTV3Lx2NyfMKcn7+eNmD97jpXt/hTwDfX1heXPxLuYdY1PUFAltkGLe3X+4g4yRnrQB0ngzx14d8ZWP2rQdShnXIDITtdSR0KnnNT+KNEudaKQC5SKxdSk6lcsRntXj2vfs1aUZFl8J6xe6PMrFshiwz2zjnivIPidonxA+Gmp2yar4jvLvSr0bGvoc7QCcMpB6EfWgD3zxv4wsfh/o9v4P8AWn9peKbxWS1tITu8knrLIegx1xx+A5rf8Agn4Bm8A+FXi1OdLvXb+U3N9OvO5z/Dk8tjJ5714B8LviT4T+F2tCzg36tp+p7ZLnWCv7+FzjKkY5UdSAc96+udL1Gz1axivdMuobu1mUNHLC4ZWBGRyKALQ4paQe9FAB9aWkzS0AGaKQiloAKKKKADvR2oooAKKKKACiijpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABrhfibZWWpnTLR9WbTdV8zzLIk4SVx/Ae3PFdzXO+OobF9CaTVLBr2GJg2UHzxH++O4x7UAeI21/qnw98Zf27Ipj0y8dbfVrAHiN84EqD6Y6etfRtvNHcW8c8Dh4ZFDow6EEZBrx2eJNf8NazomskXWo3tm66fdKMmQbPlB9CCBXn/AOzz8VLnw1cjwJ46SS38mQpaXkxOIzj/AFTH04JB9yDQB9S/SlpEZXUMhDKRkEHIIpaAEOe1LRSd6AF71R1jSrDW9MuNP1a1iu7K4UpJDKuVYH/PXrV3oaDnFAHgcfhrxx8HbqV/BEbeJvBRYyyaXczYuLQZJbymOPXsDnHIyc16J4B+KHhbxsnl6XfiDUlwJtPu18qeNj/DtP3un8JNdwM8V5r8Qfh9a69qS3d5ptte6cmGaygQQTSydnMyYcY9N1AHQfErxxpfw/8ADE2s6wWYA+XBCn3ppSCQg9M4PPYZNeXfDTwfq/j3V4viF8VVP7v95o+kSfLBaR9fMZD3OFIzycZPbHnfjDwvq2v/ABIsfCl94ku73SrXNxawRI00lic4EZMuPMOABksTXp0nwp13Xpornx/4/wBWuNMRggskVLRZY8/dkCELk4HqfegCh468Ta18V/FK+EPhhrTW2jWoL6vrNsSqD0jSQHLg/wCz1z1Kgmq/jLwN4N8K6Lp3gsaaLbT7kCa81yaMNcZHdXx97joAQM8CvVPE+t+G/hV4Ma5hsILWyjIS3srGIKZpD0CgDqT1P4ms34U6Lrdza3PiPxhfm7utXCzw2DRjy7KI8qgyM5wRn6UAXNC8NeHtX8FaXaWc15qdhY82c91I3m7h0JYgH8xU17qi6R4Ru7vxNcabfXVkGkjjRhywB2Kc/wAXTmqvj7w94n8TOml6RqsOg6DwLmaJA1xKOchB0UdOteD+OPBPhjU/Hvhbw54Mg1G8ezuP+JnP5pkicAqeWY/eyDnbxzQB7N8ENJ1O606fxd4u/e+INWYugLBltrf+GNMdB64rnvGHxT1XVPHI8LeBIVaG2l8rUNUkwI4m7qpPUj29a9I+JesWnhn4ea3f3Egt4YLN0TacEMRtUL75IxXmn7KXhOfTPh2mrauwd9Sma6hRgPljOAGY9SSVzz2xQBf+Hk/jzS/ipqWia7fx61oBg85LtWGYjxhcdQeead+1VfabB8Kr20vJYRe3DKLRHGWZgRnb+FbPwqsnk8ReKNZMpMN1cbERTlBj0rwb4/a9Z698ZrOxKC+WyjRLYQvuTcTkg49xQB1fwQ8O/DjxH4H06y13w/BFrHl7ZpLlSnnvkjcrZ64xW3d/AfVPDZlufhh4w1LSZCxdbS5k3Qn24H16g0eHWsTZWuma7p5l0WZVEc0YxJaS9skc46V6ZrfhfVb7TLO20/XpbZrbmOYDLOO26gDz7Qfih4p8Ka1baF8V9DNuknyxa1afPA57bscD0znPtXtlpdQXtrHc2c0c8Ei7kkjbcrD1BrzbVtY8Q+GoYrXxXpS6/o87eXLc28e4xg93UjkVx1z4e1zwS83iv4O3X9saHcMZLzw9KxcAdSYuchhyNvX/AHulAHv/AF4I4pe1cR8MPiXoXxD0+STS5DBqEHF1p8/EsJ+nce4+nWu3BoAWijAoNABRSZ70tABRRRQAUUUUAFFFGKACiikHWgBc0Ud6KACik70tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRTJpUhieSQ7UQZJ9BQA4FScZBNBAIIPIPaudtNT0WO9iuob3dJqDeXGC2QT6D06V0dAHnukxadafEiaG0zaSmIk20gwr9fmj/ADrx1NNh0L4u+LvDOvQLqWn6qhvLUPy8eQTwe2M19DeKfDNrr6W0js1vfWriS3uo+HjIOce49q8f/ac0C/t18PeMNHVRqWmzrHcSp8paM88+2f50AXNG8WS/DHSrSbxHqMl/4SuX8q2n275rRs8I4HJFeyaNq2n63YR3uk3cN3ayAFZImyDmvAfi1Z2niGXwOiw79DvJUl1FE5xwvb8Kd4u8KXI8Wvqnwc1MaXfaTah7qyywtrkDBCgcgkjgg/p1oA+iqO9fPOg/tJQQQQReNvDt7pF04IWUAmKUjGSuQMDkeo969A8N/GTwbrl+tlHqP2a9YZ8udCq/999P1oA9DJ29efYU7qKyJPEmhpKqHWdPErEKEFwhYntxnNX5r60gmihnuoYppf8AVxu4Vn+gPJoAsHNFB4qvfWyX1lNbSFhHMpUspwQD6GgDhPiLoNhd+IdG1C4utWtJUYqG02FizdzudeVHviuH1hbnxU2oy+JNEn8R+HdLuFj0/TLG4Ms8j8jzJwMHt0Pqetevaba6Z4R0aCzM8i24YhWmZpCSffmsTRfB8WiwaxNeXdxf2d1L9oSBMqU69MEE9aAOW+JFw/hrxL4Y8V6sqQeGLCLy5U25e2dlwowOT6V2Xgf4geFPGf2k+GtShnkiHmzRhSjgH+JgRmvNfivpd54++IXhDQ7eQNoVqxur6xd9jttwRuU9eARg+pr1g6dPYa3ajSNJ0qLTHTZcSJGI5VA6AYwCOBxQBymp/FKwijur6Wxu38IxAxT6vGpKo+duMDkjJxn3rz/4Dahe+NfGWr3SQ28PhXTJGNk0MYSSZy3y72HLfLknPtXqHjG4vdO0vV7e60SHxJp0seItIs4hvKZ5DKc569QK4v8AZP020tfB2q3tpHNaNeXzmTT5Mn7LtyAuSATxQBg/toa5JbeGNG0Vd6wXlyJZ2A4KoDgZ9c816L4f8S6dN8G2vtBgmtbSzs/JjjnTaRtAX8R714l+0rcf2v8AG3w9pUkxuIIIoylmvO6QuTtIHduBzXqviHVtQ1b4TlPFWknRdUMqolgjcSKDgYx2Izx2xQB0HgW3ttO+FUHnzNELyJy0meQz5HFfNXwn8NWWn/Gq98O6vPufYZra8duWbaCOffP6V9SeL7ZY/hXeoIxC0Gnb0UcbGVMj9a+b/gHZWHjnS9Tmup2k8X2J8yEt1ePAwQR6HIoA9b8CJd6d4xurbUoiJi5TyCMqy8YcV7OAFAUDAHTFch4Lgk1G1ttU1JY21CFfJWZcZIHUN711+fzoACOCDyK4zWfDU+mXcmteEsQXqgtNZdIrodcY7N712YIpaAPAvEXg238bvN40+Hcs3h/x/Yn97CGEazP3SUYxlhkBuh6N6jrvgz8Tf+EyguNH1+3Om+MdMyl9ZOhTdg48xAe3TI7E+hBOt440G8t7j/hJvCyhNZtxmaEcLdx91YeuO9cD8R9EuvE+l6Z8Sfh4gtPFulktNGB89wijDwuOjEDpkcg444wAe7A5pa5j4c+MbLxx4VtNXscJI6hbm2J+a3mA+ZD9D09RXT5z0oAKO9FHfNABRRRQAUUUUAFFFFABSZpaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKR0WRGR1DKwwQe4paKAPE/iHoWjaFq9lPq+oNpGgJKJkuQf9XKCfl4HcmvYtNvbfUbC3vLKdLi1mQPHMhysinoQfevN/GuhWl/qd1oPikyXmha4uyB2/wCXSYcgg9jkZB/pmsX9nDV7zSo9Y+HXiGVTq/h2ZhBx/rbVjlWB7gFvwDLQB7ZWP4u0KDxL4evNJumZY7hNu5eoPY1sUUAfOfwgM+t/Ei6sboi2XwujW89rIMiUEsFbH61uaXqI8T6P4puUi/sbzLz7NYyJ8pkAJ6/lU/jZ7L4a/EceK5U8nTddj+yXkic7ZP4WYfUjmrGi6O2iJo/hnUylzBc3z3iTqfvqSxGD+IoA2PF3g/RviD4dbwjq8ci3GnwRtHexqMwy425U9/cd/wBa8Y8NXR+EsTeE/ir4XiutCllItdet4A4VSejNjOBweCGGSMGvoLwWLiXWvEVxJIHtmuvLhPsM/wCNQfFqGyvvCM2l6gsTrfMsSrIODyPyPNAHJ+EfhP8ADjUb+08TeH5P7QEb7opYrkSR7h2IA6j0Nei6n4W0vUtfsdZvImkvbMYhJPC/hXkOofBqbwlLZ3vww8RzaDqoUb7KeYyQXrDqCGPfHcH8K0rP4p+KfD1o9v488HXf2u2GHutOIkjmx/EqjOMjnGaAPWLexnj1ae7e7keKRQBCfur9K0B7V5Jo/wAfvA+rW7Nb3VxHehtgtJ4tkjN6DseeK7vwxqOtanJcTato66Zbf8u6tKHkYerY6fSgBPES6VrOkXQuDJdQWjb5UtX/AHgK846/pXl3xNvp9Ht9N8fReMJtKt7aPy7TSrqzQ/ageseAdxYjPOOOvHWvUdd0+ytJpNalN6jQRkstpE8rPwTnYgJY/QV4z4i8TT61daJrGmaRrscNlqCxrfatC0auSTwIiMkehz+vFAHr+mTXGr+G4NetNGt9P165twypqMYR4z/ddlBYDH6V5CuueJvi34pbw/b3UOmeHdIYnVdW0iZnSaUciKKRwPbnBxyemM+r+IvF4hm1vSdFtLi+8QWFkLsW3lmNZFOcbXIwTx0Ge1ef/AbSPDDeANaurXVROurMZtVgMo3WjnIKNjle/J60AWPiJ/wkPg3wLq2uafPaX09hEos9R+0Osoh3DIkjUbJMccknPWum+BNxJqfw20vWbpo5L7U1a4uZEUKGfcQeB9K8z+LKzX1ro3hv4fg6/GybGtjOHSBB/GzH8K9D+Ascem+CxoC3S3cmlP5MkqnK7j8xUH2OaAPBPEttc6/+1eV8NSw/bbaVZQ8pyoZBk/oa90+Jck8uj+G49VSJdW+1RllQ5Xd3Kn0rxnStOtLL9q3UYdWlexuZiZNPZTlZJSBtBx64YfhXtPiOO/1Hw1bX3iuySx1HTrsMBG+9JFzwwI9R27UATfH7VI9J+GOqTyXUUUwj+SJ2x55/ugd+teQ/s1Czu/DuofZLWOw8R3RdrWZV2jAAwPof6V6N+0T4FsPG3gn+1Zbya1utNha4tirZjckA4Ye+OtedfC62upPB0c2wWF/c5cSDgMRjgfnQB7x4HaOVJpFSS2vQ2y9tH6LIP4lHoa6zFYnhO+TUtJguHdGvljCXHHzhh2atvHOaADpRRnj60tACe9cbY+Fr7SvHlxq+mXgTSb1f9Ksj08z++PeuzpMelAHzv8VtA1r4deObXxn8PpNv9qSiHUdOk/1EzE53EDpn16g9DyQfTvBPxGsde1m48P6nBJpPia2UO9jcceauM74j/GuOeOR+tbvjbw7D4p8M32lTnY80Z8qUdY3/AIWH0OK8Qs/D958QtMk8N+IfP0v4heE8fYNciBAlQH5CWHUHAyOoPI7ggH0YMnrS1438I/ihe3Wsy+CPiHEun+MLP5EkYgR34H8S443Y5wODyR3A9kP1oAKKM80UAFFGfXpRQAUUUUAFFFFABSD3paKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5Tx1c2U0Vvo18jK1+wSKbHEb9jnt0rx34nxaho+pWPjvS4TN4m8KOsGrRAEfbbNhjzDjnAG7ntnPavcvF9rY3+jyWl/OsHm48uQnBDDpj3rjNRkmudLkvmtt2q6YgtdVtSMm4tTkMffK7iPx9qAO78Na5YeJdAsdZ0mYTWN5EJY3HoeoPoQcgjsQRWmK+ffhtqf8AwrTxR/YEzO3gfW2+0aPcMd32aRjho3PYE56/419BDoMdKAOa+IvhKz8b+Eb/AELUPlS4T93JjJikH3WH0NeRfAfV7rxJcJ4W8U27Rax4KYLDJk5nTlF3A88AL9RivoI14D8W45/hv8UtI+Itgjf2Rd7bDWUXn5Sfv49vlP1UetAHqnw9sZ7LTL552LfabySdPYHH+FVfH8NjqV9o2l325WlnDxyDsQRxWl4cv0k1TUbKOVZYiEvLd0+6Y5M8D6Ff1qlr0EGoeNtHguCB9nzMg/vEDNAFDXpY734maNYXIdUgQ3ETDPLjnmu8YK4KsoYehFcbY363PxMvrK4jiL29sHhbHzY4z/Ou0oA8C8Z/Crw54v8Ai2lvf2K2dotsZG+yYiMze+Ki8Z+CvEHgXQptS034h6wIYPlt7WYGQeyDGT+denanGY/iVpcy22/fCyGXP3eDS6jqTeIPFA0OwSOSytCHv5+6MOkY9zQB5ppvw2+JOpafZTT/ABN1GKC/RZruNoBviyMhV59MdMVJB8OdI8dahqGleKNd8S6zqOkxCKC8m8u3ityejRrH95vUtnpXulw8dvayPI3lxRoSW/ugCuO+F3mS2ep3hkhlt7i6YwyxvuLKMg5oA838R2vxr8JaYNL0C4sPFGnZxFfuhW9iQY4cbgD3GRuY+1eU/De40LwlDq2t+LLC8vbm4lC3dkY5bdolySXAIVXGSeDzX2riqt/p9lqCKl/aW90inKrPErgH2yKAPkrxR8b2sNWFj8NhpmkeFyAXvmtXMkjY5BBBK46DAz3zWt8P/iJ4Y+HGtW8K6y+sWWtI1zqV/BExWGYZIwmN3t0r366+HnhG61B72fQLFrhx8zeXgH8BxUdt4V8L+D7XUNQ07SLS3ZkLSHbu3Y5xznA+lAHyzrnxG0+f46W3jnw1p9zqWm2wEd2kkR+VMkF14+Xg7hn0r3vT1g8S+HdYvNG8Rprfh7UEMqQTSBpbGTrtBzwAccHn610Hw/8ACeh2+i3t7b6RbW39tO088SxgLhsjAHYEenrXm/jL4N+F9N1GG38JahqWi6xqUwH2e3nZonjz8wI/hAHv+FAHoeg3tn4o+E86RN9oQWkts4HJDKpH59K+fvgJ4otNG8Oaj4Z8bu8Gm3V55VldScGCYjHQ8gZGQfrXuuv+EvEHh+0hk+GU9pbFI9k1jdDKTt2fcf4q4Wy/Z1i1VrjUfFesTvqF0fNe2txiGKTsR69T+dAHonhR7fSfEf8AZ+sK1vrjR7EuAcRX0YOQw/2vbjpXoJ5rwXw54o1Hwp4t03wd8RoorqeRz/ZWoMvysgwAd3Y4r2RNctkuntb0/ZrhWwqv0cZ4Kn0oA1qQUvTAooAKKO9Ie/NAB0rE8UXd9ptqLrR9NS9u3cI4xg7fqOa2wKWgDzj4wfDS1+IWiQSK5sdfsgZrK8i4ZJMZCk9duQPp1FVPgh8Q5/FljeaJ4kiW08W6M3kXkDfKZlHAmAPOCevbJB6EV3lg2rf21ereLF/Z20G3K/eznnNeYfG3wfe2mpWXxC8HxhfEOkENNGOl1BzuVh34JoA9lGe9FYvg3xLp3i3w5Z6xpEyyW9wgJUH5onx8yMOzA8EVtZ4z2oADzRSDnnjHtS5oAKKKKACiiigA70UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBieLvDtt4k0prW4JSRTvhkUkFHHQ1wdlqV2VTXLmP/ia6OTY65bIObi3zjzcd9oy34HtXqzsFUs3QDJrg/EE1nBL/wAJZpAW5ji/0bUY1GRJDkA5HqvWgDkfEukQW1rqPhuSIXelaqjXukSjJED4zsU/Xke1XP2d/HreJdEu9A1aVv7e0RzBMJGG6VASAwHXA4U5Hp61cntWmtrrw3YTKJIwNT0G4JBEkeQXjB9iWXHXBB6CvGfibDf+GPiV4Y8ceCcRzeJQLOS3MeBDc/IjIxGOWJzg85VvwAPrhWDZx24rD8beHLXxZ4V1LRL4AxXcJQMf4G7N+BxWL8P/ABtJrok0/X9Pk0fxFa2yXF5aSAhVVmZQyseo+X9RXbAggFSCDzkd6APFP2a7250y01nwR4gfOu6DcMiFuslocbGU9doOfoGWu01+3n/4WRoM8CFk2OshHYbTXmXiy1u9G+Omv+L9MnV59L0OS6uLRgcTRLGeM/gv44r1lY08UHw/4h0PUUNkQJt0ZyJUYdP5596ANOPw7YxeJZNdRCL14/KZvbj/AArYrLi1OeTxFLpxs5Ft0h8wXP8ACTkfL+p/KtUdOetAHK+IvtEfi3QZIljMBYrIzHBHB6VU8BQu+v8Aiy9lk3l79oUGMbVTPH61peIonm13RxEpLrIWJPIAwazvh8Zl1XxZFLswNTd02nna2cZ/KgDs327DvxtxznpistdV02GOEWjpLDJN5INovmKr+jbM7fxq9ezxW1nPPcf6mNGd+M/KBk1meEZ9HvdFjvvD0UUVlcszjy4hHuYMQxI9cg0AbQ4HFBOBRRQAh6elcp4+Z7qGy0qAoZLyYAozhSygjOM+2a6w9Oa43UoP7R+IenRz2LyQWUTTLcAkBHI4zg0AddDEkEEcUYxHGoUewAxXHeFoDqHjLW9XedJooiLWFepjx976dq6rV5lt9LupXcIFjPzHtxWL8PbOS18NxSTxxLNdM1wzR/x7uQT+GKAOlAxTWbaGLcACnVDeDdaTKOpQ/wAqAPO4vDdn4/tfEKeJ7dbi3kla2tJSBvgUA/NG2OD82fwrzyfxR4q+DJsdE8a2g8XaLcS+Xpl9C2blFUcoysCSQMEfjye3qXwevftPhW6EhINtfTQNu7Ywf61x1nqD2epeJPiNfpdXkocaXpNkW/dbcjLIOeS24ZGOAR3oA9D8G+PfDXi9Sug6rbzzpkNbFwsy44OU64966npXg/xS+EH2qxHjHwJBLofjS2jF0YLNgqzNjLpjpv68jg9CDnNcd8M/2gvEDwJba1odxrHlkiea0VjLBt+8XU9sAn8xQB9UYwaWuT8OeOdK1trFFc281+jS2kMuQ8sakAtj05H511g70AFFB4ooAQ/WkkVXRlkAZGG0g9CDS9+vWjGRzQB4B4mu5fgf49Os28DyeBvEE/8Ap8Eak/Ypz/y1Uds5OQOoHrivd7C8tdQtIruxnjuLaVQ8ckbBlZSMggj2NUvE+h2PiXQbzSNXiEtndJscd8HuD2PvXgfw30HxB4K1PVPDmgXUh1zSM3UdldO32bV7J2IGeoikVzw6jJwAeCaAPpHvSjj3rlPB3jaw8R3Etg8c+na9bJuu9KuhtmhGQN3oyHIIYdQRkA8V1WcA0ALRRRQAUCjvRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAEAgg9DXnPiK0j8KX9z4ksi0vh+ZTHq9hGu4YJx5qj2ydw9K9GPTBrzy6c+EfFEs11Ok/hTWpVt5VlOVs7pjtAP+xIWCnPQgZ9wDBj025sn/sKyuPMuLRjrHhm6JGHix89sW/i4ZuO6sD/AA1598YLqwk8C3viW3Wc6Xq5jvLcxyHzdM1eJiNp9M7pAfdT04z3dxpd5o+qXPhDT7lhfwFtc8NXU3IjAIWW0JPUnMnAz8j5P3a474nw2t94M0LVNDRzaeJ/E1g11o7HcIboiYzxn0dnChh/eU+tAHq2hz6X8WPhvbXiyvBNd26xTyw4WWCUAFkJHuc49CD3ruNMt3tNOtraRy7QxrHuPVsDGT9cV5No2s2vhD9oLVvCwJh0/wAQ2kWpwRgBY47oAxsAO29Yxz/eAHevY6AM6bRdNmvbi7ltI2ubiA20zkcvEcZU+3FeX/DxH+Gfi3/hAb6SV9C1FpLnQJ3ORGeWktifXqwz1yepNew1y/xE8I2/jHw9JZSN5F9CwnsrteHt51OUcHqOQM46igC/Za0JfEV1pE6COeOITx4/jTIDH8Cy/nWuBgY7V4n4d8RyP4r0TWdetJR4pgz4W1iytlz5ck0iyQ3WOMRMIWOfRxj7pz7VPKkELyzOscUY3M7MAFA5JJPQAUAcNqni61PxJ0PRNNkN3dNJIl7EgOLZPKdlkY9OqgY/2uvY6fhW0S38ReJHjZmWWWJzn1w1YvwlsIb6fxB4y8tEm8QXhZFVDgQwZgjYE8kOEMn0cda6LwdqEWpjWJ4kCNDqM9m+CDkxMVzxQBvzqrwyI6B1ZSCp/i9qzvDhhXTRDBaxWflO6m2jkD+X8x649ev41qVzPh20uoPFviieX/jznkt2t8e0WH/WgDpqKKrC7txqP2ISL9qaPz9nfZnbn8+KALGevWsrT9Lktdc1G+N48sNyqKICOIyucn8c/pWtRQByfxT1NNI8DaldzQNPCFVJEUZO1nVcj866HS7GHS9LtLC03CC1hWGPccnaoAGT34FYHxClspLTSdI1NXa21nUEsSFA67HlH/orH410tvcRXHmeRIr+W5jfac7WHUH3oAloxRR3oA4/U3Hh/R/FV5YWmYYYHu/IQffk2sXI+oUVy3ibQL61+DdjaeF4Z7q8RobmKN+XzJOsj/kHb8BW/wCIL83ETWmi3AF++uW8EkTkAyIkkUk6gd18otmtn4gHWI/CGoHwxNFBqyhPIeVcqvzruyP93cKAOhPtXifj7wnfeBPGP/CxvAtl50RVhr+lRcfaoSctKg/vjGcDuAe7A+2UYoA4TSdK8L+NrzQvGujzGVreDy7d4m2qsZwTGydiOAR2xW3rN/q+nR63eQ2gu7e2sjNawJ9+aUKx2fiQB+NcJ4i8My+FPE0upfDyRItZuoZLyXRGJFvdxxsgkZVH3XzInTua7LwR400/xXBKsIe01O3O25sJ+JYW+nce4oA29Evzqej2N80TQtcQrI0TdY2IyVPuDkfhV3OR69DSAAcAAD0HalxjAHSgAPPr2oGc80dOvOP1oz0PP0oAQDk+hpphQyiUovmAY3Y5x6VJnmg8igDnvF3hLSPFUEKapAwubZhLbXcLbJ7aQHKvG/UEHkVxus6l438AOkxs5vGnh45DG3QR31ogPBYZP2g7e4CnI5Ar1I9c89OlFAHJeCPiJ4a8aRR/2JqMb3TKWezkws8WCRh0zweDXXV554++FWjeKLldUsGfRPEsIJg1Sx/dyK2QQXAwH6Y55wTzXLaJ8Qdd8AX9voXxaRDFMT9m8QQbjbSNjOxyQNpGcZOBxQB7ZRTIZEmhSWF1kidQyupyGB5BB7in9qACiiigAo70UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmfi7TotN1a+tdaLS+DvE+y0mGebO8clVcHkgOSgB/hZQeK9Mrzn4lzTHU4tI1VtnhvxBanTVulTJsL3LGKXJ4BYsoU8YZAaAMtrTU9a8NTaE91HD428KXKT2d2y5WQAHy3A/iDwsUbPAZj3ArkfHWraddXPwfXS7A2tlrviNdbnQ53x3IdSyt775mB/wB2ui07VtVj0mG/u1L+KfCNwLHW1TLSXlmVO1ge+8GObnphulLrw0jVvjf4B02ygFxb2Vpe60XXmMNOwaOQH1LI5H1oAPHuiHxd4q8bWmlYXXbXR7FbKXAys0M8lyqgngBmMYJ7Yr0L4e+JF8WeENP1YxiG6kTy7uDaV8i4Q7ZY8Hn5XDDntg9680nnu3+IM0lrdeRcHxY9s2OPNhXTYX2H1AbnHua1dcuE+GvxMg1VmMfhjxZcJa3a5VUtdQx+7lA4wsih955yw3E0Aesmg0dqMUAeb/ErQNQ0/U7bxz4Pshc+IbFRFeWa8HULPOXiHB/eDAKn2IwcgVJqst18RtM0/wD4RvULZ/B2pwFb6ZADJIhJDxDPKkjKnuOa9Erwa+1M/Bz4hzXKvHJ8PfEF4RcLFgjSr9gNxPojAbiPTOB8o3AHuVhaQafYW9nZxLDa20SxRRr0RFGAB9ABWH4F0zTLDSrm80SVprTWLuXVt5OdzTneSPapfF/ijTfC3ha717UpQdPgjV90bA+ZuIChfXJIqlo1o/hL4aQ22kQPfTaZpp+zQFsGZkQlUz2yQBQB1dc94IvJr3TtRa4g8lotUvYVG7O5VuHCt+IAOKZr+uGw8CzarfxT2krW6hkh+Z4pJMKMH2Zhz7Vd8I2Mum+GdMtbm4N1cx26Ca4PWZ9o3OfUk5JPvQBr1htav/wm0d3vTyxpzRFPKG7PmKc7+uP9np3raaNWdWIyy5wfSs6Jkm1+crO2+CIRmLacfNhs59aALF9fR2ktrE3zS3EgREHUjuceg71aOcjFctqkEV58QtDlikf7Rp1tceYi9Ns2wDP/AH7rqqAOV8dNbpdeFWubeSYjWYhGyD/VOYpQHPtgkfjWn4etdOtTqn9mSFzLeyS3PzZ2zEDcPbtWlcwJc28kMoykilT9Kr6Vp1vpls0Vqp/eOZZHY5aRz1Yn1NAF2ig0g60Aef6V4RnvfGJ13VpNjaZq1zdacIsbZYZrWOI7vcEOfyrS+IOoT2d34Rt4mxBqGtJaXCY+/GYJ3wf+BIh/CrvgKaaXw1B9pYtMrOrd/wCI03xfp9tqd3oMc0oS4tL9b6Be5Ko6fykNAHSdqKKT2oA5TxGit428NG0ITUws5LnobT935qfi3kn/AIDVfxr4Ns9bvIdQ0+7/ALI8SpxbX0XDsB1Vh/EMVH4nimX4meDrqNiI1t72GT33GD/4ms74pyyW/iXwP5byohvZVZkOP4BjNAFrSfG11pl5Z6R44thY30qHZeqP9HmYMRjP8JIG705rvIpEliWSJ1eNhuV1OQR6g1W1bTLLVrNrbUraO4gbqrjOO2R6VxEPhjXPCcofwpefa9LViTpt02doPUI3b2oA9DpOn5da5LSfHGm3Aji1YNpF6VXfDd/IocsVChjwTnHHuK63HNAAfSlzziimuodSG6GgB2BmkA5z3pRxxjigUAFUtZ0qx1vS7nTtWtYruxuE2SwyrlWH+eQeoPIq7QaAPC4JtU+B+qxW19Ncal8Nrl9kNy6l5NIctwjkZJj5ADH6ccZ9wtp4rq3jnt5ElhkAZHQ5DD1BqDVLK01HTLqz1G3S6spo2jmhkXcHUjkEd68K0LXV+DviK00m+1J734eaw5GlXks286e68PDITjChj+AHqDgA+gKKZDLHPCksLq8bgMrKcgj1FPoAKKKKACijvRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxfju5tbm5Tw5r8AXRdZt2gS7z/q5+cD2P3SpPce1dpXIeJ20rxPJf8AhK/Dx3ZjWeLd8uSDlXU+xFAHMeGYNTOs28k4hfxDYy/2brMZUAXtqcGO5PqQu315LDsKzvhd5T/E7xtfQeVDoejQwaJDvPEK2ysGG49hkmul8Oaha3Ed1q+ro0HiLRLeSC+29XQAkEjvnGR7/hXG/A61lufg3qE2o26rf69cXBk81sGfzcAk+/LUAGj6bqOtQaFrziOPUb3xDNq0kCHP7k25t1K5527Y0PNet+MfDmn+LfDV/oerx77O8jKNjqh6q6/7SkAj3FctY6HaQ+MtDt7O5ZbnRLAQPH/CyEcfzr0KgDyf4R+Lryzv5vAHjaUR+J9LG23nc4GpW4+5KhPU4HI68HuCB6wPevEvH3haT4l+JdX0+ZjpOt6EEl0TUYGIJLZJEnUlchemCOo7g1/hp8ZLiDWW8HfFCEaV4jtiIluXGIrnsCT0BPXI+U+1AHutea/FLwZeXuh+Jbnw6iXF1qdrHFcadMf3U+wkl1HaUqQuePurXpKsGUMpBUjII6GloA+RPgh4qsNfjtPht8SFkK2d0s2l+eSrJImVFu4xzjJK5+noK+qtVk1CI2q6ZbxSKzgSl2xsT2ryr47/AAetvGNhJrPhuBLXxdbESQyxsI/tBBHDn+8ADtb146dKXw08a3Ou+LtM0TXdUudA1fRrRbS60a8UKdSmAIM0bkjcOM4AzjkZHNAHoXjqeS7vNI0OFiJLqYSzLgFTGuTg/wDAsflXYKoVQqgAAYAHauL8LpFq/i7WNaxC4iP2SF04JUeo+ua7WgArldK0y9t/iBrV+8eLG6hiCP5hOWVVB+XOB09K6quQ8J/bx4n8QrfrJ5XnZgZuhX2oAYNO8v4pvqC+aPOsUibBOw7S+M+/NdlXG6Tqt1cfEPVrCYyC3gjQxjb8vI55rsqACig0h6470AL3qlrEzw6dcGGVIZyhWJ36ByPl/Wrtc7r9yLrV7HRkjWUSfvpwR91AeMH8/wAqAL9gj2GiEtEgnSMyOqdGbGa4CHXJ9cvPBOuyW7WzXMlzA8B/h2yBQfx2/rXo+oSiz0u5kUcQwswz7A1wlwHS28IRxReaWleUyKOFyc/1/SgD0akPtS0h7UAcF8Q53tfFPg2YFtv2qSNsdOdnX8q63Um03zrVNQMPmFt0Ak65HpVDV5RN4i06zktEnhAMofvGwp+u/wBijUNMGryxJdliLUOcEtxnH6UAbbdD/KgEc4pfr1pCNwI9qAPMNVSyuPGvimLxHBBc6Rb2kVw6umTGrKF3DHORtY5HIxxXMeGNQ8aaJ46Xw1/bUV3otxD9t0i5vEyLi34xEH67wCo5x6113iGGWx8Y67ql7EiaLPp8VpLOPvb85C/T5v1rV1bwhZ+JvA1npvnyWskKrNY3lu22S2kA+R1P8x3BoA0PC/iK51S8vNP1TSptO1C1b5+d8Ug7MjcZB+ldJzmuA8FeMbpdYbwn4zVLXxNCuYZVG2LUYh0liJ6nruXtXfkgUALRTWOOcge5pevt+FAC0UgxngUuecUAFczr/gTw5r+m31hqmmxy2t4S0seSAHJzvXB+Vs85GPeumooA8s03wj4l8BWEcHhK/OrabESq2V6QHROoCt3xW74e+IFnd3yaZrsTaPrD8LbXHHmdvlPQ8+9dtXPeMvCGk+LrAW+qwZlTmC5j+WWBv7yN2oA6GivKtD8Tav4H1GLQviBMJrGV9lhrQHySeiSf3Wr1RWDKGUgqRkEcg0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxPxA0sanLDc6S6x+JdLX7Rajo0iH7ye4OD9D9a7avNPE01xqurTRQI9j4n0NvtVif4b2A/eUeoIBBHY/jQBifEjVNLl+E3ibxNA/2PUNTtVsZnzzG/C7D7jNLptkNL0b4a+GbvzHj+zJK8yHB8wKpxj0yTWF8ToIfFnjrwh4M04CO3luP7W1uyQ/dwR97PQ53CvYIfDxPiyTWLqQOkUKwWsI6RAdT9eaAJGn1FfGHlJpsX9nNAC14PvFv7prerA8I63d63BdSXmmzWHlSmNFl6uP7wqtY6beabrWsa3q+pF7VlLRwD7sKKP54oAp6fED8TdQmibcn2dVf2NV/ir8L9C+I+nRRatGYL6DPkXsQ/eR5HT/aXODg+lRfCvzNUm1fxI6tHFqE7eTG3ZAeteg0AfPnhew+Jfwg0l4rtIfFvhm3fPlwO32mCPnJQHkgddvPXivYPAnjPQ/HGijU/Dt2J4M7ZEIw8Tf3XXsa6OvAfHFrP8HfH/wDwm+h2bSeFNYcR65bRLu8iQtkTKO2SfpnI7igD36uP8feA9I8XwBru1iTUNhhW+RcTRRtw21h3xXUafe2+o2Nve2MyT2twiyxSIch1IyCKsUAeQ+B5rz4WT2vhPxPeG50KVimk6oy4CkknyZcdDk8HpXr1UNd0iy13SrnTtThE1rOpVlPUe4PYjsa43wVd33hnUT4U1x554U/5Bt9Id3mxdldifvDgUAd5dzx2ttLPMxWKNS7MATgDqcCua+HqXDaXPdXF4LxLiZnilwQ23JwDmqPxBu/FKz2mmeGLH7SuoMUmupFAjs0HUk55J54xW+3l6B4bxIHk8mIK3kIAzt0+UDHOaAMfwpNd33ifW5762W38mXyohglmUdDnpXYDFc/4Hsbyy0Qfb5JWmmcyhZfvqD0B966DPNAC45zSfhS0UAVdRvIdOsbi8uXCQQoXYk4/Cuc8C2z3a3HiG9V1utQO5UbJ8uMfdAzU/irQbjxFd2dpPKItGiYTTKp+eZx0X2HeukVQqBUACgYAHagDmPHWrw2Gn3dpOWQ3lrIkLAcb9rcH9KrfCgTP4HsFvRumjyuW5P15qHx+97dFrKwsFvJUj3xjqQxzyf0ro/C9rNZ6HaxXSBLjYDIo7HvQBq0hHOaWk/CgDH07SGh1q81O4lLSzkKqZ4RRwBWP4kOg6h4w0jT9VtZJNSgDT2soHypnrk/hXYcAZNY2h6xpuvyTz6evmrbuYvPKDBI67T1oA2sUnBIH40c+h5qlrV2un6Te3buEEMLPuPQEDj9aAPL/ABBeQXXhTxle+dLcWlxfJFBA3QSLsBx7HH6V6V4ZSRPDunLOmyQQJlRzjgV5Q1rdSeEvCeny25KX92bi48sfNnOQf5V7SiBEVFHyqMCgDn/GvhHS/GGmra6rG6yxN5ltdwnbNbSdnRux/Q965fR/FGteFNTj0Xx6nmaeQEs/EagCKc9lnA4jfH8Rwpx+Ndxr99b6dol/eXt3HZ28MLM88pwsYx94mvMPDd1e3PiBdI1KSHWPD97ZtKFZA0UkeScqp4P5UAevIwkjDo4ZGGVZTkEetPAwOK8a8MNdaXDcXvwu1GDX/DUErJc6DcysJLVh94W7kE564jbC+hruvDfjvRdcd4PMk07U4v8AXaffgRTxfVckfkTQB1fNHUU1JFkUNGQynuKUUALRRRQAUEZ4oooAzfEWh6d4i0i40zWbVLmynGHRx+RB7EdjXnHw61HU/B3iV/Avie7+0wFTJo99IcNPFn/Vtn+IdOvavWa4r4r+B4/HHh0W8Vw1nqto/wBosLtDzDKPX1B6EUAdrRWR4Ti1aDQLOLxDLHNqccYWaWPo5A+9+Na9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Fallopian tube is grasped with the bipolar device and cauterized in adjacent areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30000=[""].join("\n");
var outline_f29_19_30000=null;
var title_f29_19_30001="Vessel changes in optic fundi";
var content_f29_19_30001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Vessel changes in optic fundi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vessel changes in the optic fundi of patients with cerebral malaria. Vessels which are normally red in color become orange or yellow because they contain parasitized red cells. The parasite consumes some of the hemoglobin in solution, so those red cells become less red. In the image on the left, all three features of malarial retinopathy are present (white-centered hemorrhages, vessel changes and whitening in areas of the retina).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Lewallen and Nicholas Beare.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30001=[""].join("\n");
var outline_f29_19_30001=null;
var title_f29_19_30002="Patient information: Subarachnoid hemorrhage (The Basics)";
var content_f29_19_30002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17180\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/49/29459\">",
"         Subarachnoid hemorrhage",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/17/5394\">",
"         Patient information: Brain aneurysm (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/34/22050\">",
"         Patient information: Hemorrhagic stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/63/8180\">",
"         Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Subarachnoid hemorrhage (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/subarachnoid-hemorrhage-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H19129030\">",
"      <span class=\"h1\">",
"       What is a subarachnoid hemorrhage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A subarachnoid hemorrhage is a type of stroke that causes bleeding around your brain. &ldquo;Hemorrhage&rdquo; is the medical term for bleeding.",
"     </p>",
"     <p>",
"      If you have a subarachnoid hemorrhage, the bleeding happens in a part of your head called the &ldquo;subarachnoid space.&rdquo; This is the area between your brain and the thin layer of tissue that covers it (",
"      <a class=\"graphic graphic_figure graphicRef61435 \" href=\"UTD.htm?28/49/29459\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      The most common cause of a subarachnoid hemorrhage is a bulging blood vessel that bursts. Doctors call this a &ldquo;ruptured aneurysm.&rdquo;",
"     </p>",
"     <p>",
"      A subarachnoid hemorrhage is life threatening, especially when it is caused by a ruptured aneurysm. Many people who have a subarachnoid hemorrhage die from it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19129045\">",
"      <span class=\"h1\">",
"       What are the symptoms of a subarachnoid hemorrhage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is a sudden and very painful headache. It can feel like the worst headache you ever had.",
"     </p>",
"     <p>",
"      Other symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fainting (passing out)",
"       </li>",
"       <li>",
"        Having a seizure",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Stiff neck",
"       </li>",
"       <li>",
"        Being bothered by bright light",
"       </li>",
"       <li>",
"        Low back pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19129060\">",
"      <span class=\"h1\">",
"       Is there a test for subarachnoid hemorrhage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor suspects you have had a subarachnoid hemorrhage, he or she can order one or more of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        CT scan of your head - This test uses a type of X-ray to take pictures of the inside of your head. If there is bleeding around your brain, a CT scan will likely show it. &nbsp;",
"       </li>",
"       <li>",
"        Lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor puts a needle into your lower back and takes out a small sample of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. If this fluid has more red blood cells than usual, you could have a subarachnoid hemorrhage. This test is done if the CT scan does not show bleeding but your doctor still thinks you might have a subarachnoid hemorrhage.",
"       </li>",
"       <li>",
"        Other imaging tests &ndash; If the CT scan or lumbar puncture shows a subarachnoid hemorrhage, your doctor might do other tests to see if the cause is a ruptured aneurysm. These tests include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        CT angiography (often called &ldquo;CTA&rdquo;) or magnetic resonance angiography (often called &ldquo;MRA&rdquo;) &ndash; These tests use special types of CT and MRI scans to create pictures of the blood vessels in the brain. Doctors use a dye injection in CTA, and sometimes in MRA. The dye is a chemical that makes blood vessels show up more clearly. &nbsp;",
"       </li>",
"       <li>",
"        Catheter angiography &ndash; For this test, the doctor puts a thin tube into a large artery in your leg. Then the doctor moves the tube into the large blood vessels that carry blood to your head. Next the doctor injects a dye into the tube that shows up on an X-ray. The dye can show problems with the blood vessels in the brain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19129075\">",
"      <span class=\"h1\">",
"       How is a subarachnoid hemorrhage treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people who have a subarachnoid hemorrhage go to the intensive care unit (ICU) of a hospital for treatment. In the hospital, the doctor might:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Give medicines and other treatments to reduce the brain damage caused by the bleeding",
"       </li>",
"       <li>",
"        Give medicines such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?20/21/20821?source=see_link\">",
"         labetalol",
"        </a>",
"        (brand name: Trandate",
"        <sup>",
"         &reg;",
"        </sup>",
"        ) to",
"       </li>",
"       <li>",
"        lower blood pressure if it is too high",
"       </li>",
"       <li>",
"        Stop medicines that thin the blood, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"         warfarin",
"        </a>",
"        (brand names: Coumadin",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Jantoven",
"        <sup>",
"         &reg;",
"        </sup>",
"        ). If you take blood-thinning medicines, your doctor might give you treatments to help your blood clot. This can help stop bleeding.",
"       </li>",
"       <li>",
"        Do tests to figure out the cause of the bleeding",
"       </li>",
"       <li>",
"        Watch the pressure in the brain to make sure it does not get too high",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If an aneurysm caused the subarachnoid hemorrhage, doctors must do surgery or another procedure to keep the bleeding from happening again. Depending on the size and location of the aneurysm, they might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Do surgery to put a small clip on the aneurysm.",
"       </li>",
"       <li>",
"        Put tiny coils in the aneurysm. (This is done during a catheter angiography procedure.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After a subarachnoid hemorrhage, most people stay in the ICU for a few days, weeks, or sometimes longer. Doctors and nurses watch for problems such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Irregular heartbeat",
"       </li>",
"       <li>",
"        Seizures",
"       </li>",
"       <li>",
"        Blood clots in the legs",
"       </li>",
"       <li>",
"        Lung infections",
"       </li>",
"       <li>",
"        Electrolytes out of balance &ndash; Electrolytes are chemicals in the body that must be present in the right amounts for your body to work correctly &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19129090\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A subarachnoid hemorrhage is very serious. Many people die from this type of stroke. Many people who survive &ndash; but not all &ndash; have long lasting health problems afterwards.",
"     </p>",
"     <p>",
"      People who have severe subarachnoid hemorrhages can have certain health problems later, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Memory problems",
"       </li>",
"       <li>",
"        Mood changes or problems with emotions",
"       </li>",
"       <li>",
"        Thinking problems",
"       </li>",
"       <li>",
"        Trouble speaking, walking, or doing other activities",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For some people, these problems can be disabling. For others, they may not exist or cause only mild problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H19129107\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=see_link\">",
"       Patient information: Hemorrhagic stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/17/5394?source=see_link\">",
"       Patient information: Brain aneurysm (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=see_link\">",
"       Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/19/30002?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17180 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-201.248.109.99-36184B143A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30002=[""].join("\n");
var outline_f29_19_30002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19129030\">",
"      What is a subarachnoid hemorrhage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19129045\">",
"      What are the symptoms of a subarachnoid hemorrhage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19129060\">",
"      Is there a test for subarachnoid hemorrhage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19129075\">",
"      How is a subarachnoid hemorrhage treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19129090\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19129107\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17180\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/49/29459\">",
"      Subarachnoid hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/17/5394?source=related_link\">",
"      Patient information: Brain aneurysm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=related_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_19_30003="Valacyclovir: An overview";
var content_f29_19_30003=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Valacyclovir: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30003/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30003/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30003/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30003/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30003/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30003/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/19/30003/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    is the valyl ester of the antiviral drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/1\">",
"     1",
"    </a>",
"    ]. Acting as an oral prodrug, valacyclovir is converted in vivo to acyclovir. Acyclovir, a nucleoside analog, is phosphorylated by virally-encoded thymidine kinase and subsequently by cellular enzymes, yielding acyclovir triphosphate, which competitively inhibits viral DNA polymerase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link\">",
"     \"Acyclovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiviral activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    reflects its in vivo conversion to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , which is active against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus. Cytomegalovirus (CMV), which does not encode thymidine kinase, is resistant at the oral doses approved by the US Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    has three to fivefold greater oral bioavailability (about 55 percent) than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ; it then undergoes rapid and extensive first-pass intestinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic hydrolysis to yield acyclovir and L-valine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Food does not affect absorption.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    , at a dose of 250 mg four times daily, generates essentially the same",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    AUC (area under the curve, or exposure over 24 hours) as oral acyclovir at a dose 800 mg five times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/3\">",
"     3",
"    </a>",
"    ]. Valacyclovir, at a dose of 1000 mg three times daily, produces a similar acyclovir AUC as intravenous acyclovir at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    generates higher peak levels than oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    . Although this feature may confer more potent activity, it may also increase the risk of renal toxicity due to precipitation of acyclovir crystals in the renal tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/3\">",
"     3",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    ). On the other hand, the safety of high-dose oral valacyclovir, especially in immunocompromised persons, remains controversial.",
"   </p>",
"   <p>",
"    The main route of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    elimination is renal, and dose modification is recommended for patients with a creatinine clearance below 30",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2. Dose adjustment is not required in patients with hepatic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H499155513\">",
"    <span class=\"h1\">",
"     MECHANISM OF RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    are identical to those described for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced or absent thymidine kinase",
"     </li>",
"     <li>",
"      Altered thymidine kinase activity resulting in decreased",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      phosphorylation",
"     </li>",
"     <li>",
"      Altered viral DNA polymerase with decreased affinity for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      triphosphate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H4#H4\">",
"     \"Acyclovir: An overview\", section on 'Mechanism of resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When administered at approved doses (up to 1000 mg three times daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    has been remarkably well tolerated, similar to the experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a trial examining the effectiveness of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (2000 mg four times daily) in preventing cytomegalovirus (CMV) disease was halted when interim analysis revealed significantly shorter survival in patients receiving this regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/6\">",
"     6",
"    </a>",
"    ]. This complication has also been observed at this high dose in recipients of allogeneic bone marrow or kidney transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Much of this phenomenon was attributed to the development of a thrombotic microangiopathy associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ; however, causality has not been established conclusively, since several other medications (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    , clofazimine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) were also significantly associated with this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     USE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    has been assigned to Pregnancy Category B, which denotes no clear evidence of risk in humans despite the lack of controlled studies documenting safety. For certain patients, the potential benefits may outweigh the potential risks to the fetus. In order to monitor the outcome of pregnancies exposed to this drug, Glaxo Wellcome Inc. maintains a Valacyclovir in Pregnancy Registry at 800-722-9292, extension 39437 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30003/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    can generally be regarded as an acceptable alternative to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    when this drug is indicated and features a more convenient dosing schedule. The use of valacyclovir for patients with herpes zoster and genital herpes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of herpes zoster in the immunocompetent host\", section on 'Clinical trial data on antiviral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564280\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      is converted in vivo to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , a nucleoside analog that competitively inhibits viral DNA polymerase. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      is active in vitro against herpes simplex viruses types 1 and 2, varicella-zoster virus, and Epstein-Barr virus (EBV), but is not usually used clinically for EBV infections. Valacyclovir has three to fivefold greater oral bioavailability (about 55 percent) than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Basic pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism of resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      is identical to that described for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      . Three mechanisms have been shown to endow herpes simplex viruses with resistance to acyclovir, a phenomenon rare in the immunocompetent host: reduced or absent thymidine kinase, altered thymidine kinase activity, and altered viral DNA polymerase with decreased affinity for acyclovir triphosphate. (See",
"      <a class=\"local\" href=\"#H499155513\">",
"       'Mechanism of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When administered at approved doses (up to 1000 mg three times daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      is well tolerated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      has been assigned to Pregnancy Category B, which denotes no clear evidence of risk in humans despite the lack of controlled studies documenting safety. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Use in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      can generally be regarded as an acceptable alternative to oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      when this drug is indicated and offers a more convenient dosing schedule. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Valtrex (valacyclovir hydrochloride) Product Information, Glaxo Wellcome Inc, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30003/abstract/2\">",
"      Alrabiah FA, Sacks SL. New antiherpesvirus agents. Their targets and therapeutic potential. Drugs 1996; 52:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30003/abstract/3\">",
"      Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30003/abstract/4\">",
"      H&ouml;glund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30003/abstract/5\">",
"      Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30003/abstract/6\">",
"      Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30003/abstract/7\">",
"      Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore) 1997; 76:369.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8337 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30003=[""].join("\n");
var outline_f29_19_30003=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1564280\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H499155513\">",
"      MECHANISM OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      USE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564280\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_19_30004="X-ray scaphoid fracture lateral view";
var content_f29_19_30004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    X-ray scaphoid fracture lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral view of the left wrist (A, magnified in B) reveals a fracture through the scaphoid (arrow). A small fragment has been displaced from the fracture line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30004=[""].join("\n");
var outline_f29_19_30004=null;
var title_f29_19_30005="Contact dermatitis bullae";
var content_f29_19_30005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles and bullae developed on the volar forearm after application of perfume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Elder AD, Elenitsas R, Johnson BL, et al. Synopsis and Atlas of Lever's Histopathology of the Skin, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30005=[""].join("\n");
var outline_f29_19_30005=null;
var title_f29_19_30006="Buspirone: Drug information";
var content_f29_19_30006=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Buspirone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/2/21540?source=see_link\">",
"    see \"Buspirone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/55/11126?source=see_link\">",
"    see \"Buspirone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Buspirone&reg;;",
"     </li>",
"     <li>",
"      BuSpar&reg;;",
"     </li>",
"     <li>",
"      Bustab&reg;;",
"     </li>",
"     <li>",
"      Dom-Buspirone;",
"     </li>",
"     <li>",
"      Novo-Buspirone;",
"     </li>",
"     <li>",
"      Nu-Buspirone;",
"     </li>",
"     <li>",
"      PMS-Buspirone;",
"     </li>",
"     <li>",
"      Riva-Buspirone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianxiety Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anxiety disorders (GAD): Oral: 15 mg/day (7.5 mg twice daily); may increase in increments of 5 mg/day every 2-3 days to a maximum of 60 mg/day. Target dose for most people is 20-30 mg/day (10-15 mg twice daily).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 5 mg twice daily, increase by 5 mg/day every 2-3 days as needed up to 20-30 mg/day; maximum daily dose: 60 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F143301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with impaired renal function demonstrated increased plasma levels and a prolonged half-life of buspirone. Use in patients with severe renal impairment not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F143302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with impaired hepatic function demonstrated increased plasma levels and a prolonged half-life of buspirone. Use in patients with severe hepatic impairment not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 7.5 mg, 10 mg, 15 mg, 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of generalized anxiety disorder (GAD)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F143334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of aggression in mental retardation and secondary mental disorders; major depression; potential augmenting agent for antidepressants; premenstrual syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       BusPIRone may be confused with buPROPion",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Dizziness (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness (10%), headache (6%), nervousness (5%), lightheadedness (3%), anger/hostility (2%), confusion (2%), excitement (2%), dream disturbance (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (8%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness (2%), weakness (2%), incoordination (1%), musculoskeletal pain (1%), paresthesia (1%), tremor (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (&ge;1%), sore throat (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Akathisia, alcohol abuse, allergic reaction, alopecia, ALT increased, amenorrhea, angioedema, anorexia, AST increased, ataxia, bleeding disorder, bradycardia, bruising, cardiomyopathy, claustrophobia, cogwheel rigidity, conjunctivitis, CVA, dyskinesia, dystonia, edema, enuresis, eosinophilia, epistaxis, EPS, extrapyramidal symptoms, galactorrhea, hallucination, heart failure, hyper-/hypotension, hyperventilation, irritable colon, leukopenia, memory impairment, menstrual irregularity, MI, ocular pressure increased, parkinsonism, personality disorders, photophobia, PID, psychosis, rectal bleeding, restless leg syndrome, seizure, serotonin syndrome, slow reaction time, slurred speech, suicidal ideation, syncope, thrombocytopenia, thyroid abnormality, transaminase increases, visual disturbances (tunnel vision)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to buspirone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cognitive/motor impairment: Low potential for cognitive or motor impairment; until effects on patient known, patients should be warned to use caution when performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Restlessness syndrome: Has been reported in small number of patients; may be attributable to buspirone&rsquo;s antagonism of central dopamine receptors. Monitor for signs of any dopamine-related movement disorders (eg, dystonia, akathisia, pseudo-parkinsonism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use in patients with severe hepatic impairment is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use in patients with severe renal impairment is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Use with MAO inhibitors may result in hypertensive reactions; concurrent use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy of buspirone have not been established in children &lt;6 years of age. No long-term safety/efficacy data available in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedative/hypnotic withdrawal: Buspirone does not exhibit cross-tolerance with benzodiazepines or other sedative/hypnotic agents. If substituting buspirone for any of these agents, gradually withdraw the drug(s) prior to initiating buspirone.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): BusPIRone may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of BusPIRone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: BusPIRone may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of BusPIRone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: BusPIRone may enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: BusPIRone may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of BusPIRone. Management: The degree to which rifampin alters buspirone concentrations warrants the consideration of an alternative to buspirone that is not metabolized by CYP3A4.  If these agents are used together, buspirone dose adjustments may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: BusPIRone may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F143290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may decrease the absorption of buspirone, but it may also decrease the first-pass metabolism, thereby increasing the bioavailability of buspirone. Grapefruit juice may cause increased buspirone concentrations. Management: Avoid intake of large quantities of grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease buspirone levels or increase CNS depression. Kava kava, valerian, and gotu kola may increase CNS depression; yohimbe may diminish the therapeutic effect of buspirone. Management: Avoid St John's wort, kava kava, valerian, gotu kola, and yohimbe.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5628102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16136355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if buspirone is excreted in breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9460172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid large quantities of grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (BusPIRone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $77.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $158.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $134.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $201.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (60): $218.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F143269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mental status, symptoms of anxiety",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F143281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actium (PY);",
"     </li>",
"     <li>",
"      Ansial (AR);",
"     </li>",
"     <li>",
"      Ansitec (BR);",
"     </li>",
"     <li>",
"      Anxiolan (TH);",
"     </li>",
"     <li>",
"      Anxiron (AE, BH, CY, EG, HN, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Anxut (DE);",
"     </li>",
"     <li>",
"      Bespar (DE, GR);",
"     </li>",
"     <li>",
"      Buporin (TW);",
"     </li>",
"     <li>",
"      Busiral (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Busp (TW);",
"     </li>",
"     <li>",
"      Buspar (AT, AU, BE, CH, CZ, DK, EC, EE, ES, FI, FR, GB, HK, IE, IT, KP, LU, MT, MX, NL, NO, NZ, PK, PT, RU, SE, SK, TR, ZA);",
"     </li>",
"     <li>",
"      Busparium (UY);",
"     </li>",
"     <li>",
"      Buspin (IN);",
"     </li>",
"     <li>",
"      Buspon (TR);",
"     </li>",
"     <li>",
"      Dalpas (VE);",
"     </li>",
"     <li>",
"      Dergelasen (CO);",
"     </li>",
"     <li>",
"      Kallmiren (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Normaton (DO, GT, PA, SV);",
"     </li>",
"     <li>",
"      Pasrin (ZA);",
"     </li>",
"     <li>",
"      Paxon (CN);",
"     </li>",
"     <li>",
"      Relac (TW);",
"     </li>",
"     <li>",
"      Sepirone (TW);",
"     </li>",
"     <li>",
"      Sorbon (IL);",
"     </li>",
"     <li>",
"      Spamilan (PL);",
"     </li>",
"     <li>",
"      Spitomin (BG, HU);",
"     </li>",
"     <li>",
"      Suxin (CL);",
"     </li>",
"     <li>",
"      Travin (HR);",
"     </li>",
"     <li>",
"      Xiety (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The mechanism of action of buspirone is unknown. Buspirone has a high affinity for serotonin 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     receptors, without affecting benzodiazepine-GABA receptors. Buspirone has moderate affinity for dopamine D",
"     <sub>",
"      2",
"     </sub>",
"     receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 5.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 86% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic oxidation, primarily via CYP3A4; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 40-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine: 29% to 63% (&lt;0.1% dose excreted unchanged); feces: 18% to 38%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Buitelaar JK, van der Gaag RJ, and van der Hoeven J, &ldquo;Buspirone in the Management of Anxiety and Irritability in Children With Pervasive Developmental Disorders: Results of an Open-Label Study,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1998, 59(2):56-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carrey NJ, Wiggins DM, and Milin RP, &ldquo;Pharmacological Treatment of Psychiatric Disorders in Children and Adolescents,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1996, 51(5):750-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fanciullacci M, Sicuteri R, Alessandri M, et al, &ldquo;Buspirone, But Not Sumatriptan, Induces Miosis in Humans: Relevance for a Serotoninergic Pupil Control,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(3):349-55.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gammans RE, Mayol RF, and LaBudde JA, &ldquo;Metabolism and Disposition of Buspirone,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1986, 80(3B):41-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30006/abstract-text/3515929/pubmed\" id=\"3515929\" target=\"_blank\">",
"        3515929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gammans RE, Westrick ML, Shea JP, et al, &ldquo;Pharmacokinetics of Buspirone in Elderly Subjects,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1989, 29(1):72-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goetz CM, Krenzelok EP, Lopez G, et al, &ldquo;Buspirone Toxicity: A Prospective Study,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1989, 31:371.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green WH,",
"      <i>",
"       Child and Adolescent Clinical Psychopharmacology",
"      </i>",
"      , 3rd ed, Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanna GL, Feibusch EL, and Albright KJ, &ldquo;Buspirone Treatment of Anxiety, Associated With Pharyngeal Dysphagia in a Four-Year Old,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1997, 7(2):137-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jann MW, &ldquo;Buspirone: An Update on a Unique Anxiolytic Agent,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1988, 8(2):100-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30006/abstract-text/3041384/pubmed\" id=\"3041384\" target=\"_blank\">",
"        3041384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kivisto KT, Lamberg TS, and Kantola T, &ldquo;Plasma Buspirone Concentrations Are Greatly Increased by Erythromycin and Itraconazole,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1997, 62(3):348-54.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kunik ME, Yudofsky SC, Silver JM, et al, &ldquo;Pharmacologic Approach to Management of Agitation Associated With Dementia,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1994, 55(Suppl 2):13-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kutcher SP, Reiter S, Gardner DM, et al, &ldquo;The Pharmacotherapy of Anxiety Disorders in Children and Adolescents,&rdquo;",
"      <i>",
"       Psychiatr Clin North Am",
"      </i>",
"      , 1992, 15(1):41-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, et al, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2:132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIvor RJ and Sinanan K, &ldquo;Buspirone-Induced Mania,&rdquo;",
"      <i>",
"       Br J Psychiatry",
"      </i>",
"      , 1991, 158:136-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Norden MJ, &ldquo;Buspirone Treatment of Sexual Dysfunction Associated With Selective Serotonin Reuptake Inhibitors,&rdquo;",
"      <i>",
"       Depression",
"      </i>",
"      , 1994, 2:109-12.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer CR, Jiang H, and Domeshek LJ, &ldquo;Buspirone Treatment of Psychiatrically Hospitalized Prepubertal Children With Symptoms of Anxiety and Moderately Severe Aggression,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1997, 7(3):145-55.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Preskorn SH, &ldquo;Recent Pharmacologic Advances in Antidepressant Therapy for the Elderly,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1993, 94(5A):2S-12S.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schweizer E and Rickels K, &ldquo;New and Emerging Clinical Uses for Buspirone,&rdquo;",
"      <i>",
"       J Clin Psychiatry Monograph",
"      </i>",
"      , 1994, 12(1):46-54.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeon JG, Knott VJ, DuBois C, et al, &ldquo;Buspirone Therapy of Mixed Anxiety Disorders in Childhood and Adolescence: A Pilot Study,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 1994, 4(3):159-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soni P and Weintraub AL, &ldquo;Buspirone-Associated Mental Status Changes,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1992, 31(6):1098-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sussman N, &ldquo;The Usage of Buspirone in Psychiatry,&rdquo;",
"      <i>",
"       J Clin Psychiatry Monograph",
"      </i>",
"      , 1994, 12(1):3-19.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tiller JW, Burrows GD, and O'Sullivan BT, &ldquo;Buspirone Overdose,&rdquo;",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 1989, 150(1):54-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weis KJ, &ldquo;Management of Anxiety and Depression Syndromes in Elderly,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1994, 55(Suppl 2):5-12.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9172 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-8539BEA455-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30006=[""].join("\n");
var outline_f29_19_30006=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143295\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143337\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143299\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143300\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143301\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143302\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143271\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143257\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143274\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143334\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143346\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143335\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143277\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143261\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143331\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143266\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143290\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143267\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5628102\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143304\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136355\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460172\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143280\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143269\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143281\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143260\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143276\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9172\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9172|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/2/21540?source=related_link\">",
"      Buspirone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/55/11126?source=related_link\">",
"      Buspirone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_19_30007="Monitoring of the patient with classical Hodgkin lymphoma during and after treatment";
var content_f29_19_30007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30007/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30007/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30007/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30007/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30007/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30007/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/19/30007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Hodgkin lymphoma (formerly called Hodgkin's disease) are evaluated at the time of initial presentation to determine the stage of the disease, which is then used to determine whether the patient will be treated with radiotherapy, chemotherapy, or both. Patients are then re-evaluated at regular intervals during and after treatment to assess the response and detect possible recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended approach to monitoring during and after therapy for Hodgkin lymphoma will be reviewed here. The treatment of patients who develop recurrent disease depends upon whether they were initially treated with radiotherapy or chemotherapy. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=see_link\">",
"     \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient evaluation after individual treatment cycles consists of a history and physical examination, laboratory studies, and imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should be directed toward the presence or absence of B symptoms (fever, weight loss, and night sweats) or treatment-related toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .) Performance status should be recorded after each treatment cycle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should document both the reduction in size of previous sites of lymphadenopathy and the continued absence of involvement of previously unaffected sites. This is particularly important with cyclical chemotherapy, which may be discontinued or changed if the patient fails to show objective evidence of response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete blood counts, serum electrolytes, and liver function tests are followed with each cycle of chemotherapy treatment. Therapy should be altered based upon these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of computed tomography (CT) scans and positron emission tomography (PET) is the current preferred approach to radiologic work-up of patients with Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Checking a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    mid-treatment is controversial, but often done in clinical practice. While it is clear that mid-treatment",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    provides prognostic information, there are no prospective data to guide patient care based on the results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/8\">",
"     8",
"    </a>",
"    ]. Additionally, there is controversy regarding the interpretation of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scans and what constitutes a positive or negative scan in this scenario.",
"   </p>",
"   <p>",
"    Studies are in progress to determine whether mid-treatment PET scanning can be used to determine whether or not adjuvant involved field radiation is needed in individual patients with early stage disease, or to modify the treatment approach in patients who continue to have PET-positive disease after one or more courses of chemotherapy. As an example, one large trial evaluating this question (the EORTC H10 trial) has separate randomized arms for chemotherapy alone if the PET scan is normal after two cycles of chemotherapy. However, both the favorable stage I-II and unfavorable stage I-II arms with chemotherapy alone in PET negative patients have been closed due to stopping rules in these arms. A similar study, the UK RAPID trial, is ongoing. While awaiting more data, PET scanning should not be used to determine the need for adjuvant radiation therapy in patients with stage I-II Hodgkin lymphoma outside of a clinical trial.",
"   </p>",
"   <p>",
"    In summary, there is no current consensus approach to the evaluation of the patient undergoing chemotherapy. At our institution, a history, physical examination, and laboratory studies are performed before each cycle of chemotherapy. If no response is observed by the third or fourth cycle, changes to the therapeutic regimen are considered.",
"   </p>",
"   <p>",
"    Although in patients with advanced stage disease PET scanning at the end of treatment is prognostic for frequency of recurrence, its importance in early stage patients who are to receive radiation therapy is less clear. Several studies have evaluated the role of PET after completion of treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of 260 patients with newly diagnosed advanced stage HL underwent PET scanning after two cycles of ABVD [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/6\">",
"       6",
"      </a>",
"      ]. Approximately half of these were combined",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scans and half were dedicated PET scans. Treated physicians were blinded to PET results. No treatment change was allowed on the basis of these scans and patients finished chemotherapy with or without radiation therapy as initially planned. The two-year progression-free survival was significantly lower for patients with a positive PET scan (13 versus 95 percent).",
"     </li>",
"     <li>",
"      A second study of 81 patients examined the predictive value of PET scans performed after the completion of Stanford V chemotherapy but before the initiation of planned radiation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/9\">",
"       9",
"      </a>",
"      ]. Again, some scans were performed with a combined",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scanner and some were performed with a dedicated PET scanner. At a median follow-up of four years, freedom from disease progression was statistically lower in patients who had positive PET scans after chemotherapy but before radiation therapy (33 versus 96 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of PET in the follow-up of patients after completion of treatment is even more controversial because of the high false positive rates seen with",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning. In our practice, once a patient has a negative PET, we switch our radiographic surveillance to chest and abdominal pelvic CT scans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876933\">",
"    <span class=\"h2\">",
"     Monitoring for chemotherapy-specific toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throughout the course of treatment, patients should be monitored periodically for chemotherapy-related toxicities that may affect the treatment course, specifically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    -induced neuropathy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced pneumonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876964\">",
"    <span class=\"h3\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathy is an uncommon yet potentially serious complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    administration. The neuropathy can involve both motor and sensory neurons and often presents with paresthesias in the fingertips and feet, with or without muscle cramps. Constipation is also frequently seen. The diagnosis of vinblastine-associated neuropathy is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link&amp;anchor=H19#H19\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Other microtubule binding agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1876971\">",
"    <span class=\"h3\">",
"     Pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    therapy is associated with a potentially life-threatening interstitial pulmonary fibrosis (also called fibrosing alveolitis) in up to 10 percent of patients receiving the drug. Symptoms and signs include nonproductive cough, dyspnea, pleuritic or substernal chest pain, fever, tachypnea, auscultatory crackles, lung restriction, and hypoxemia. Although the symptoms and signs usually develop subacutely between one and six months after bleomycin treatment, they may occur while the patient is still receiving therapy.",
"   </p>",
"   <p>",
"    We do not perform routine pulmonary function testing (PFT) during therapy, but any complaints of dyspnea or cough should prompt a chest radiograph and PFTs (with diffusing capacity for carbon monoxide) to rule out evolving pneumonitis. The diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     AFTER TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;One to two months following the completion of planned therapy (or sooner if the outcome is unfavorable), the response should be documented by history, physical examination, and laboratory studies (complete blood count, erythrocyte sedimentation rate, and biochemical profile). Persistent and otherwise unexplained elevation of the erythrocyte sedimentation rate, while not diagnostic of active disease, is an indication for close surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up imaging studies should be obtained one month after finishing chemotherapy in those who do not receive radiation therapy. Among those in whom radiation therapy is also performed, follow-up imaging studies should be obtained three to six months after its completion.",
"   </p>",
"   <p>",
"    The imaging study of choice is a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which provides information on the size and activity of residual masses and allows the distinction of active disease versus fibrosis, but once the PET scan normalizes, only CT scans should be performed (see above). In unusual or highly suspicious lesions (ie, bone lesions), tissue biopsy may be required to establish the presence or absence of active disease. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Radiologic studies'",
"    </a>",
"    <span class=\"nowrap\">",
"     above.)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     PET/CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET/CT",
"    scan is the examination of choice for detecting disease activity during and right after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Compared with CT scan alone,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning is better able to distinguish between active tumor and necrosis or fibrosis in residual masses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/12,16-26\">",
"     12,16-26",
"    </a>",
"    ]. A positive PET scan can be determined by visual assessment and does not require the use of the standardized uptake value (SUV) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The negative predictive value of PET, or the ability of a negative scan to exclude persistent disease or future relapse, averages 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/13\">",
"     13",
"    </a>",
"    ]. There is a 10 to 20 percent false-negative rate, which is likely due to the inability of imaging techniques to detect microscopic disease.",
"   </p>",
"   <p>",
"    As an example, of 817 patients with newly diagnosed advanced stage HL who received BEACOPP-based chemotherapy as part of the GHSG HD15 trial, 311 of these patients had residual disease measuring 2.5 cm or greater after completion of planned chemotherapy and therefore underwent PET scan [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/29\">",
"     29",
"    </a>",
"    ]. Twelve-month rates of progression and relapse free survival were 85 and 96 percent for patients with a positive or negative PET scan, respectively. Although this suggests that radiation therapy may be avoided in patients with a negative PET scan after BEACOPP based therapy, the follow-up time in this study is too short to make this a current recommendation.",
"   </p>",
"   <p>",
"    The positive predictive value (PPV) of PET scans in response assessment is more variable with an average of 65 percent. Up to 40 percent of patients with a positive PET scan will not relapse. It is therefore imperative that positive PET scans be confirmed by tissue biopsy prior to giving more therapy. Causes of false positive PET scans include post-inflammatory changes after chemotherapy and radiation treatment, rebound thymic hyperplasia, infectious and inflammatory processes, and brown fat [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/30\">",
"     30",
"    </a>",
"    ]. This high frequency of false positive PET scans after treatment raises the question of whether CT scans should be used in place of PET scans once a baseline negative PET scan has been obtained. In our practice, CT scanning is the preferred follow-up imaging study for patients who attain a complete remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is used in the initial staging of Hodgkin lymphoma and is a key component of re-assessing disease status after treatment. CT scans should include all areas of previous disease involvement and new areas of increased activity on PET scan or physical exam. CT is performed with contrast if it is done alone, but without contrast if it is performed as part of a combined",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    study.",
"   </p>",
"   <p>",
"    Since mediastinal nodes are involved in the majority of patients at presentation, chest CT scanning has a significant role in assessing the response to therapy in Hodgkin lymphoma. Following mediastinal irradiation, the reassessment chest CT should be postponed for three to six months; regression of disease may be slow after radiation therapy and, if evaluation is performed too early, a residual mass may still be visible.",
"   </p>",
"   <p>",
"    Any residual abnormality seen on CT after radiation therapy must be evaluated to distinguish between residual fibrosis and necrosis and active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/16\">",
"     16",
"    </a>",
"    ]. This distinction can be made by serial studies over time since benign disease will remain stable or decrease in size [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/17,31\">",
"     17,31",
"    </a>",
"    ], while persistent Hodgkin lymphoma will at some time begin to increase in size. An abnormal widening of the mediastinum or architectural distortion of lymphographic studies may persist for many years without therapy and without evidence of recurrent Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/17,31,32\">",
"     17,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is evidence of worsening disease in the follow-up CT scans, then the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be helpful to additional evidence of a potential recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance (MR) imaging is not usually employed in the follow-up of patients with Hodgkin lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bone marrow biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow involvement eventually occurs in approximately 7 percent of patients with HL, although involvement at presentation is exceptionally rare. If the bone marrow was involved at initial diagnosis, a repeat bone marrow biopsy should be performed after treatment to assess response. A bone marrow biopsy should also be performed in the patient with persistently abnormal blood counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In unusual or highly suspicious lesions (eg, bone lesions) as detected by",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, tissue biopsy is required to establish the presence or absence of active disease. Biopsy must document persistent lymphoma in cases of progressive disease or relapse before proceeding with further salvage therapy.",
"   </p>",
"   <p>",
"    A positive PET scan in a previously negative site as determined by",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan may represent active disease or a false positive. In this setting, a CT scan should be performed to confirm the abnormality:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If a mass is detected by CT scan, recurrent disease is most likely. Most clinicians would obtain a biopsy to help guide further therapy.",
"     </li>",
"     <li>",
"      If a mass cannot be found by CT scan,",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scans should be repeated at regular intervals until the PET reverts to normal.",
"     </li>",
"     <li>",
"      If the CT scan is most consistent with an inflammatory process and not recurrent malignancy, serial",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scans",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other modalities may be used to follow the lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1515431811\">",
"    <span class=\"h1\">",
"     RESPONSE CATEGORIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Working Group (IWG) response criteria originally defined clinical and computed tomography (CT) based categories of complete remission, complete remission unconfirmed, partial remission, stable disease, and progressive disease. In 2007, revised IWG response criteria were devised to incorporate positron emission tomography (PET) scan findings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30007/abstract/13\">",
"     13",
"    </a>",
"    ]. This eliminated the category of complete remission unconfirmed. The following is a summary of these criteria (",
"    <a class=\"graphic graphic_table graphicRef58779 \" href=\"UTD.htm?38/42/39596\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1515431818\">",
"    <span class=\"h2\">",
"     Complete remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in complete remission (CR) have no clinical evidence of disease or disease-related symptoms. Since HL is typically FDG-avid, a post-treatment residual mass of any size is permitted as long as it is PET negative. Spleen and liver must be non-palpable and without nodules. If a pre-treatment bone marrow biopsy was positive, an adequate bone marrow biopsy (with a core size of at least 20mm) from the same site must be cleared of infiltrate; if this is indeterminate by morphology, immunohistochemistry should be negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1515431825\">",
"    <span class=\"h2\">",
"     Partial remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial remission (PR) is defined as a decrease by at least 50 percent in the sum of the products of the largest perpendicular diameters (SPD) of up to six of the largest measurable lesions. Since HL is typically FDG-avid, the post-treatment PET should be positive in at least one previously involved site. There should be no increase in the size of other nodes, liver, or spleen and no new areas of disease. Splenic or hepatic nodules must decrease by at least 50 percent in the SPD (or in the greatest transverse diameter for single nodules). Bone marrow biopsy results are not useful in determining PR. However, if the patient otherwise fits the CR criteria but has a positive bone marrow biopsy, the patient is labeled as having a PR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1515431832\">",
"    <span class=\"h2\">",
"     Stable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stable disease (SD) occurs when treatment fails to attain a CR or PR but does not have progressive disease. Since HL is typically FDG-avid, the post-treatment PET should be positive at prior sites of disease and no new sites should be present on PET or CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1515431839\">",
"    <span class=\"h2\">",
"     Progressive disease or relapse after CR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse after CR or progressive disease (PD) is defined as having any new lesion or an increase from nadir by at least 50 percent of previously involved sites. Development of a new lesion is defined by the appearance of any new lesion more than 1.5 cm in long axis. If the long axis diameter is from 1.1 to 1.5 cm, the lesion should only be considered abnormal if its short axis is more than 1.0 cm. PD is also defined as increase of at least 50 percent in the longest diameter of a previously identified node more than 1 cm in short axis or in the SPD of more than one node. Lesions should be PET positive unless they are below a detectable size (ie, &lt;1.5 cm in long axis by CT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20583337\">",
"    <span class=\"h1\">",
"     LONG-TERM FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy and restaging after the documentation of complete response, patients are seen at periodic intervals to assess a possible relapse and for the emergence of long-term toxicities. When planning the post-treatment surveillance strategy, care should be taken to limit the number of computed tomography (CT) scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. There is no role for routine positron emissions tomography (PET) or",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging in the longitudinal follow-up of asymptomatic patients after response assessment. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=see_link\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167671657\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Throughout treatment, patients should be asked about the presence or absence of B symptoms, treatment-related toxicities, and markers of performance status. Tumor measurements should be recorded and complete blood counts, serum electrolytes, and liver function tests are followed with each cycle of chemotherapy treatment. While the combination of computed tomography (CT) scans and positron emission tomography (PET) is the current preferred approach to radiologic follow-up of patients with Hodgkin lymphoma, the use of",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      mid treatment is controversial and should be reserved for patients enrolled on clinical trials. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'During treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response should be documented by history, physical examination, and laboratory studies (complete blood count, erythrocyte sedimentation rate, and biochemical profile). The follow-up imaging studies of choice are",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scans, or CT scans.",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      should be obtained one month after finishing chemotherapy (in those who do not receive radiation therapy) or three to six months after completing radiation therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Residual masses on CT or",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      require careful consideration as they may represent residual fibrosis and necrosis or active disease. Serial studies over time can help with this distinction since benign disease will remain stable or decrease in size, while persistent Hodgkin lymphoma will at some time begin to increase in size. Biopsy is strongly recommended if there is suspicion of residual disease and the site is accessible. Close monitoring is preferred if major surgical exploration would be required to confirm residual disease, with pathologic confirmation being performed at the first sign of disease progression before salvage treatments are initiated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The revised International Working Group (IWG) response criteria should be used to define complete remission, partial remission, stable disease, progressive disease or relapse (",
"      <a class=\"graphic graphic_table graphicRef58779 \" href=\"UTD.htm?38/42/39596\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/1\">",
"      Hagemeister FB, Purugganan R, Podoloff DA, et al. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol 1994; 5 Suppl 2:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/2\">",
"      Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/3\">",
"      Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/4\">",
"      Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/5\">",
"      Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/6\">",
"      Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/7\">",
"      Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/8\">",
"      Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood 2012; 120:4913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/9\">",
"      Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007; 25:3902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/10\">",
"      Friedman S, Henry-Amar M, Cosset JM, et al. Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease. J Clin Oncol 1988; 6:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/11\">",
"      Henry-Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991; 114:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/12\">",
"      Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006; :259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/13\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/14\">",
"      Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/15\">",
"      Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/16\">",
"      Devizzi L, Maffioli L, Bonfante V, et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997; 8 Suppl 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/17\">",
"      Jochelson M, Mauch P, Balikian J, et al. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985; 3:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/18\">",
"      Salloum E, Brandt DS, Caride VJ, et al. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J Clin Oncol 1997; 15:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/19\">",
"      Front D, Bar-Shalom R, Israel O. The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging. Semin Nucl Med 1997; 27:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/20\">",
"      Gasparini MD, Balzarini L, Castellani MR, et al. Current role of gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 1993; 72:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/21\">",
"      Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/22\">",
"      Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/23\">",
"      Guay C, L&eacute;pine M, Verreault J, B&eacute;nard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/24\">",
"      Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/25\">",
"      Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/26\">",
"      Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009; 27:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/27\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/28\">",
"      Kobe C, Dietlein M, Fuchs M. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma. Leuk Lymphoma 2010; 51:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/29\">",
"      Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112:3989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/30\">",
"      Fallanca F, Giovacchini G, Ponzoni M, et al. Cervical thymic hyperplasia after chemotherapy in an adult patient with Hodgkin lymphoma: a potential cause of false-positivity on [18F]FDG PET/CT scanning. Br J Haematol 2008; 140:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/31\">",
"      Nyman R, Forsgren G, Glimelius B. Long-term follow-up of residual mediastinal masses in treated Hodgkin's disease using MR imaging. Acta Radiol 1996; 37:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30007/abstract/32\">",
"      Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6:940.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4762 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-956556EC73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30007=[""].join("\n");
var outline_f29_19_30007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1167671657\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiologic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1876933\">",
"      Monitoring for chemotherapy-specific toxicities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1876964\">",
"      - Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1876971\">",
"      - Pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - PET/CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bone marrow biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1515431811\">",
"      RESPONSE CATEGORIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1515431818\">",
"      Complete remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1515431825\">",
"      Partial remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1515431832\">",
"      Stable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1515431839\">",
"      Progressive disease or relapse after CR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20583337\">",
"      LONG-TERM FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1167671657\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4762|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/42/39596\" title=\"table 1\">",
"      IWG response criteria for Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=related_link\">",
"      Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_19_30008="Flurbiprofen (systemic): Drug information";
var content_f29_19_30008=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flurbiprofen (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/35/36405?source=see_link\">",
"    see \"Flurbiprofen (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/46/7911?source=see_link\">",
"    see \"Flurbiprofen (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8101425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8101443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Flurbiprofen;",
"     </li>",
"     <li>",
"      Ansaid&reg;;",
"     </li>",
"     <li>",
"      Apo-Flurbiprofen&reg;;",
"     </li>",
"     <li>",
"      Froben-SR&reg;;",
"     </li>",
"     <li>",
"      Froben&reg;;",
"     </li>",
"     <li>",
"      Novo-Flurprofen;",
"     </li>",
"     <li>",
"      Nu-Flurprofen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8101447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8101540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis and osteoarthritis:",
"     </b>",
"     Oral: 200-300 mg/day in 2, 3, or 4 divided doses; do not administer more than 100 mg for any single dose; maximum: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Management of postoperative dental pain (unlabeled use):",
"     </b>",
"     Oral: 100 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8101541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8101542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended in patients with advanced renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; patients with hepatic insufficiency may require reduced doses due to extensive hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8101571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8101445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8101438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085913.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085913.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8101552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8101486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of rheumatoid arthritis and osteoarthritis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12817043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of postoperative pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8101437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flurbiprofen may be confused with fenoprofen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ansaid&reg; may be confused with Asacol&reg;, Axid&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8101495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;1%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Amnesia, anxiety, depression, dizziness, headache, insomnia, malaise, nervousness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, nausea, vomiting, weight changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Reflexes increased, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic reaction, anemia, angioedema, asthma, bruising, cerebrovascular ischemia, CHF, confusion, eczema, eosinophilia, epistaxis, exfoliative dermatitis, fever, gastric/peptic ulcer, hematocrit decreased, hematuria, hemoglobin decreased, hepatitis, hypertension, hyperuricemia, interstitial nephritis, jaundice, leukopenia, paresthesia, parosmia, photosensitivity, pruritus, purpura, renal failure, stomatitis, thrombocytopenia, toxic epidermal necrolysis, urticaria, vasodilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8101491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flurbiprofen, aspirin, other NSAIDs, or any component of the formulation; perioperative pain in the setting of coronary artery bypass (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8101492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure, anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding/hemostasis: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly, or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs, even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8101509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8101510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8101514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may decrease the rate but not the extent of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8101488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8101489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies flurbiprofen as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8101490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9772336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low levels of flurbiprofen are found in breast milk. Breast-feeding is not recommended by the manufacturer. The pharmacokinetics of flurbiprofen immediately postpartum are similar to healthy volunteers.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8101544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food, milk, or antacid to decrease GI effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8101573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Flurbiprofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $78.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $118.65",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anflupin (TW);",
"     </li>",
"     <li>",
"      Ansaid (CN, EC, PK);",
"     </li>",
"     <li>",
"      Arflur (IN);",
"     </li>",
"     <li>",
"      Bifen Cataplasma (KP);",
"     </li>",
"     <li>",
"      Cebutid (FR);",
"     </li>",
"     <li>",
"      Clinadol Forte (AR, UY);",
"     </li>",
"     <li>",
"      Distex (CN);",
"     </li>",
"     <li>",
"      Eyefen (IN);",
"     </li>",
"     <li>",
"      Flugalin (PL);",
"     </li>",
"     <li>",
"      Flurbic (AR);",
"     </li>",
"     <li>",
"      Flurofen (GR);",
"     </li>",
"     <li>",
"      Flurofen Retard (DK);",
"     </li>",
"     <li>",
"      Flurozin (TH);",
"     </li>",
"     <li>",
"      Froben (AT, BE, CH, GB, IN, KP, NL, PK, PT, SG, ZA);",
"     </li>",
"     <li>",
"      Froben SR (ZA);",
"     </li>",
"     <li>",
"      Lapole (JP);",
"     </li>",
"     <li>",
"      Lefenine (TW);",
"     </li>",
"     <li>",
"      Luarprofeno (AR);",
"     </li>",
"     <li>",
"      Majezik (TR);",
"     </li>",
"     <li>",
"      Strefen (FR);",
"     </li>",
"     <li>",
"      Strepfen (AU, DK, GB, PT);",
"     </li>",
"     <li>",
"      Strepsils (EE, FI, IE);",
"     </li>",
"     <li>",
"      Strepsils Intensive (BG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8101515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8101517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.12 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%, primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C9; forms metabolites such as 4-hydroxy-flurbiprofen (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bragger U, Muhle T, Fourmousis I, et al, &ldquo;Effect of the NSAID Flurbiprofen on Remodeling After Periodontal Surgery,&rdquo;",
"      <i>",
"       J Periodontal Res",
"      </i>",
"      , 1997, 32(7):575-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/9401929/pubmed\" id=\"9401929\" target=\"_blank\">",
"        9401929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1984, 13(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/6731166/pubmed\" id=\"6731166\" target=\"_blank\">",
"        6731166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clive DM and Stoff JS, &ldquo;Renal Syndromes Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(9):563-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/6363936/pubmed\" id=\"6363936\" target=\"_blank\">",
"        6363936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper SA and Kupperman A, &ldquo;The Analgesic Efficacy of Flurbiprofen Compared to Acetaminophen With Codeine,&rdquo;",
"      <i>",
"       J Clin Dent",
"      </i>",
"      , 1991, 2(3):70-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/1930699/pubmed\" id=\"1930699\" target=\"_blank\">",
"        1930699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper SA, Mardirossian G, and Miles M, &ldquo;Analgesic Relative Potency Assay Comparing Flurbiprofen 50, 100, and 150 mg, Aspirin 600 mg, and Placebo in Postsurgical Dental Pain,&rdquo;",
"      <i>",
"       Clin J Pain",
"      </i>",
"      , 1988, 4:175-81.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis NM, &ldquo;Clinical Pharmacokinetics of Flurbiprofen and its Enantiomers,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(2):100-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/7736686/pubmed\" id=\"7736686\" target=\"_blank\">",
"        7736686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, &ldquo;Suppression of Dental Pain by the Preoperative Administration of Flurbiprofen,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1986, 80(3A):41-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, Snyder J, and Hargreaves KM, &ldquo;Analgesic Efficacy of Flurbiprofen in Comparison With Acetaminophen, Acetaminophen Plus Codeine, and Placebo After Impacted Third Molar Removal,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 1994, 52(9):919-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/8064454/pubmed\" id=\"8064454\" target=\"_blank\">",
"        8064454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JA, Yorio CC, Selinger LR, et al, &ldquo;An Evaluation of Flurbiprofen, Aspirin, and Placebo in Postoperative Oral Surgery Pain,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1989, 9(2):66-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/2657675/pubmed\" id=\"2657675\" target=\"_blank\">",
"        2657675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gallardo F and Rossi E, &ldquo;Analgesic Efficacy of Flurbiprofen as Compared to Acetaminophen and Placebo After Periodontal Surgery,&rdquo;",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 1990, 61(4):224-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/2324921/pubmed\" id=\"2324921\" target=\"_blank\">",
"        2324921",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf. Accessed August 2, 2003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeffcoat MK, Reddy MS, Haigh S, et al, &ldquo;A Comparison of Topical Ketorolac, Systemic Flurbiprofen, and Placebo for the Inhibition of Bone Loss in Adult Periodontitis,&rdquo;",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 1995, 66(5):329-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/7623251/pubmed\" id=\"7623251\" target=\"_blank\">",
"        7623251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeffcoat MK, Reddy MS, Wang IC, et al, &ldquo;The Effect of Systemic Flurbiprofen on Bone Supporting Dental Implants,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1995, 126(3):305-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/7646652/pubmed\" id=\"7646652\" target=\"_blank\">",
"        7646652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lesko SM and Mitchell AA, &ldquo;An Assessment of the Safety of Pediatric Ibuprofen; A Practitioner-Based Randomized Clinical Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 273(12):929-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/7884951/pubmed\" id=\"7884951\" target=\"_blank\">",
"        7884951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, \"A Meta-analysis of the Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressure,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pounder R, &ldquo;Silent Peptic Ulceration: Deadly Silence or Golden Silence?&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/2642448/pubmed\" id=\"2642448\" target=\"_blank\">",
"        2642448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/19/30008/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9134 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30008=[""].join("\n");
var outline_f29_19_30008=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101425\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101443\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101447\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101540\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101541\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101542\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896256\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101571\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101445\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101438\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101552\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101486\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817043\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101437\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101495\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101491\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101492\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101509\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101510\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101514\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101488\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101489\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101490\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9772336\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101544\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101573\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961976\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101515\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101517\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9134|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/29/22995?source=related_link\">",
"      Flurbiprofen (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/3/38963?source=related_link\">",
"      Flurbiprofen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/61/42962?source=related_link\">",
"      Flurbiprofen (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/35/36405?source=related_link\">",
"      Flurbiprofen (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/46/7911?source=related_link\">",
"      Flurbiprofen (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_19_30009="Idiopathic CD4+ lymphocytopenia";
var content_f29_19_30009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic CD4+ lymphocytopenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30009/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30009/contributors\">",
"     Karin Nielsen-Saines, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30009/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30009/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/19/30009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic CD4+ T cell lymphocytopenia (ICL) was first described at the beginning of the HIV epidemic, following the recognition that AIDS was caused by the human immunodeficiency virus (HIV-1). A subset of patients suspected of having HIV because of profound CD4+ lymphopenia had no evidence of infection. Additional immunologic defects were present in a few of these patients, including CD8+ lymphocytopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low immunoglobulin levels.",
"   </p>",
"   <p>",
"    Many of these individuals also had risk factors for HIV infection. However, a thorough search for an etiologic agent in subsequent years has failed to yield a pathogen. The syndrome of ICL describes the immunologic findings in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICL is a heterogeneous clinical syndrome that is defined by persistent CD4+ T cell lymphopenia in the absence of infection with HIV-1 or any other cause of immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. CD4+ T cell counts should be below 300",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or less than 20 percent of total lymphocytes. Patients with ICL are usually symptomatic, but some are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICL is a rare condition. The prevalence of ICL was addressed in a review of 230,179 cases referred to the Centers for Disease Control and Prevention (CDC) AIDS Reporting System during the 1980s and early 1990s because of CD4+ lymphocytopenia or illnesses indicative of immunodeficiency; 47 (0.02 percent) had ICL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/2\">",
"     2",
"    </a>",
"    ]. Among these 47 patients, 40 percent had AIDS-defining illnesses, 53 percent had conditions that were not AIDS-defining, and 6 percent were asymptomatic.",
"   </p>",
"   <p>",
"    In 1992, a study was initiated to follow this cohort of patients prospectively and define the natural history of ICL. The study ended in 2006, and reported on the outcomes of 39 of the 47 patients, which represents the largest series of patients with ICL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ]. The results are presented throughout this topic.",
"   </p>",
"   <p>",
"    ICL appears to have no gender predilection and has a worldwide distribution. Most of the ICL patients originally reported were adults, although the disease has subsequently been described in a small number of children and adolescents and also in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. ICL has a higher prevalence among intravenous drug users and hemophiliacs, although no causative infectious agents have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICL is a disorder of unknown etiology. Because of the clinical similarities with HIV infection, the search for an underlying viral cause was the focus of initial investigations. More recently, research has focused on identifying abnormalities in various aspects of immune function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Attempts to identify an infectious agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infectious etiology of ICL has not been identified thus far. ICL was initially investigated by the United States Centers for Disease Control (CDC) in the early 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/2\">",
"     2",
"    </a>",
"    ]. Forty-seven patients of various age, gender, ethnicity, and risk factors for HIV infection were identified. Approximately 40 percent had engaged in high-risk sexual behavior or had a history of blood or blood product exposure. However, investigation of close contacts, sexual partners, children, blood donors, and recipients of the patients' blood did not demonstrate evidence of transmissibility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/2\">",
"     2",
"    </a>",
"    ]. An extensive search for a viral etiology, utilizing serologic, culture, and PCR testing, was negative [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following the initial CDC report, a retrospective investigation of over 1200 HIV-seronegative drug users, followed over eight years, identified only four patients who fulfilled the CDC case definition of ICL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening blood donors by assessing CD4+ T cell numbers was suggested because of concerns that an unknown retrovirus was responsible for ICL. In a pilot study of approximately 2000 blood donors, 0.25 percent of HIV-seronegative individuals were found to have transient CD4-lymphocytopenia associated with temporary illnesses. No true cases of ICL were identified and CD4 cell count donor screening proved to be costly and ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1995, an investigation of over 300 HIV-seronegative hemophiliac men and their female sexual partners demonstrated that 2.3 percent of patients (seven men) and one female partner met the ICL case definition, although three patients recovered spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/13\">",
"     13",
"    </a>",
"    ]. The presence of hepatitis C antibodies was nearly universal in both sets of patients; however, those individuals with ICL were more likely to have a history of liver disease and splenomegaly.",
"   </p>",
"   <p>",
"    Although no infectious agent has been identified as causative in ICL, the data are not entirely reassuring. One study demonstrated a cytopathic effect (CPE) of an ICL patient's peripheral blood mononuclear cells (PBMCs) co-cultured with a lymphoblastoid cell line, and identified A-type retroviral particles [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/14\">",
"     14",
"    </a>",
"    ]. In this same study, sera from 8 of 13 ICL patients reacted by Western immunoblotting with these retroviral particles, while control sera remained negative. These results were not duplicated in subsequent studies, however.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Functions of CD4 T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD4 is a glycoprotein expressed on the surface of various types of helper and regulatory T cells. CD4 is necessary for interaction of T cells with cells expressing MHC class II, such as B cells and monocytes. The",
"    <span class=\"nowrap\">",
"     CD4/MHC",
"    </span>",
"    II interaction is a critical co-stimulatory event in the response of these T cells to antigen. The other required stimulus is the interaction of the T cell receptor and antigen.",
"   </p>",
"   <p>",
"    Binding of the T cell receptor to antigen",
"    <strong>",
"     without",
"    </strong>",
"    the co-stimulatory input of",
"    <span class=\"nowrap\">",
"     CD4/MHC",
"    </span>",
"    II leads to a state of anergy (unresponsiveness or refractoriness to activation) and possibly even to deletion by apoptosis (programmed cell death). This may be an important mechanism in T cell tolerance. Certain subpopulations of CD4+ T cells are also believed to be important in tumor surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cytoplasmic domain of CD4 is associated with the protein tyrosine kinase Lck, a member of the src family of tyrosine kinases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanism of CD4 cell loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence for increased activation and turnover of CD4+ cells, as well as accelerated CD4+ cell apoptosis in patients with ICL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5,15\">",
"     5,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased activation may be the result of stimulation by an unidentified pathogen, either transiently with impaired homeostatic mechanisms, or persistently, resulting in a lasting decrease in the numbers of CD4+ lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"       5",
"      </a>",
"      ]. One study found increased levels of serum lipopolysaccharide (LPS) and markers of CD4+ lymphocyte activation in patients with ICL, and hypothesized that abnormally increased microbial translocation through the intestinal wall (\"leaky gut\") may be an underlying etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apoptosis may be associated with enhanced expression of Fas and Fas ligand. One study demonstrated that a patient with ICL and disseminated Mycobacterium xenopi infection had over expression of",
"      <span class=\"nowrap\">",
"       Fas/CD95c",
"      </span>",
"      and spontaneous and Fas-induced apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/17\">",
"       17",
"      </a>",
"      ]. Patients with stable, physiologic, CD4 cell lymphopenia without opportunistic infections, however, did not demonstrate accelerated apoptosis, suggesting that infection may be a necessary initial stimulus for this phenomenon.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other immunologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterogeneous immune defects have been identified in patients with ICL. No unifying theory of pathogenesis to connect these findings has been proposed, however. Thus, ICL is currently viewed as a syndrome that likely encompasses different disorders that have in common the isolated reduction of CD4 cell numbers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defective expression of CXCR4 (which binds the chemokine stromal cell-derived factor 1) on the surface of CD4 cells was demonstrated in a small series of six patients with ICL [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/18\">",
"       18",
"      </a>",
"      ]. The interaction of the",
"      <span class=\"nowrap\">",
"       receptor/ligand",
"      </span>",
"      pair is critical for multiple aspects of normal T cell differentiation and trafficking.",
"     </li>",
"     <li>",
"      Some patients also have low CD8+ T cells. In the series of 39 patients described above, patients with CD8 counts &lt;180",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      were found to have a higher risk of serious opportunistic infections and death [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"       5",
"      </a>",
"      ]. This subgroup of patients may represent a more severe variant of ICL. The complete absence of specific CD8+ cells (CD8+28+) has been reported in a small number of patients with ICL [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       gamma/",
"      </span>",
"      delta T cell repertoires of ICL patients are highly restricted, suggesting a problem in differentiation or maturation during T cell development [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Biochemical defects of the T cell receptor transduction pathway have been demonstrated, possibly due to an abnormality of tyrosine kinase activity of p56 (Lck) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Defects in this kinase appear to impact CD4 cell function and maintenance of adequate numbers of cells.",
"     </li>",
"     <li>",
"      Findings in one child with ICL suggested dysfunctional thymic T cell maturation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/6\">",
"       6",
"      </a>",
"      ]. Expression of CD45RA (a marker for na&iuml;ve T cells) was reduced, coupled with enhanced CD45RO (marker for memory T cells) expression and an increase in",
"      <span class=\"nowrap\">",
"       gamma/delta",
"      </span>",
"      TCR-bearing T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/6\">",
"       6",
"      </a>",
"      ]. Accelerated apoptosis was noted only in the CD45RO+ T cell subsets.",
"     </li>",
"     <li>",
"      ICL has been associated with increases in immature or transitional B cells and increased serum levels of IL-7 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/23\">",
"       23",
"      </a>",
"      ]. Some patients have low B cell numbers or even a complete absence of B cells [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5,19\">",
"       5,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some studies suggest that ICL may be due to decreased bone marrow clonogenic capability, or the inability of bone marrow stem cells to mature successfully [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Possible genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found higher proportions of HLA-DR+ CD4 cells in ICL patients compared to controls, suggesting that there could be a genetic predisposition to ICL, or that ICL is more common in certain populations. [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ]. If this association proves to be true, it may lead to greater insight regarding disease progression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prognosis.",
"   </p>",
"   <p>",
"    At least two specific mutations have been identified in patients with ICL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypomorphic mutations in the recombination activating gene 1 (RAG1) were identified in a young girl with Varicella infection and recurrent pneumonias [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/25\">",
"       25",
"      </a>",
"      ]. RAG mutations more typically result in either T-B-SCID or Omenn syndrome.",
"     </li>",
"     <li>",
"      Mutations were identified in the human Uncoordinated 119 gene (UNC119), which codes for a signaling adaptor protein that is essential for normal T cell signaling through the T cell receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most typical manifestations of ICL are cryptococcal, mycobacterial and other opportunistic infections, malignancies, and autoimmune disorders. Allergic conditions are seen less commonly. These conditions are all believed to result from immune dysregulation.",
"   </p>",
"   <p>",
"    Clinical manifestations vary depending upon the degree of immunosuppression. With rare exceptions, the degree of lymphopenia predicts disease. Most patients become susceptible to opportunistic infections when the absolute CD4 cell count drops below 200",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients only have mild laboratory abnormalities and no clinical findings. ICL may be a transient phenomenon in a subset of patients, with subsequent complete or partial reversal of CD4+ lymphocytopenia.",
"     </li>",
"     <li>",
"      Other individuals have illnesses suggestive of moderate immune suppression (such as recurrent herpes zoster or oral thrush).",
"     </li>",
"     <li>",
"      Some patients may be clinically indistinguishable from those with advanced HIV-disease and present with life-threatening opportunistic infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest study of ICL followed 39 patients prospectively over a median of 50 months (range 0 months to 17 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority of patients (82 percent) presented with an opportunistic infection, while in 18 percent, the diagnosis was made as a result of evaluation for lymphopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Asymptomatic ICL",
"    </span>",
"    &nbsp;&mdash;&nbsp;In studies where screening of T cell subsets was performed in cohorts of patients, a very small number of individuals who fulfilled laboratory criteria for ICL were identified. In most cases this was a transient event, with reversal occurring spontaneously. Individuals with lower CD4 cell subsets however, do exist in the general population, and a genetic predisposition is likely accountable for this finding. Limited information is available about such individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple reports of opportunistic infections in patients with ICL, while other patients have no infections despite prolonged duration of CD4 specific lymphopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5,27\">",
"     5,27",
"    </a>",
"    ]. In most cases, coinfections are secondary to the underlying immunosuppressed state, although mycobacterial infections are a possible exception, as these pathogens can cause CD4 lymphopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cryptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcal meningitis was the most common presenting opportunistic infection (one-third of subjects) in the prospective series of 39 patients mentioned previously [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ]. Cryptococcal species also infect the bone, skin, and musculoskeletal systems, any may lead to disseminated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/8,28-33\">",
"     8,28-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Human papilloma virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent genital infection with human papilloma virus (HPV) was the most common infection in patients following diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ]. Types 2, 3, and 18 cause various clinical manifestations including chronic pruritic papules, skin warts, alopecia areata, and Bowen's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/34-40\">",
"     34-40",
"    </a>",
"    ]. An extraordinary case of generalized verrucosis was reported in a patient with idiopathic ICL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mycobacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ICL may suffer from mycobacterial infections, including tuberculosis and atypical mycobacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5,42,43\">",
"     5,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differentiating between ICL as a cause of severe tuberculosis and tuberculosis as a cause of profound CD4 cell lymphocytopenia can be challenging, because in most cases T cell subsets were not evaluated until the patient became overtly ill and it is impossible to say which condition was present first. Disseminated tuberculosis is believed to be a possible cause of profound lymphocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. On the other hand, patients with preexisting CD4 lymphopenia may be at increased risk for tuberculosis. In a West African study, 14 percent of patients with advanced, disseminated tuberculosis presented with CD4 cell subsets below 300",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    in the absence of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/46\">",
"     46",
"    </a>",
"    ]. Under such circumstances, the diagnosis of ICL cannot technically be made.",
"   </p>",
"   <p>",
"    The interaction between CD4 cell subsets and mycobacteria is complex, because increases in CD4 cell subsets and improvement in immune function can trigger clinical manifestations of tuberculosis, as seen in HIV-infected patients with immune reconstitution syndrome following antiretroviral treatment. Despite this, CD4 lymphopenia is considered a negative prognostic indicator in HIV seronegative patients with severe pulmonary tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Varicella zoster virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella zoster, sometimes affecting multiple dermatomes simultaneously, was reported in approximately 10 percent of patients in the series of 39 mentioned previously [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5,47\">",
"     5,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Candida",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 10 percent of patients suffered from chronic mucocutaneous candidiasis in the same series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other opportunistic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICL has been identified in a number of patients with opportunistic infections, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumocystis jirovecii (carinii) pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/3,5,48\">",
"       3,5,48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Aspergillosis infecting the larynx [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Toxoplasmosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Histoplasmosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5,50\">",
"       5,50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hepatitis C [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Epstein Barr virus (EBV) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cytomegalovirus (CMV) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5,52\">",
"       5,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unusual pathogens, such as Fusobacterium nucleatum and Salmonella typhimurium causing sepsis-like presentations [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      JC virus and other polyoma viruses in association with progressive multifocal leukoencephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Uncommon presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICL is an uncommon cause of recurrent bacterial infections, a presentation seen more often in children. Patients presenting in this way usually have additional findings of immune dysfunction. In most cases, there is another identifiable cause for CD4 lymphopenia, such as AIDS or common variable immunodeficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of neoplastic disorders have been described in ICL patients, similarly to those described in HIV infected patients with advanced disease or chronically immunocompromised patients with post transplant lymphoproliferative disorder.",
"   </p>",
"   <p>",
"    Lymphomas are prevalent in the ICL population, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      non-Hodgkin lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/52,58,59\">",
"       52,58,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Leptomeningeal lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intravascular cerebral lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      EBV related lymphoproliferative disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"       5",
"      </a>",
"      ] and Burkitt lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/51,62\">",
"       51,62",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other virally-mediated malignancies, such as Kaposi's sarcoma of the digestive tract or skin have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Skin neoplasias, such as vulvar carcinoma or epidermoid carcinomas have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of autoimmune conditions, particularly those involving skin and mucous membranes have been associated with ICL. In the series of 39 patients previously mentioned, 23 percent were diagnosed with an autoimmune disorder, either before or after the detection of ICL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ]. Reported conditions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antiphospholipid antibody syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sj&ouml;gren&rsquo;s Syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Polyarteritis/",
"      </span>",
"      vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Erosive lichen planus of the scalp [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autoimmune vitiligo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Beh&ccedil;et&rsquo;s-like syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other associated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic conditions, such as atopic dermatitis have been linked to ICL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/73\">",
"     73",
"    </a>",
"    ]. Associations with sarcoidosis and idiopathic bronchiolitis obliterans have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/48,74\">",
"     48,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ICL may have multiple manifestations of immune dysregulation. One study reported on six patients with primary Sj&ouml;gren&rsquo;s syndrome and ICL (none had retroviral infections), of whom one progressed to lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from persistently low CD4+ T cells counts, laboratory findings in ICL are variable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with differential demonstrates lymphopenia.",
"     </li>",
"     <li>",
"      Flow cytometry demonstrates a significant decrease in the percentage and absolute numbers of CD4 cell subsets. The percentage of CD8+ cells may be increased, although not the absolute numbers. This is not consistently observed, however, and in a smaller number of patients, there may be reduced numbers of CD8+ T cells, natural killer cells, and B cells [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunoglobulin levels may be normal or slightly low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICL is a diagnosis of exclusion. CD4+ T cells should be below 300",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    or less than 20 percent of total lymphocytes on at least two separate analyses. It should first be confirmed that the patient was actually the source of the sample. If there is no underlying illness, then allowing one to three months between measurements is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus diagnostic criteria have not been formulated, and the approach described below is based upon the author's clinical experience as well as the evaluation performed in the initial CDC report defining the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immune evaluation of a patient with suspected ICL is described below. More information about the performance and interpretation of specific tests is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .) The following tests are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood cell count and differential.",
"     </li>",
"     <li>",
"      Determination of lymphocyte subpopulations by flow cytometry.",
"     </li>",
"     <li>",
"      In vitro studies of T cell function, including response to mitogens and response to specific antigens. Lymphocyte transformation may be depressed or normal [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serologic tests for HIV-1. A serologic diagnosis by EIA with confirmatory western blot or immunofluorescence assays will usually suffice for diagnosis of HIV-1. Nevertheless, in patients with very advanced immunodeficiency and HIV infection, serologic diagnosis might not always be reliable in the presence of severe malfunction of the humoral immune system, particularly in children. HIV-specific DNA polymerase chain reaction assays (PCR) can be measured in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tests for HIV-2 infection. Testing for HIV-2 is not a routine component of HIV testing in the United States. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testing for tuberculosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some centers perform delayed type hypersensitivity (DTH) testing, typically with candida and tetanus toxoid antigens. Skin test responsiveness is dependent on the degree of lymphopenia.",
"     </li>",
"     <li>",
"      Measurement of serum immunoglobulins (IgG, IgA, and IgM).",
"     </li>",
"     <li>",
"      Measurement of serum specific antibodies in vaccinated children and adults, such as titers of anti-tetanus, anti-diphtheria, and anti-pneumococcal antibodies to assess the functional status of the humoral immune system. If titers are low, the patient should be revaccinated and post-vaccination titers measured one month later. Vaccination response may be normal or weak, depending upon the degree of immune derangement. Results are usually normal if the only detectable defect is CD4 lymphopenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link\">",
"       \"Assessing the immunologic response to vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic assays for active infection with hepatitis B and C viruses, Epstein Barr virus, human herpesvirus-6, cytomegalovirus, respiratory syncytial virus, parainfluenza virus, enterovirus, adenovirus, parvovirus B19, coronavirus, and congenital rubella. These infections should be excluded, although exclusive involvement of CD4 cell subsets is very unusual. Testing for HTLV-1 and HTLV-2 would be appropriate in areas of the world in which infections with these viruses are prevalent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other possible tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;One or more of the following tests may be indicated if the patient has suggestive symptoms or findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serologic assays for measles virus and human papilloma virus",
"     </li>",
"     <li>",
"      Serologic assays for mycoplasma, rickettsia, and Borrelia burgdorferi",
"     </li>",
"     <li>",
"      Cultivation of peripheral-blood mononuclear cells with normal peripheral-blood mononuclear cells, lymphoid cell lines, or both",
"     </li>",
"     <li>",
"      Evaluation of cell cultures for cytopathicity, formation of syncytia, and reverse transcriptase activity",
"     </li>",
"     <li>",
"      Immunobiologic studies including autoimmune profiles, measurements of 2-microglobulin levels, and selective typing of human lymphocyte antigen",
"     </li>",
"     <li>",
"      Disseminated fungal infections should be excluded if clinically indicated, although these are usually a consequence of prolonged immune suppression rather than a cause of CD4 lymphopenia, as previously discussed. Evaluation may include blood cultures, biopsy of lesions seen on imaging, galactomannan testing for Aspergillus, and other studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"       \"Pulmonary infections in immunocompromised patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"       \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"       \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ICL includes acute or chronic retroviral infections, sarcoidosis, common variable immunodeficiency, congenital immunodeficiencies, and immunosuppressive states induced by chemotherapy, neoplastic disease, acute respiratory distress syndrome, or autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/48,76-78\">",
"     48,76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many infectious states can lead to transient CD4 lymphopenia because the cells are being consumed in the infectious process. This is seen in bacterial sepsis, measles, and other serious infections. Alternative diagnoses would be suggested by the clinical presentation and comorbidities. There are few diseases, however, that exclusively affect CD4+ T cell subsets in isolation. Tests to exclude these infections were reviewed previously. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Diagnostic evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Other possible tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     OKT4 epitope deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who appear to have low or absent CD4 cells should be evaluated for OKT4 epitope deficiency, a condition in which the antigen recognized by the monoclonal antibody most commonly used to detect CD4 cells by flow cytometry, OKT4, is deficient or absent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/79\">",
"     79",
"    </a>",
"    ]. This condition is found in approximately 8 percent of individuals of African descent, and fewer than one percent of those of Asian or Caucasian descent. Homozygotes have a complete absence of the epitope, while heterozygotes have about 50 percent of the normal level [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The monoclonal antibody Leu-3a, or others, can be used to detect CD4 instead in such individuals. Individuals with OKT4 epitope deficiency usually have normal CD4+ T cell number and do not develop infections, although there may be an association with autoimmune conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard treatment for ICL, except for management of the associated conditions and the prompt treatment of infections. Infections (such as mycobacteria) further deplete the CD4 cell pool, and treatment may improve the degree of CD4 specific lymphopenia. There are no controlled trials evaluating different approaches to the management of ICL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published guidelines for monitoring patients with ICL. For patients who are well, measurement of CD4 subsets every three to four months would suffice. Patients who become ill must be assessed for likely infections and treated accordingly. It would not be advisable for these individuals to donate blood, as an unidentified infectious etiology may ultimately be identified in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Prophylaxis against infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis for opportunistic infections is suggested for most patients with ICL and CD4+ T cell counts below 200",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    using the protocols advocated for HIV-1 infected patients with advanced disease. Although reports suggested that patients with ICL may not be at identical risk for infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ], a relatively small number of patients have been studied. Thus, we advocate following the recommendations for patients with HIV, with which there is extensive clinical experience. Protocols and indications for initiation are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who present with an opportunistic infection should be treated and then started on secondary prophylaxis for that particular organism. If CD4 counts improve subsequently, the need for prophylaxis can be revisited.",
"   </p>",
"   <p>",
"    In addition, immune globulin replacement should be considered for children with recurrent serious bacterial infections as a presenting symptom. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Therapies to increase CD4 cell counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of reports of the use of IL-2 and hematopoietic cell transplantation in ICL are available. There are no controlled trials evaluating therapies for ICL, and reports in the medical literature are exclusively anecdotal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     IL-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of IL-2 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/33/30231?source=see_link\">",
"     aldesleukin",
"    </a>",
"    ) in patients with ICL would only be considered in individuals with significant recalcitrant infections and CD4 counts that remained very low (eg, less than 100",
"    <span class=\"nowrap\">",
"     cells/mm3).",
"    </span>",
"    IL-2 does effect an increase in CD4 counts in most patients, although it is not clear that these cells are functionally normal.",
"   </p>",
"   <p>",
"    There are a few case reports of successful use of interleukin 2 or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    (PEG) IL-2 for this purpose, in patients with mycobacterial disease, cryptococcal meningitis, and generalized herpes zoster and gastrointestinal candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/47,49,82-85\">",
"     47,49,82-85",
"    </a>",
"    ]. IL-2 therapy has significant side effects and should be administered with informed consent, as part of a comprehensive investigational protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic bone marrow transplantation resulted in restoration of CD4+ T lymphocyte counts in one patient with ICL complicated by opportunistic infections and aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/86\">",
"     86",
"    </a>",
"    ]. The benefits of this intervention would only outweigh the risks for patients with recurrent infections that could not be prevented with prophylaxis, or in patients who could not tolerate prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis ultimately depends on the degree and duration of immune suppression and the presence and type of associated infections and comorbidities. The prognosis of patients with ICL is variable, likely reflecting different underlying etiologies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small group of patients, lymphopenia can be a temporary finding which reverses over time [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In most of the cases reported, CD4 cells stabilize at a low level rather than continuing to fall to undetectable levels as in HIV infection, although there are reports of ICL patients with gradual ongoing decline in CD4 cells [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5,75\">",
"       5,75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with low CD8+ T cell counts at presentation and higher percentages of CD4+ T cells expressing HLA-DR appear to be at higher risk of death from opportunistic infections (OIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ]. In the prospective study of 39 patients followed for a median time of 4.2 years (discussed previously), four patients died of an OI or a condition directly related to an OI, all of whom had low CD8+ cell counts at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"     5",
"    </a>",
"    ]. Three additional patients in this cohort died of causes deemed unrelated to ICL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic CD4+ lymphocytopenia (ICL) is a heterogeneous and relatively rare clinical syndrome characterized by persistent CD4+ T-lymphocyte depletion below 300",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      or less than 20 percent of total lymphocytes in the absence of HIV-1 or 2 infection or other known causes of immunodeficiency. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The condition is most commonly identified in adults, although it can affect all ages, both genders, and has a worldwide distribution. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology(ies) of ICL is currently unknown. The mechanism of CD4 cell loss in ICL appears to be due to increased activation and turnover",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      accelerated CD4+ cell apoptosis (programmed cell death) in patients with advanced immune suppression and opportunistic infections. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical findings depend on the duration and degree of immune suppression and range from an isolated laboratory finding without clinical illness to life-threatening opportunistic infections. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ICL is a diagnosis of exclusion. HIV infection, congenital immunodeficiencies, malignancies and exogenous causes of immune dysfunction must be excluded. It can be difficult to differentiate whether coinfections presenting in conjunction with ICL are the trigger or the consequence of this syndrome. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The opportunistic infections most commonly associated with ICL are cryptococcal, human papilloma virus, and mycobacterial infections. Patients are also susceptible to autoimmune disorders and malignancies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis is variable and depends on the extent and duration of immunosuppression. Concomitant CD8+ lymphocytopenia confers an increased risk of opportunistic infections. In many patients, CD4 values stabilize at low levels rather than progress to zero. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Treatment recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of ICL should be directed at treatment of associated conditions. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with CD4 counts &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm3,",
"      </span>",
"      we suggest prophylaxis against opportunistic infections using the protocols developed for AIDS patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Prophylaxis against cryptococcal infections may be of particular importance in patients with lCL and low CD8+ T cell counts. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Prophylaxis against infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who present with an opportunistic infection, we suggest that secondary prophylaxis for that specific infection be administered following appropriate treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest immune globulin replacement for children with ICL who present with recurrent bacterial infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Prophylaxis against infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CD4 counts that are persistently very low (eg, &lt;100",
"      <span class=\"nowrap\">",
"       cell/mm3)",
"      </span>",
"      and who suffer from recalcitrant or recurrent infections that cannot be prevented or treated by other means, we suggest therapies to increase CD4 counts (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Two such therapies, IL-2 and hematopoietic cell transplantation, have been used successfully. IL-2 should be administered in the setting of an investigational protocol. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Therapies to increase CD4 cell counts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/1\">",
"      Centers for Disease Control (CDC). Unexplained CD4+ T-lymphocyte depletion in persons without evident HIV infection--United States. MMWR Morb Mortal Wkly Rep 1992; 41:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/2\">",
"      Smith DK, Neal JJ, Holmberg SD. Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force. N Engl J Med 1993; 328:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/3\">",
"      Ho DD, Cao Y, Zhu T, et al. Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection. N Engl J Med 1993; 328:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/4\">",
"      Spira TJ, Jones BM, Nicholson JK, et al. Idiopathic CD4+ T-lymphocytopenia--an analysis of five patients with unexplained opportunistic infections. N Engl J Med 1993; 328:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/5\">",
"      Zonios DI, Falloon J, Bennett JE, et al. Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood 2008; 112:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/6\">",
"      Fr&uuml;hwirth M, Clodi K, Heitger A, Neu N. Lymphocyte diversity in a 9-year-old boy with idiopathic CD4+ T cell lymphocytopenia. Int Arch Allergy Immunol 2001; 125:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/7\">",
"      Lobato MN, Spira TJ, Rogers MF. CD4+ T lymphocytopenia in children: lack of evidence for a new acquired immunodeficiency syndrome agent. Pediatr Infect Dis J 1995; 14:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/8\">",
"      Menon BS, Shuaib IL, Zamari M, et al. Idiopathic CD4+ T-lymphocytopenia in a child with disseminated cryptococcosis. Ann Trop Paediatr 1998; 18:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/9\">",
"      Kaiser FE, Morley JE. Idiopathic CD4+ T lymphopenia in older persons. J Am Geriatr Soc 1994; 42:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/10\">",
"      Matsuyama W, Tsurukawa T, Iwami F, et al. Two cases of idiopathic CD4+ T-lymphocytopenia in elderly patients. Intern Med 1998; 37:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/11\">",
"      Des Jarlais DC, Friedman SR, Marmor M, et al. CD4 lymphocytopenia among injecting drug users in New York City. J Acquir Immune Defic Syndr 1993; 6:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/12\">",
"      Busch MP, Valinsky JE, Paglieroni T, et al. Screening of blood donors for idiopathic CD4+ T-lymphocytopenia. Transfusion 1994; 34:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/13\">",
"      O'Brien TR, Diamondstone L, Fried MW, et al. Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. Multicenter Hemophilia Cohort Study. Am J Hematol 1995; 49:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/14\">",
"      Garry RF, Fermin CD, Kohler PF, et al. Antibodies against retroviral proteins and nuclear antigens in a subset of idiopathic CD4+ T lymphocytopenia patients. AIDS Res Hum Retroviruses 1996; 12:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/15\">",
"      Laurence J, Mitra D, Steiner M, et al. Apoptotic depletion of CD4+ T cells in idiopathic CD4+ T lymphocytopenia. J Clin Invest 1996; 97:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/16\">",
"      Lee PI, Ciccone EJ, Read SW, et al. Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia. J Infect Dis 2009; 199:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/17\">",
"      Roger PM, Bernard-Pomier G, Counillon E, et al. Overexpression of Fas/CD95 and Fas-induced apoptosis in a patient with idiopathic CD4+ T lymphocytopenia. Clin Infect Dis 1999; 28:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/18\">",
"      Scott-Algara D, Balabanian K, Chakrabarti LA, et al. Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. Blood 2010; 115:3708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/19\">",
"      Kutukculer N, Aksu G, Genel F, Ozturk C. Idiopathic CD4+ T cell lymphocytopenia with the absence of B cells and CD8+28+ cells in peripheral blood. Clin Exp Med 2002; 2:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/20\">",
"      Signorini S, Pirovano S, Fiorentini S, et al. Restriction of T-cell receptor repertoires in idiopathic CD4+ lymphocytopenia. Br J Haematol 2000; 110:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/21\">",
"      Hubert P, Bergeron F, Grenot P, et al. [Deficiency of the CD3-TCR signal pathway in three patients with idiopathic CD4+ lymphocytopenia]. J Soc Biol 1999; 193:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/22\">",
"      Hubert P, Bergeron F, Ferreira V, et al. Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia. Int Immunol 2000; 12:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/23\">",
"      Malaspina A, Moir S, Chaitt DG, et al. Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 2007; 109:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/24\">",
"      Isgr&ograve; A, Sirianni MC, Gramiccioni C, et al. Idiopathic CD4+ lymphocytopenia may be due to decreased bone marrow clonogenic capability. Int Arch Allergy Immunol 2005; 136:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/25\">",
"      Kuijpers TW, Ijspeert H, van Leeuwen EM, et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood 2011; 117:5892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/26\">",
"      Gorska MM, Alam R. A mutation in the human Uncoordinated 119 gene impairs TCR signaling and is associated with CD4 lymphopenia. Blood 2012; 119:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/27\">",
"      Cascio G, Massobrio AM, Cascio B, Anania A. Undefined CD4 lymphocytopenia without clinical complications. A report of two cases. Panminerva Med 1998; 40:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/28\">",
"      Zonios DI, Falloon J, Huang CY, et al. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 2007; 86:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/29\">",
"      Kumlin U, Elmqvist LG, Granlund M, et al. CD4 lymphopenia in a patient with cryptococcal osteomyelitis. Scand J Infect Dis 1997; 29:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/30\">",
"      N&uacute;&ntilde;ez MJ, de Lis JM, Rodr&iacute;guez JR, et al. [Disseminated encephalic cryptococcosis as a form of presentation of idiopathic T-CD4 lymphocytopenia]. Rev Neurol 1999; 28:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/31\">",
"      Santos Gil I, Gonz&aacute;lez-Ruano P, Sanz Sanz J. [Idiopathic CD4+ T-cell lymphocytopenia associated with disseminated cryptococcosis]. Rev Clin Esp 2002; 202:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/32\">",
"      Watanabe H, Inukai A, Doyu M, Sobue G. [CNS cryptococcosis with idiopathic CD4+ T lymphocytopenia]. Rinsho Shinkeigaku 2000; 40:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/33\">",
"      Zanelli G, Sansoni A, Ricciardi B, et al. Muscular-skeletal cryptococcosis in a patient with idiopathic CD4+ lymphopenia. Mycopathologia 2001; 149:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/34\">",
"      Gubinelli E, Posteraro P, Girolomoni G. Idiopathic CD4+ T lymphocytopenia associated with disseminated flat warts and alopecia areata. J Dermatol 2002; 29:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/35\">",
"      Hayashi T, Hinoda Y, Takahashi T, et al. Idiopathic CD4+ T-lymphocytopenia with Bowen's disease. Intern Med 1997; 36:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/36\">",
"      Manchado Lopez P, Ruiz de Morales JM, Ruiz Gonz&aacute;lez I, Rodriguez Prieto MA. Cutaneous infections by papillomavirus, herpes zoster and Candida albicans as the only manifestation of idiopathic CD4+ T lymphocytopenia. Int J Dermatol 1999; 38:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/37\">",
"      Paolini R, D'Andrea E, Poletti A, et al. B non-Hodgkin's lymphoma in a haemophilia patient with idiopathic CD4+ T-lymphocytopenia. Leuk Lymphoma 1996; 21:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/38\">",
"      Purnell D, Ilchyshyn A, Jenkins D, et al. Isolated human papillomavirus 18-positive extragenital bowenoid papulosis and idiopathic CD4+ lymphocytopenia. Br J Dermatol 2001; 144:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/39\">",
"      Stetson CL, Rapini RP, Tyring SK, Kimbrough RC. CD4+ T lymphocytopenia with disseminated HPV. J Cutan Pathol 2002; 29:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/40\">",
"      Wakeel RA, Urbaniak SJ, Armstrong SS, et al. Idiopathic CD4+ lymphocytopenia associated with chronic pruritic papules. Br J Dermatol 1994; 131:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/41\">",
"      Alisjahbana B, Dinata R, Sutedja E, et al. Disfiguring generalized verrucosis in an indonesian man with idiopathic CD4 lymphopenia. Arch Dermatol 2010; 146:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/42\">",
"      Anzalone G, Cei M, Vizzaccaro A, et al. M. Kansasii pulmonary disease in idiopathic CD4+ T-lymphocytopenia. Eur Respir J 1996; 9:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/43\">",
"      Schantz V, Pedersen C, Homburg KM, Hansen ER. [Mycobacterium avium complex infection in a patient with idiopathic CD4+ T-lymphocytopenia]. Ugeskr Laeger 2000; 162:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/44\">",
"      Pilheu JA, De Salvo MC, Gonzalez J, et al. CD4+ T-lymphocytopenia in severe pulmonary tuberculosis without evidence of human immunodeficiency virus infection. Int J Tuberc Lung Dis 1997; 1:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/45\">",
"      Zaharatos GJ, Behr MA, Libman MD. Profound T-lymphocytopenia and cryptococcemia in a human immunodeficiency virus-seronegative patient with disseminated tuberculosis. Clin Infect Dis 2001; 33:E125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/46\">",
"      Kony SJ, Hane AA, Larouz&eacute; B, et al. Tuberculosis-associated severe CD4+ T-lymphocytopenia in HIV-seronegative patients from Dakar. SIDAK Research Group. J Infect 2000; 41:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/47\">",
"      Warnatz K, Draeger R, Schlesier M, Peter HH. Successful IL-2 therapy for relapsing herpes zoster infection in a patient with idiopathic CD4+ T lymphocytopenia. Immunobiology 2000; 202:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/48\">",
"      Sinicco A, Maiello A, Raiteri R, et al. Pneumocystis carinii in a patient with pulmonary sarcoidosis and idiopathic CD4+ T lymphocytopenia. Thorax 1996; 51:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/49\">",
"      Nakahira M, Matsumoto S, Mukushita N, Nakatani H. Primary aspergillosis of the larynx associated with CD4+ T lymphocytopenia. J Laryngol Otol 2002; 116:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/50\">",
"      Tassinari P, Deibis L, Bianco N, Echeverr&iacute;a de P&eacute;rez G. Lymphocyte subset diversity in idiopathic CD4+ T lymphocytopenia. Clin Diagn Lab Immunol 1996; 3:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/51\">",
"      Shimano S, Murata N, Tsuchiya J. [Idiopathic CD4+ T-lymphocytopenia terminating in Burkitt's lymphoma]. Rinsho Ketsueki 1997; 38:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/52\">",
"      Longo F, H&eacute;buterne X, Michiels JF, et al. [Multifocal MALT lymphoma and acute cytomegalovirus gastritis revealing CD4 lymphopenia without HIV infection]. Gastroenterol Clin Biol 1999; 23:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/53\">",
"      Etienne M, Gueit I, Abboud P, et al. Fusobacterium nucleatum hepatic abscess with pylephlebitis associated with idiopathic CD4(+) T lymphocytopenia. Clin Infect Dis 2001; 32:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/54\">",
"      Burg S, Weber W, K&uuml;cherer C. [Idiopathic CD4 lymphocytopenia with lethal Salmonella typhimurium sepsis]. Dtsch Med Wochenschr 1994; 119:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/55\">",
"      Haider S, Nafziger D, Gutierrez JA, et al. Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases. Clin Infect Dis 2000; 31:E20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/56\">",
"      Iwase T, Ojika K, Katada E, et al. An unusual course of progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia. J Neurol Neurosurg Psychiatry 1998; 64:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/57\">",
"      Chikezie PU, Greenberg AL. Idiopathic CD4+ T lymphocytopenia presenting as progressive multifocal leukoencephalopathy: case report. Clin Infect Dis 1997; 24:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/58\">",
"      Campbell JK, Prince HM, Juneja SK, et al. Diffuse large cell lymphoma and t(8;22) (q24;q11) in a patient with idiopathic CD4+ T-lymphopenia. Leuk Lymphoma 2001; 41:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/59\">",
"      Hanamura I, Wakita A, Harada S, et al. Idiopathic CD4+ T-lymphocytopenia in a non-Hodgkin's lymphoma patient. Intern Med 1997; 36:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/60\">",
"      Busse PJ, Cunningham-Rundles C. Primary leptomeningeal lymphoma in a patient with concomitant CD4+ lymphocytopenia. Ann Allergy Asthma Immunol 2002; 88:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/61\">",
"      Guilloton L, Drouet A, Bernard P, et al. [Cerebral intravascular lymphoma during T CD4+ idiopathic lymphopenia syndrome]. Presse Med 1999; 28:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/62\">",
"      Kanno H, Sasaki M, Kumagai H, et al. Epstein - Barr virus-positive malignant lymphoma of salivary gland developing in an infant with selective depletion of CD4-positive lymphocytes. Leuk Lymphoma 2007; 48:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/63\">",
"      Ben Rejeb A, Ebdelli N, Bouali MR, et al. [Primary digestive tract Kaposi sarcoma with idiopathic CD4+ lymphocytopenia, HIV negative, HHV8 positive]. Gastroenterol Clin Biol 2001; 25:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/64\">",
"      Inhoff O, Doerries K, Doerries R, et al. Disseminated cutaneous Kaposi sarcoma and progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia. Arch Dermatol 2007; 143:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/65\">",
"      Rijnders RJ, van den Ende IE, Huikeshoven FJ. Suspected idiopathic CD4+ T-lymphocytopenia in a young patient with vulvar carcinoma stage IV. Gynecol Oncol 1996; 61:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/66\">",
"      Michel JL, Perrot JL, Mitanne D, et al. [Metastatic epidermoid carcinoma in idiopathic CD4+ T lymphocytopenia syndrome]. Ann Dermatol Venereol 1996; 123:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/67\">",
"      Kirtava Z, Blomberg J, Bredberg A, et al. CD4+ T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sj&ouml;gren's syndrome. Clin Exp Rheumatol 1995; 13:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/68\">",
"      Bordin G, Ballar&eacute; M, Paglino S, et al. Idiopathic CD4+ lymphocytopenia and systemic vasculitis. J Intern Med 1996; 240:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/69\">",
"      Hardman CM, Baker BS, Lortan J, et al. Active psoriasis and profound CD4+ lymphocytopenia. Br J Dermatol 1997; 136:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/70\">",
"      Brudy L, Janier M, Reboul D, et al. [Erosive lichen of the scalp]. Ann Dermatol Venereol 1997; 124:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/71\">",
"      Yamauchi PS, Nguyen NQ, Grimes PE. Idiopathic CD4+T-cell lymphocytopenia associated with vitiligo. J Am Acad Dermatol 2002; 46:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/72\">",
"      Venzor J, Hua Q, Bressler RB, et al. Beh&ccedil;et's-like syndrome associated with idiopathic CD4+ T-lymphocytopenia, opportunistic infections, and a large population of TCR alpha beta+ CD4- CD8- T cells. Am J Med Sci 1997; 313:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/73\">",
"      Goodrich AL, Tigelaar RE, Watsky KL, Heald PW. Idiopathic CD4+ lymphocyte deficiency. Report of an unusual case associated with atopic dermatitis and allergic contact dermatitis and review of the literature. Arch Dermatol 1993; 129:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/74\">",
"      Pohl W. [A patient with idiopathic bronchiolitis obliterans with organizing pneumonia and idiopathic CD4+ T-lymphocytopenia]. Wien Klin Wochenschr 1996; 108:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/75\">",
"      Duncan RA, von Reyn CF, Alliegro GM, et al. Idiopathic CD4+ T-lymphocytopenia--four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med 1993; 328:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/76\">",
"      Bloch-Michel C, Viallard JF, Blanco P, et al. [Common variable immunodeficiency: 17 observations in the adult]. Rev Med Interne 2003; 24:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/77\">",
"      Miller AC, Chacko T, Rashid RM, Ledford DK. Fever of unknown origin and isolated noncaseating granuloma of the marrow: could this be sarcoidosis? Allergy Asthma Proc 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/78\">",
"      Viallard JF, Monlun E, Neau D, et al. Aspergillosis of the muscle in a woman with sarcoidosis and CD4+ T lymphocytopenia. Clin Infect Dis 1995; 21:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/79\">",
"      Bach MA, Phan-Dinh-Tuy F, Bach JF, et al. Unusual phenotypes of human inducer T cells as measured by OKT4 and related monoclonal antibodies. J Immunol 1981; 127:980.",
"     </a>",
"    </li>",
"    <li>",
"     Stiehm ER, Ochs HD, Winkelstein JA. Other well-defined immunodeficiency syndromes. In: Immunologic disorders in infants and children, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.544.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/81\">",
"      Tanaka H, Mizutani H, Okada H, Shimizu M. Primary Sj&ouml;gren's syndrome and psoriasis vulgaris in a case of OKT4 epitope deficiency. J Dermatol 1995; 22:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/82\">",
"      Wilhelm M, Weissinger F, Kunzmann V, et al. Idiopathic CD4+ T cell lymphocytopenia evolving to monoclonal immunoglobulins and progressive renal damage responsive to IL-2 therapy. Clin Immunol 2001; 99:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/83\">",
"      Cunningham-Rundles C, Murray HW, Smith JP. Treatment of idiopathic CD4 T lymphocytopenia with IL-2. Clin Exp Immunol 1999; 116:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/84\">",
"      Trojan T, Collins R, Khan DA. Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare. Clin Exp Immunol 2009; 156:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/85\">",
"      Yilmaz-Demirdag Y, Wilson B, Lowery-Nordberg M, et al. Interleukin-2 treatment for persistent cryptococcal meningitis in a child with idiopathic CD4(+) T lymphocytopenia. Allergy Asthma Proc 2008; 29:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30009/abstract/86\">",
"      Petersen EJ, Rozenberg-Arska M, Dekker AW, et al. Allogeneic bone marrow transplantation can restore CD4+ T-lymphocyte count and immune function in idiopathic CD4+ T-lymphocytopenia. Bone Marrow Transplant 1996; 18:813.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3917 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30009=[""].join("\n");
var outline_f29_19_30009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Attempts to identify an infectious agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Functions of CD4 T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanism of CD4 cell loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other immunologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Possible genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Asymptomatic ICL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cryptococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Human papilloma virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Varicella zoster virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Candida",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other opportunistic infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Uncommon presentations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other associated disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other possible tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OKT4 epitope deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Prophylaxis against infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Therapies to increase CD4 cell counts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - IL-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_19_30010="Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history";
var content_f29_19_30010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30010/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30010/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30010/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30010/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30010/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/19/30010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/19/30010/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/19/30010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic urticaria (CU) is defined by the presence of urticaria (hives), on most days of the week, for a period of six weeks or longer. About 40 percent of patients with CU have accompanying episodes of angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/1\">",
"     1",
"    </a>",
"    ]. No external allergic cause or contributing disease process can be identified in 80 to 90 percent of adults and children with CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. There are several theories regarding the pathogenesis of idiopathic CU, none of which have been conclusively established. CU is a self-limited disorder in most patients, although the average duration of disease is two to five years.",
"   </p>",
"   <p>",
"    The clinical manifestations, epidemiology, diagnosis, theories of pathogenesis, and natural history of CU will be reviewed here. The management of CU is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"     \"Chronic urticaria: Standard management and patient education\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=see_link\">",
"     \"Chronic urticaria: Treatment of refractory symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1263694\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this review, the terms &ldquo;chronic urticaria&rdquo; and &ldquo;chronic idiopathic urticaria&rdquo; are used synonymously. These terms refer to patients with urticaria alone, as well as those with accompanying angioedema.",
"   </p>",
"   <p>",
"    There are several syndromes of CU in which symptoms are elicited by specific physical factors. These include dermographism, delayed pressure urticaria, cholinergic urticaria, local heat urticaria, and cold, aquagenic, solar, and vibratory urticaria. Another term that is gaining in favor is &ldquo;chronic spontaneous urticaria (CSU),&rdquo; which excludes physical urticaria syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physical urticaria syndromes are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"     \"Physical urticarias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link\">",
"     \"Cold urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1183511\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At any given time, CU affects up to 1 percent of the general population in the United States, and the prevalence is believed to be similar in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Both children and adults can develop CU, although it is more common in adults. Women are affected twice as often as men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/7-14\">",
"     7-14",
"    </a>",
"    ], and the condition typically begins in the third to fifth decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/7,10,13\">",
"     7,10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1263753\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticarial lesions (ie, hives) are circumscribed, raised, erythematous plaques, often with central pallor (",
"    <a class=\"graphic graphic_picture graphicRef72519 \" href=\"UTD.htm?29/2/29728\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63644 \" href=\"UTD.htm?23/55/24433\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81678 \" href=\"UTD.htm?11/2/11311\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77506 \" href=\"UTD.htm?22/12/22720\">",
"     picture 4",
"    </a>",
"    ). They may be round, annular, or serpiginous and variable in size. The lesions may appear flattened if the patient is currently taking H1 antihistamines.",
"   </p>",
"   <p>",
"    Lesions are extremely pruritic, and pruritus may be severe enough to disrupt work, school, or sleep. The pruritus of CU is often most noticeable at night. Any area of the body may be affected. Areas in which clothing compresses the skin (ie, under waistbands) or the skin rubs together (axillae) are sometimes affected more extensively. Patients whose symptoms have resolved sometimes have difficulty describing urticarial lesions in a sufficiently detailed manner to assist in diagnosis. In this situation, showing patients photographs of urticaria and asking if the lesions looked similar can be helpful.",
"   </p>",
"   <p>",
"    Individual lesions usually appear and resolve within 24 hours. If the patient is having difficulty estimating how long an individual lesion lasts, they can trace a newly developed lesion with a pen and monitor the time to resolution. Lesions lasting longer than 24 hours and those that are painful or burning in nature or leave residual bruising are suggestive of a vasculitic process. (See",
"    <a class=\"local\" href=\"#H1264349\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Angioedema, if present, is defined as episodic submucosal or subcutaneous swelling that is usually asymmetric in distribution, affects nondependent parts of the body, develops over minutes to hours, and is nonpitting. Affected area typically feel numb or tingling, rather than pruritic. Angioedema in the setting of CU commonly involves the lips, cheeks, periorbital areas of the face, extremities, and genitals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, angioedema involving the throat, tongue, or lips, WITHOUT urticaria, should prompt consideration of drug-induced angioedema (such as that seen with ACE inhibitors), hereditary angioedema, or acquired C1-inhibitor deficiency. Episodic abdominal pain due to angioedema of the intestinal mucosa is another distinguishing feature of these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37465?source=see_link\">",
"     \"ACE inhibitor-induced angioedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94602611\">",
"    <span class=\"h2\">",
"     Aggravating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not the sole cause of symptoms, certain factors aggravate CU in a substantial subset of patients. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical factors &mdash; Some patients with CU have some flares that are triggered by physical stimuli. As an example, heat (hot showers, extreme humidity) is a common trigger for many CU patients, and tight clothing or straps can also aggravate symptoms. In contrast, patients in whom physical factors are the",
"      <strong>",
"       main",
"      </strong>",
"      trigger for symptoms are more appropriately diagnosed as having a physical urticarial syndrome, such as cholinergic urticaria or delayed pressure urticaria. Physical urticarias are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"       \"Physical urticarias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link\">",
"       \"Cold urticaria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antiinflammatory medications and alcohol &mdash; Nonsteroidal antiinflammatory drugs (NSAIDs) and alcohol worsen symptoms in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stress &mdash; Patients often report more severe symptoms during periods of physical or psychological stress [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/16-23\">",
"       16-23",
"      </a>",
"      ]. However, evidence that psychosocial factors are in some way causative is lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variations in dietary habits &mdash; Although food allergy is a rare cause of chronic urticaria, some patients will report that variations in diet, particularly rich meals, or spicy foods will aggravate symptoms. The interactions between diet and chronic urticaria are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link&amp;anchor=H7#H7\">",
"       \"Chronic urticaria: Standard management and patient education\", section on 'Dietary manipulations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94601710\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CU is associated with various autoimmune disorders. There is a possible association with malignancies, although data are conflicting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94601717\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various autoimmune conditions are more prevalent among patients with CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/8,15,25-27\">",
"     8,15,25-27",
"    </a>",
"    ]. In the largest study to date, the prevalence of autoimmune disorders in nearly 13,000 patients with CU was compared to over 10,000 control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/8\">",
"     8",
"    </a>",
"    ]. The following autoimmune disorders were more prevalent in patients with CU: thyroid disorders, celiac disease, Sj&ouml;gren syndrome, systemic lupus erythematosus, rheumatoid arthritis, and type I diabetes mellitus, with considerable variability between males and females. Antinuclear antibodies were also more prevalent than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/8\">",
"     8",
"    </a>",
"    ]. Among patients with CU, an autoimmune disorder was more likely to be diagnosed in the decade after the onset of CU, rather than before it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H557583\">",
"    <span class=\"h3\">",
"     Thyroid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism was diagnosed in 9.8 percent of CU patients (versus 0.6 percent of controls) and hyperthyroidism, in 2.6 percent (versus 0.5 percent of controls) in the larger study mentioned previously [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thyroid autoantibodies, specifically thyroid peroxidase antibodies or antimicrosomal antibodies, are more prevalent among patients with CU (12 to 30 percent), compared with members of the general population (5 to 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/9,28-30\">",
"     9,28-30",
"    </a>",
"    ]. However, the presence of thyroid autoantibodies does not necessarily correlate with abnormal thyroid function, and the majority of patients with CU who have demonstrable thyroid autoantibodies have",
"    <strong>",
"     normal",
"    </strong>",
"    thyroid function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/29\">",
"     29",
"    </a>",
"    ]. The role of these autoantibodies in CU in patients with normal thyroid function is not clear. Their presence may simply reflect an underlying tendency to develop autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/26\">",
"     26",
"    </a>",
"    ]. However, even in the absence of hypo or hyperthyroidism, patients with thyroid autoantibodies are often poorly responsive to standard therapies for CU and have more persistent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of autoimmune thyroid disease is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=see_link\">",
"     \"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the association between CU and thyroid autoimmunity, several studies have examined the use of thyroid supplementation therapy in the treatment of CU, with mixed results. These studies are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link&amp;anchor=H19#H19\">",
"     \"Chronic urticaria: Standard management and patient education\", section on 'Patients with hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94601739\">",
"    <span class=\"h2\">",
"     Unclear association with malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with noncutaneous malignancies can develop associated dermatologic disorders, and urticarial vasculitis has been associated with malignancy, although infrequently [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link\">",
"     \"Cutaneous manifestations of internal malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link&amp;anchor=H34#H34\">",
"     \"Urticarial vasculitis\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between CU (without vasculitis) and malignancy is less clear cut. Current guidelines do not suggest that malignancy screening be performed in patients with CU, unless indicated by specific abnormalities in the clinical history or physical exam [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/5,33-35\">",
"     5,33-35",
"    </a>",
"    ]. Studies that support this approach include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 1155 Swedish patients with CU, subjects were followed by academic dermatologists for an average of 8.2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/36\">",
"       36",
"      </a>",
"      ]. The incidence of malignant cancer during the period of observation was compared with the expected number of cancers from the Swedish Cancer Registry, yielding a relative risk of 0.88 (95% CI 0.61 to 1.12). Thus, this study found no increased risk of malignancy in patients with CU.",
"     </li>",
"     <li>",
"      In a systematic review of 6462 patients described in 29 studies, internal diseases were detected as an underlying cause of chronic urticaria in only 105 patients, or 1.6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/15\">",
"       15",
"      </a>",
"      ]. Within this group, there were 60 cases of urticarial vasculitis, 17 patients with thyroid disease, 7 with lupus, and 16 with other connective tissue disorders. Three patients had a paraproteinemia, 4 had polycythemia vera, and 5 had various malignancies (breast cancer, acute myeloid leukemia, renal cell carcinoma, and two unidentified cancers). Therefore, few malignancies were detected in this review and no one type of cancer predominated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent to the publication of current CU guidelines, a study of 12,720 Taiwanese patients found that there may be an increased risk of malignancy among patients with CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/37\">",
"     37",
"    </a>",
"    ]. In this cohort, subjects were identified as having CU based upon the ICD-9-CM code for urticaria, combined with use of an antihistamine for at least six months over a two year period. Patients with coexisting allergic disorders that could require chronic antihistamines, patients receiving immunosuppressant drugs for any reason, and those with preexisting malignancies, rheumatoid arthritis, lupus erythematosus, or Sj&ouml;gren's syndrome were excluded. The rate of malignancies diagnosed in this cohort over an average follow-up period of five years was compared to expected rates, obtained from the Taiwan National Cancer Registry. The standardized incidence ratio (SIR) for patients with CU was 2.2 (95% CI 2.0 to 2.4).",
"   </p>",
"   <p>",
"    Both the Swedish and Taiwanese studies were performed in countries in which people have unique identifying patient numbers and health data can be reliably captured. Neither study included data about possible confounders, such as smoking or alcohol use. The diagnosis of CU in the first study may have been made with greater accuracy, since patients were recruited and followed at an academic dermatology center, while those in the second study were gleaned from the entire population and were diagnosed in a variety of settings. Accordingly, patients in the second study may not have been as extensively evaluated for signs or symptoms of underlying disorders. In addition, the authors of the second study noted that there was no diagnostic code for urticarial vasculitis, so this diagnosis, which is known to be associated with malignancy, would not have been easily distinguished from uncomplicated urticaria. Therefore, although the Taiwanese study may have overestimated cancer risk, the association warrants further evaluation.",
"   </p>",
"   <p>",
"    Until the association between chronic idiopathic urticaria and malignancy is better defined, it seems logical to continue to perform additional testing only if indicated by the patient&rsquo;s clinical history and physical exam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic urticaria (CU) is diagnosed clinically based upon the episodic appearance of characteristic urticarial lesions, with or without angioedema, on most days of the week, for a period of six weeks or longer. A detailed history and physical examination form the basis of the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Several practice parameters have been published for the diagnosis of CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/5,33-35\">",
"     5,33-35",
"    </a>",
"    ]. The suggestions in this review are consistent with these, although some variation exists among guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history is an important element of the evaluation. The history should include the signs and symptoms associated with the lesions, duration of individual lesions, and accompanying angioedema. If signs and symptoms are consistent with CU, then questioning should focus on identifying a possible underlying cause, and on ensuring that the patient does not have evidence of a more serious systemic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To exclude a specific cause, clinicians should question patients about any newly administered drugs, including antibiotics, nonsteroidal antiinflammatory drugs (NSAIDS), and hormones [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Inquiries should be made about recent travel, infections, changes in health status, other atopic conditions, sexual history, and complete review of systems. No external cause can be identified in 80 to 90 percent of adults and children with CU, as mentioned previously [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/2-4,44\">",
"       2-4,44",
"      </a>",
"      ]. The various identifiable causes of urticaria are discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"       \"New onset urticaria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients should be thoroughly questioned about signs and symptoms of systemic disease, such as fever, weight loss, arthralgias, arthritis, cold or heat sensitivity, abdominal pain, and bone pain [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/25,45\">",
"       25,45",
"      </a>",
"      ]. Occasionally, urticaria or urticarial vasculitis will be a presenting feature of an underlying systemic disorder, such as lupus erythematosus. Systemic diseases that can present with urticaria accompanied by other signs and symptoms, and disorders that involve urticarial vasculitis are reviewed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link&amp;anchor=H30#H30\">",
"       \"New onset urticaria\", section on 'Systemic disorders that may include urticaria'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link&amp;anchor=H27#H27\">",
"       \"Urticarial vasculitis\", section on 'Associated conditions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory tests are unlikely to reveal abnormalities when the clinical history does not suggest an underlying allergic etiology or the presence of systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/15,33,46-48\">",
"     15,33,46-48",
"    </a>",
"    ]. The utility of extensive laboratory testing in patients with CU was analyzed in the systematic review mentioned previously. This review analyzed 29 studies (including 6462 patients), in which investigations for underlying medical disorders were performed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/15\">",
"     15",
"    </a>",
"    ]. Potentially causative internal diseases were identified in only 1.6 percent of patients, and there was no association between the number of tests ordered and the identification of an underlying disorder. The reviewers concluded that erythrocyte sedimentation rate (ESR), complete blood count, and differential were useful screening tests. Guidelines suggest initially obtaining a limited set of laboratories to screen for the systemic disorders that may involve urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/5,33-35\">",
"     5,33-35",
"    </a>",
"    ]. The author and editors agree with this approach and suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       A complete blood count with differential",
"      </strong>",
"      : This is usually normal in patients with CU. Eosinophilia should prompt evaluation for an atopic disorder or parasitic infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"       \"Approach to the patient with eosinophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR)",
"      </strong>",
"      : Both tests are normal in the majority of cases of CU, although an elevation of ESR of a few points is also common in uncomplicated CU [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/48\">",
"       48",
"      </a>",
"      ]. Significant elevations in ESR or CRP should prompt further investigation for systemic diseases, such as autoimmune, rheumatologic, infectious, or neoplastic diseases. Such an evaluation may include measurement of antinuclear antibodies (ANA), cryoglobulins, hepatitis B and C serologies, total hemolytic complement, and a serum protein electrophoresis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"       \"Acute phase reactants\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1264349\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Thyroid stimulating hormone (TSH) level",
"      </strong>",
"      : Some clinicians also obtain thyroid autoantibodies (antithyroglobulin, antimicrosomal antibodies, or both) in adults, while others do so only if the TSH level is abnormal [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/49\">",
"       49",
"      </a>",
"      ]. Autoimmune thyroid disease is uncommon in children with CU [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1519355\">",
"    <span class=\"h3\">",
"     Investigational tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigational tests include the \"autologous serum skin test\" (ASST), various tests of basophil activation, and tests for autoantibodies to the IgE receptor or the Fc region of IgE. These tests are discussed separately. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Theories of pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy is not routinely needed for the diagnosis of CU. However, a 3 mm punch biopsy of a newly formed lesion should be performed to exclude urticarial vasculitis in patients with one or more of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individual lesions that persist beyond 24 hours, are painful rather than pruritic, have accompanying petechial or purpuric characteristics, or leave residual pigmentation upon resolution [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/41,51\">",
"       41,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An elevated",
"      <span class=\"nowrap\">",
"       CRP/ESR",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      systemic symptoms (eg, arthralgias, fever).",
"     </li>",
"     <li>",
"      Symptoms that are unresponsive to appropriate doses of antihistamines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link&amp;anchor=H9#H9\">",
"       \"Chronic urticaria: Standard management and patient education\", section on 'H1 antihistamines'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biopsy should also be obtained in patients with any features suggestive of mastocytosis. Mastocytosis is a rare disease that would be suspected in a patient in whom CU was accompanied by episodic signs and symptoms of systemic mast cell mediator release, such as flushing, abdominal cramping and diarrhea, wheezing, lightheadedness or syncope. (See",
"    <a class=\"local\" href=\"#H1264349\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biopsy sample should be obtained from a fresh lesion. Patients receiving glucocorticoids may need to discontinue these medications for several days in order to allow new lesions to form. Biopsy specimens should be submitted in formalin for routine hematoxylin and eosin (H&amp;E) staining and in those patients in whom urticarial vasculitis is a strong consideration, in Michel&rsquo;s media or freshly snap frozen for direct immunofluorescence microscopy. Consider testing for immunoglobulins in lesional skin when vasculitis is a strong consideration and in perilesional, noninvolved skin when considering autoimmune blistering disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Biopsy findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biopsy findings of CU vary somewhat among patients. Consistent features include interstitial edema with a perivascular mixed infiltrate, consisting of lymphocytes, eosinophils, and in some areas, a few neutrophils or basophils. Lymphocytes are generally CD4+ T lymphocytes. B lymphocytes are not usually seen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/1\">",
"     1",
"    </a>",
"    ]. Angioedema, if present, often shows a similar infiltrate and is characterized by more prominent edema of the interstitial tissues.",
"   </p>",
"   <p>",
"    Neutrophil-predominant urticaria, without vasculitis, is a variant of CU that is often refractory to standard pharmacologic treatments. The significance of neutrophil-predominant urticaria, in terms of preferred treatment or prognosis, is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings that are",
"    <strong>",
"     not",
"    </strong>",
"    characteristic of CU include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several disorders in the differential diagnosis for CU may also show a predominance of neutrophils, such as Schnitzler's syndrome, delayed pressure urticaria, and the Cryopyrin-Associated Periodic Syndromes (CAPS). Biopsies in these disorders may also mistakenly be interpreted as leukocytoclastic vasculitis. (See",
"      <a class=\"local\" href=\"#H1264349\">",
"       'Differential diagnosis'",
"      </a>",
"      below.).",
"     </li>",
"     <li>",
"      Leukocytoclasis should",
"      <strong>",
"       not",
"      </strong>",
"      be present in CU. Leukocytoclasis is the fragmentation of neutrophils resulting in scattered nuclear fragments (nuclear dust) in the infiltrate, red blood cell extravasation within the lumen of affected vessels or in the interstitium, and fibrinoid degeneration of the endothelial cells resulting in a blunted vascular outline with fibrin deposits. If leukocytoclasis is found, the diagnosis of leukocytoclastic vasculitis and associated conditions should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link&amp;anchor=H11#H11\">",
"       \"Urticarial vasculitis\", section on 'Histology'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1264349\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Leukocytoclasis accompanied by a dense cellular infiltrate consisting almost entirely of neutrophils, without evidence of vasculitis, should prompt evaluation for the rare disorder, neutrophilic urticarial dermatosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link\">",
"       \"Neutrophilic dermatoses\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     THEORIES OF PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the theories of pathogenesis of CU has been fully established [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/53\">",
"     53",
"    </a>",
"    ]. The best-developed hypotheses include the autoimmune theory, theories involving histamine releasing factors, and the cellular defects theory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Autoimmune theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept that CU could represent an autoimmune disorder arose from the recognition that thyroid dysfunction and thyroid autoantibodies are more prevalent in patients with CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/8,25,28,29\">",
"     8,25,28,29",
"    </a>",
"    ]. This led to a search for autoantibodies and other serum factors that could be responsible for increased release of histamine from cutaneous mast cells and basophils. A European taskforce panel of CU experts published a statement in 2013 concluding that there was persuasive, but not conclusive evidence for the existence of autoimmune chronic spontaneous urticaria as a specific disease entity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/54\">",
"     54",
"    </a>",
"    ]. The evidence suggesting that CU may be an autoimmune disorder in some patients is reviewed below. (See",
"    <a class=\"local\" href=\"#H94601717\">",
"     'Autoimmune disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10997853\">",
"    <span class=\"h3\">",
"     The autologous serum skin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;One area of investigation suggesting that CU is an autoimmune disorder was introduced in the 1980s with the description of the \"autologous serum skin test\" (ASST) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/55\">",
"     55",
"    </a>",
"    ]. The ASST is proposed to provide an in vivo assay of mast cell activation induced by factors in the patient&rsquo;s serum. The ASST involves intradermal injection of the patients' own serum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In preparation for this test, patients must refrain from taking antihistamines for three to seven days (depending upon the half-life of the specific drug), which can cause an exacerbation in symptoms.",
"   </p>",
"   <p>",
"    In up to one-half of patients with CU, the intradermal injection of serum produces a wheal and flare reaction (ie, area of cutaneous edema and erythema) at the site of injection within 30 minutes (note that the time to maximal reaction is longer than 15 minutes seen in allergen skin testing) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/57\">",
"     57",
"    </a>",
"    ]. In vitro tests of mast cell activation are lacking because mast cells are tissue-based cells that are not easily collected or cultured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link\">",
"     \"Mast cells: Development, identification, and physiologic roles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1519631\">",
"    <span class=\"h4\">",
"     Problems with the ASST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The leading argument against the clinical significance of the ASST is that a positive test is not unique to patients with CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In one study, positive ASSTs were found in 53 percent of patients with CU, 20 percent of patients with nonallergic",
"    <span class=\"nowrap\">",
"     asthma/rhinitis,",
"    </span>",
"    and 56 percent of healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, the positivity of the ASST persists in patients with CU, even when the disorder is in clinical remission [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Finally, the ASST has not demonstrated clinical utility in identifying patients who respond differently to treatment or whose disease follows a difference clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/50,63,64\">",
"     50,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sera of patients with CU and positive ASSTs are capable of causing in vitro histamine release from basophils collected from control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/55\">",
"     55",
"    </a>",
"    ]. It was therefore proposed that an autoantibody or other histamine releasing factor was present in the serum of these patients.",
"   </p>",
"   <p>",
"    At least two candidate autoantibodies have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/56,61,65,66\">",
"     56,61,65,66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Human IgG molecules directed against the IgE receptor alpha subunit (anti-Fc&epsilon;R1alpha)",
"     </li>",
"     <li>",
"      Human IgG molecules directed against the Fc region of IgE (anti-IgE)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of IgG autoantibodies to the IgE receptor or the Fc region of IgE can be demonstrated in as many as 30 to 50 percent of children and adults with CU [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/1,54,67-71\">",
"     1,54,67-71",
"    </a>",
"    ]. These autoantibodies can trigger histamine release when incubated with normal basophils [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/65\">",
"     65",
"    </a>",
"    ] and can activate mast cells, possibly through a mechanism involving complement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/1,44,72-76\">",
"     1,44,72-76",
"    </a>",
"    ]. Assays are commercially available for detecting anti-Fc&epsilon;RI-alpha antibodies (eg, the Chronic Urticaria Index) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/77\">",
"     77",
"    </a>",
"    ], although the clinical utility of this test is not well established, as discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180552\">",
"    <span class=\"h4\">",
"     Evidence against a pathogenic role of autoantibodies to IgE or FcEpsilonRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the ASST, the autoantibodies described above are not specific to CU. Anti-Fc&epsilon;RI-alpha antibodies have been identified in healthy subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/78\">",
"     78",
"    </a>",
"    ] and in people with other autoimmune diseases, including pemphigus vulgaris, systemic lupus erythematosus, dermatomyositis, and pemphigoid, suggesting that they may represent an epiphenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/72,79-81\">",
"     72,79-81",
"    </a>",
"    ]. In addition, the levels of autoantibodies in CU do not appear to change with the clinical activity of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/82\">",
"     82",
"    </a>",
"    ], and the presence of these autoantibodies does not appear to predict more difficult to manage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Also problematic is the fact that commercial assays for anti-Fc&epsilon;RI-alpha antibodies are based upon basophil-activation tests, for which there are no widely accepted standards across laboratories. The technical difficulties of studying basophils are reviewed below. (See",
"    <a class=\"local\" href=\"#H1181729\">",
"     'Problems in basophil studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180430\">",
"    <span class=\"h2\">",
"     Theories involving other serum or plasma factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other factors in the serum or plasma have been implicated in the pathogenesis of CU because of an ability to activate mast cells or basophils, either directly or indirectly. No one factor has been shown to be essential for a positive ASST, and it remains unclear why serologic factors would activate only skin mast cells rather than causing more generalized mast cell and basophil activation leading to anaphylaxis, yet patients with CU are not at increased risk for anaphylaxis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study tested sera from patients with CU and normal controls for the ability to induce endothelial cell permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/83\">",
"       83",
"      </a>",
"      ]. Although neither group&rsquo;s sera alone induced endothelial cell permeability, the majority of CU sera caused mast cell degranulation when incubated with different mast cell lines, one of which lacked IgE receptors. Supernatants from activated mast cell cultures did increase endothelial cell permeability. This property persisted when the sera were depleted of IgG, and was unrelated to the ability of the sera to cause a positive ASST.",
"     </li>",
"     <li>",
"      Histamine releasing factors in the plasma have also been proposed. Some patients with chronic idiopathic urticaria demonstrate excessive or abnormal production of platelet-derived clotting factors, such as thrombin, possibly resulting from activation of the extrinsic pathway of the clotting cascade [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/84-86\">",
"       84-86",
"      </a>",
"      ]. In one study, the plasma of 28 patients with CU contained higher levels of the polypeptide F1+2, which is produced upon activation of prothrombin to thrombin, compared to control plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/84\">",
"       84",
"      </a>",
"      ]. The levels of this peptide correlated with the severity of the patients' urticaria. Thrombin, in turn, is capable of activating mast cells and basophils, and also increasing the permeability of blood vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/87-89\">",
"       87-89",
"      </a>",
"      ]. In addition, thrombin can stimulate the generation of C5a, which has been shown to enhance IgG-dependent mast cell histamine release in patients with CU [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/76\">",
"       76",
"      </a>",
"      ]. Other groups have also found abnormalities in the coagulation system that correlate with CU severity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/90\">",
"       90",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The identification of abnormalities in clotting factors lead to the autologous plasma skin test (APST), a variant of the ASST in which sodium citrate-anticoagulated plasma is injected intradermally [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/84\">",
"       84",
"      </a>",
"      ]. However, the APST does not appear to provide information that is different from that of the ASST [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/84,91-93\">",
"       84,91-93",
"      </a>",
"      ]. Of note, one study showed that if a control solution of 0.105",
"      <span class=\"nowrap\">",
"       mol/L",
"      </span>",
"      sodium citrate was included as a negative control, then there were no patients with positive APSTs who did not also have positive ASSTs [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/93\">",
"       93",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The finding that the extrinsic pathway of the clotting cascade is activated in CU is consistent with reports of successful treatment of CU with the anticoagulant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , in a small double-blind, placebo-controlled, crossover study of patients with CU refractory to antihistamines and a case report [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/94-96\">",
"       94-96",
"      </a>",
"      ]. Subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and the antifibrinolytic agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      were both reported to be effective in small numbers of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/97,98\">",
"       97,98",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=see_link&amp;anchor=H25#H25\">",
"       \"Chronic urticaria: Treatment of refractory symptoms\", section on 'Antifibrinolytics and anticoagulants'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cellular defects theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular defects theory generally proposes that patients with CU have defects in mast cell",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basophil trafficking, signaling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function. The following observations support this concept:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mast cell numbers are normal in the skin of patients with CU, although the cells release histamine more readily than cells from healthy controls in response to compounds that trigger nonimmunologic mast cell degranulation, such as",
"      <span class=\"nowrap\">",
"       48/80",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      sulfate [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/99,100\">",
"       99,100",
"      </a>",
"      ]. Functional studies of mast cells from patients with CU are difficult to perform because mast cells are tissue-based cells that are not easily collected or cultured.",
"     </li>",
"     <li>",
"      Peripheral blood basophil counts are low in patients with CU and even lower with more severe disease, a finding attributed to increased migration of basophils to the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/101-104\">",
"       101-104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several groups have identified functional differences in basophils from patients with CU. Histamine release was reduced following in vitro activation through Fc&epsilon;RI, although not with activation through other receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/100,105,106\">",
"       100,105,106",
"      </a>",
"      ], even though the cells contained normal amounts of histamine [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. Subsequently, two basophil phenotypes were identified in patients with CU: one type with an apparently normal response to Fc&epsilon;RI activation (\"responders\"), and another type of basophil that does not respond to IgE-mediated activation (\"nonresponders\") [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/107\">",
"       107",
"      </a>",
"      ]. These phenotypes are present in approximately equal numbers in patients with CU, unlike in normals, where \"nonresponders\" comprise only about 10 to 15 percent of the population. The nonresponder phenotype demonstrates elevated intracellular levels of regulatory proteins that normally inhibit signaling through Fc&epsilon;RI. Of note, normalization in basophil responsiveness has been demonstrated in patients with CU as their symptoms improve, unlike levels of autoantibodies or ASST status [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/82,106\">",
"       82,106",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1181729\">",
"    <span class=\"h3\">",
"     Problems in basophil studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basophils are notoriously difficult to study for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Different laboratories using different basophil donors will yield different results with the same tested serum.",
"     </li>",
"     <li>",
"      Basophils from individual donors can show variability in response to the same serum over time.",
"     </li>",
"     <li>",
"      There are no standardized procedures for handling basophils for use in serum testing, including uniform approaches to cell isolation, dilution of serum, or addition of a basophil priming cytokine (ie, IL-3) to the assay mix.",
"     </li>",
"     <li>",
"      Basophils are typically obtained for study from peripheral blood, although it has not been established that circulating basophils are fully representative of cutaneous basophils, and the two populations may have different characteristics in this disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sometimes, basophils from normal donors are used to test serum from CU patients, although histamine release may be due to several factors, such as activated complement, chemokines, or even IL-3 in the tested sample. Thus, the readout of the assay itself represents a complex cellular response that can be elicited through a variety of mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1519709\">",
"    <span class=\"h2\">",
"     Other theories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theories about infectious causes and food additives continue to draw periodic attention in the medical literature and lay news. However, the evidence for these theories remains anecdotal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Infectious agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to associate some common chronic infections with CU, including Helicobacter pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/109-112\">",
"     109-112",
"    </a>",
"    ], hepatitis A [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/113\">",
"     113",
"    </a>",
"    ], and hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/114\">",
"     114",
"    </a>",
"    ]. However, case reports and small series are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Foods and food additives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergies to foods or food additives are rarely identified as a cause of CU, although up to one-half of adult patients initially perceive a relationship between food and episodes of urticaria. In one study, only 10 percent of these individuals demonstrated signs or symptoms with placebo-controlled challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/116\">",
"     116",
"    </a>",
"    ]. IgE-mediated food allergy is far more likely to present with acute urticaria as part of generalized allergic reactions. Studies of food additives as an etiology of acute and CU are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link\">",
"     \"Allergic and asthmatic reactions to food additives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients&rsquo; suspicion about the role of foods and food additives is fueled by the fact that many will notice that dietary variations can cause temporary fluctuations in CU symptoms. In particular, rich meals, spicy or fermented foods, alcohol, and dramatic changes in diet will often worsen the condition temporarily. This may be related to the histamine content or innate histamine-releasing properties of these foods, as well as the vasodilatory effects of alcohol and certain spices. However, when CU is in remission, the same patients can eat these foods without symptoms. Dietary factors that can aggravate CU, and lists of foods that are potentially problematic are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link&amp;anchor=H7#H7\">",
"     \"Chronic urticaria: Standard management and patient education\", section on 'Dietary manipulations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1264349\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systemic disorders can present with urticaria-like lesions in the context of other signs and symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Urticarial vasculitis",
"      </strong>",
"      &mdash; Urticarial vasculitis should be considered when the hives are painful rather than pruritic, last longer than 48 hours, leave residual bruising or pigmentation changes, or recur whenever glucocorticoids are tapered (",
"      <a class=\"graphic graphic_picture graphicRef66203 \" href=\"UTD.htm?35/25/36240\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77924 \" href=\"UTD.htm?38/53/39760\">",
"       picture 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef54877 \" href=\"UTD.htm?9/45/9939\">",
"       picture 7",
"      </a>",
"      ). Patients with urticarial vasculitis may also report fever, chills, and arthralgias. Urticarial vasculitis may occur in isolation or in patients previously diagnosed with other systemic inflammatory diseases, such as Sj&ouml;gren's syndrome or systemic lupus erythematosus (SLE). Skin biopsy is indicated if signs or symptoms of vasculitis are present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"       \"Urticarial vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Systemic lupus erythematosus",
"      </strong>",
"      &mdash; Urticaria and urticarial vasculitis are among the many reported cutaneous manifestations of systemic lupus erythematosus (",
"      <a class=\"graphic graphic_picture graphicRef55903 \" href=\"UTD.htm?12/11/12467\">",
"       picture 8",
"      </a>",
"      ). Patients with lupus should have some of the other manifestations of this disease, such as fever, weight loss, arthritis, lymphadenopathy, or renal, pulmonary, or cardiac manifestations. This disorder is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cryoglobulinemia",
"      </strong>",
"      &mdash; Cryoglobulinemia causing cold-induced urticarial or vasculitic lesions can be seen in hepatitis B or C infection. Lesions are more prominent on the buttocks and lower extremities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link\">",
"       \"Cryopyrin-associated periodic syndromes and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Schnitzler's syndrome",
"      </strong>",
"      &mdash; Schnitzler's syndrome has been described in patients with a monoclonal IgM or IgG component (monoclonal gammopathy) who have associated fever, weight loss, bone pain, adenopathy, and urticaria, presumably due to circulating immune complexes and complement activation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link\">",
"       \"Cutaneous manifestations of internal malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link&amp;anchor=H7#H7\">",
"       \"Urticarial vasculitis\", section on 'Schnitzler's syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mastocytosis",
"      </strong>",
"      &mdash; Mastocytosis includes a variety of disorders that are characterized by the overproliferation and accumulation of tissue mast cells. The cutaneous form of this disorder may present with lesions of urticaria pigmentosa (",
"      <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"       picture 9",
"      </a>",
"      ). These are pigmented papules that demonstrate the distinctive Darier's sign, wheals that appear with mild trauma, such as gentle stroking. Biopsy of these lesions reveals a focal collection of mast cells and requires a thorough evaluation for systemic mastocytosis. However, CU should not be considered a reason to evaluate a patient for mastocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Polymorphic eruption of pregnancy",
"      </strong>",
"      &mdash; Polymorphic eruption of pregnancy (PEP, also called pruritic urticarial papules and plaques and papules of pregnancy or PUPPP) is a pruritic dermatitis affecting pregnant women, which typically presents as erythematous papules within abdominal striae with periumbilical sparing (",
"      <a class=\"graphic graphic_picture graphicRef56116 \" href=\"UTD.htm?36/25/37267\">",
"       picture 10",
"      </a>",
"      ). The lesions then spread to the extremities and coalesce to form urticarial plaques. The face, palms, and soles are usually spared. Lesions may also be target-like. PEP is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link\">",
"       \"Dermatoses of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypereosinophilic syndrome",
"      </strong>",
"      &mdash; Hypereosinophilic syndrome refers to a group of disorders characterized by persistent overproduction of eosinophils that infiltrate and damage tissues. Cutaneous symptoms can include recurrent urticaria, although angioedema or erythroderma are more characteristic. The diagnosis requires persistent unexplained blood eosinophilia of",
"      <span class=\"nowrap\">",
"       &ge;1500/microliter,",
"      </span>",
"      signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of eosinophil-mediated end-organ dysfunction, and no other apparent etiologies for eosinophilia, such as parasitic infection or allergic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cryopyrin-associated periodic syndromes",
"      </strong>",
"      &mdash; The cryopyrin-associated periodic syndromes (CAPS) include two syndromes that involve urticarial eruption: Familial cold autoinflammatory syndrome and the Muckle-Wells syndrome. These are rare genetic disorders that are discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=see_link\">",
"       \"Cryopyrin-associated periodic syndromes and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Familial cold autoinflammatory syndrome presents with periodic fever, urticaria, leukocytosis, conjunctivitis, and muscle and skin tenderness after exposure to cold. The onset of symptoms occurs during infancy in most cases.",
"     </li>",
"     <li>",
"      The Muckle-Wells syndrome involves periodic urticarial eruptions and is associated with mutations in cryopyrin. It has a similar phenotype to familial cold autoinflammatory syndrome except that patients are not cold sensitive, experience sensorineural hearing loss and arthritis, and can progress to amyloidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CU is an episodic and self-limited disorder in most patients. The average duration of disease is two to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/6,117\">",
"     6,117",
"    </a>",
"    ]. In patients in whom no trigger or underlying disorder is identified, there is a rate of spontaneous remission at one year of approximately 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/4,118\">",
"     4,118",
"    </a>",
"    ]. Remission rates in children may be somewhat higher [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/119\">",
"     119",
"    </a>",
"    ]. However, symptoms persist beyond five years in up to 30 percent of patients and disease duration in this subgroup is not as well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/11,120,121\">",
"     11,120,121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a representative prospective study, 139 patients with CU of all severities were followed over a period of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/120\">",
"     120",
"    </a>",
"    ]. Disease severity, the presence of angioedema, and various laboratory parameters were assessed in relation to disease duration. CU persisted beyond one and five years in 70 and 14 percent of patients, respectively. A longer duration of symptoms was associated with more severe disease, the presence of angioedema, and thyroid autoimmunity. This study also found that a positive ASST was associated with longer-lasting disease, although other studies did not find this correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have also found that more severe disease tends to last longer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/117,119\">",
"     117,119",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective analysis of 117 patients with CU who were not controlled on a standard dose of oral antihistamine, the remission rates (ie, no urticaria for one month in the absence of any medication) were 12 and 28 percent at one and five years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 228 patients with moderate to severe CU, a correlation was observed between the presence of systemic hypertension and more persistent symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?29/19/30010/abstract/117\">",
"       117",
"      </a>",
"      ]. Among hypertensive patients, resolution was seen in 19 and 26 percent at two and five years, respectively, compared with 37 and 46 percent in normotensive patients. The type of antihypertensive medication administered did not appear to impact duration of urticaria. The association with hypertension warrants further study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18706?source=see_link\">",
"       \"Patient information: Chronic hives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic urticaria (CU) is defined by the presence of urticaria (hives), on most days of the week, for a period of six weeks or longer. Forty percent of patients also experience angioedema. Up to 1 percent of the adult population develops CU at some point in their lives. Adults are affected more often than children, and women are affected more often than men. (See",
"      <a class=\"local\" href=\"#H1183511\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made clinically, based upon the episodic appearance of characteristic urticarial lesions, with or without angioedema, on most days of the week, for a period of six weeks or longer. No specific cause can be identified in 80 to 90 percent of adults and children with CU. A complete blood count with differential, a CRP or ESR, and a TSH level are suggested at diagnosis, although these laboratories are normal in most patients who lack signs and symptoms of systemic disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin biopsy is not needed for routine diagnosis of CU, although it is indicated to exclude urticarial vasculitis if there are signs or symptoms consistent with a vasculitic process, or in the rare patients with features of mastocytosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Skin biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests used in investigations of pathogenesis include the autologous serum and plasma skin tests, assays for autoantibodies directed against IgE or Fc&epsilon;RI, and in vitro assessments of basophil function. However, these tests lack specificity and prognostic value, are not standardized across laboratories, and cannot be recommended for routine clinical use. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Theories of pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several theories regarding the pathogenesis of chronic idiopathic urticaria have been proposed, although the data for each are incomplete and none appears to be helpful for determining treatment or prognosis. The best developed hypotheses involve histamine releasing factors and defects in basophil signaling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      function. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Theories of pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CU is a self-limited disease in the vast majority of patients. Spontaneous remission occurs in 30 to 50 percent of patients by one year, and the average duration of disease is two to five years. Up to 20 percent of patients still have symptoms persisting beyond five years. Those with more severe symptoms tend to have longer lasting disease. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Natural history and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/1\">",
"      Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/2\">",
"      Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol 2005; 5:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/3\">",
"      Harris A, Twarog FJ, Geha RS. Chronic urticaria in childhood: natural course and etiology. Ann Allergy 1983; 51:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/4\">",
"      Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/5\">",
"      Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/6\">",
"      Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/7\">",
"      Gaig P, Olona M, Mu&ntilde;oz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004; 14:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/8\">",
"      Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012; 129:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/9\">",
"      Najib U, Bajwa ZH, Ostro MG, Sheikh J. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2009; 103:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/10\">",
"      Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergol&oacute;gica 2005. J Investig Allergol Clin Immunol 2009; 19 Suppl 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/11\">",
"      Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969; 81:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/12\">",
"      Hellgren L. The prevalence of urticaria in the total population. Acta Allergol 1972; 27:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/13\">",
"      Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981; 104:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/14\">",
"      Buss YA, Garrelfs UC, Sticherling M. Chronic urticaria--which clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patients. J Dtsch Dermatol Ges 2007; 5:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/15\">",
"      Kozel MM, Bossuyt PM, Mekkes JR, Bos JD. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol 2003; 48:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/16\">",
"      Hunkin V, Chung MC. Chronic idiopathic urticaria, psychological co-morbidity and posttraumatic stress: the impact of alexithymia and repression. Psychiatr Q 2012; 83:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/17\">",
"      Staubach P, Dechene M, Metz M, et al. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol 2011; 91:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/18\">",
"      Chung MC, Symons C, Gilliam J, Kaminski ER. The relationship between posttraumatic stress disorder, psychiatric comorbidity, and personality traits among patients with chronic idiopathic urticaria. Compr Psychiatry 2010; 51:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/19\">",
"      Malhotra SK, Mehta V. Role of stressful life events in induction or exacerbation of psoriasis and chronic urticaria. Indian J Dermatol Venereol Leprol 2008; 74:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/20\">",
"      Kimyai-Asadi A, Usman A. The role of psychological stress in skin disease. J Cutan Med Surg 2001; 5:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/21\">",
"      Ozkan M, Oflaz SB, Kocaman N, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007; 99:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/22\">",
"      Chung MC, Symons C, Gilliam J, Kaminski ER. Stress, psychiatric co-morbidity and coping in patients with chronic idiopathic urticaria. Psychol Health 2010; 25:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/23\">",
"      Herg&uuml;ner S, Kili&ccedil; G, Karako&ccedil; S, et al. Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria. Br J Dermatol 2011; 164:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/24\">",
"      Ben-Shoshan M, Blinderman I, Raz A. Psychosocial factors and chronic spontaneous urticaria: a systematic review. Allergy 2013; 68:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/25\">",
"      Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/26\">",
"      Dreskin SC, Andrews KY. The thyroid and urticaria. Curr Opin Allergy Clin Immunol 2005; 5:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/27\">",
"      Caffarelli C, Cuomo B, Cardinale F, et al. Aetiological Factors Associated with Chronic Urticaria in Children: A Systematic Review. Acta Derm Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/28\">",
"      Leznoff A, Josse RG, Denburg J, Dolovich J. Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 1983; 119:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/29\">",
"      Kaplan AP, Finn A. Autoimmunity and the etiology of chronic urticaria. Can J Allergy Clin Immunol 1999; 4:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/30\">",
"      Kikuchi Y, Fann T, Kaplan AP. Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol 2003; 112:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/31\">",
"      Zhang Y, Morita E, Matsuo H, et al. Urticarial erythema associated with IgA myeloma. J Dermatol 2004; 31:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/32\">",
"      Calvo-Romero JM. Diffuse large B cell lymphoma in a patient with hypocomplementemic urticarial vasculitis. J Postgrad Med 2003; 49:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/33\">",
"      Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/34\">",
"      Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2000; 85:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/35\">",
"      Tedeschi A, Girolomoni G, Asero R, AAITO Committee for Chronic Urticaria and Pruritus Guidelines. AAITO Position paper. Chronic urticaria: diagnostic workup and treatment. Eur Ann Allergy Clin Immunol 2007; 39:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/36\">",
"      Lindel&ouml;f B, Sigurgeirsson B, Wahlgren CF, Eklund G. Chronic urticaria and cancer: an epidemiological study of 1155 patients. Br J Dermatol 1990; 123:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/37\">",
"      Chen YJ, Wu CY, Shen JL, et al. Cancer risk in patients with chronic urticaria: a population-based cohort study. Arch Dermatol 2012; 148:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/38\">",
"      Charlesworth EN. The spectrum of urticaria: All that urticates may not be urticaria. Immunol Allergy Clin North Am 1995; 15:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/39\">",
"      Beltrani VS. Urticaria and angioedema. Dermatol Clin 1996; 14:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/40\">",
"      Charlesworth EN. Urticaria and angioedema: a clinical spectrum. Ann Allergy Asthma Immunol 1996; 76:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/41\">",
"      Beltrani VS. Urticaria: reassessed. Allergy Asthma Proc 2004; 25:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/42\">",
"      deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/43\">",
"      Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 89:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/44\">",
"      Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/45\">",
"      Laman SD, Provost TT. Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 1994; 20:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/46\">",
"      Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/47\">",
"      Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998; 134:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/48\">",
"      Jacobson KW, Branch LB, Nelson HS. Laboratory tests in chronic urticaria. JAMA 1980; 243:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/49\">",
"      Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/50\">",
"      Jirapongsananuruk O, Pongpreuksa S, Sangacharoenkit P, et al. Identification of the etiologies of chronic urticaria in children: a prospective study of 94 patients. Pediatr Allergy Immunol 2010; 21:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/51\">",
"      Zuberbier T. Urticaria. Allergy 2003; 58:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/52\">",
"      Llamas-Velasco M, Fraga J, Requena L, et al. [Neutrophilic urticaria or urticaria with predominantly neutrophilic inflammatory infiltrate: study of its clinical and histopathologic characteristics and its possible association with rheumatic disease]. Actas Dermosifiliogr 2012; 103:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/53\">",
"      Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol 2008; 20:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/54\">",
"      Konstantinou GN, Asero R, Ferrer M, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013; 68:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/55\">",
"      Grattan CE, Wallington TB, Warin RP, et al. A serological mediator in chronic idiopathic urticaria--a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/56\">",
"      Grattan CE, Hamon CG, Cowan MA, Leeming RJ. Preliminary identification of a low molecular weight serological mediator in chronic idiopathic urticaria. Br J Dermatol 1988; 119:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/57\">",
"      Sabroe RA, Grattan CE, Francis DM, et al. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/58\">",
"      Mari A. Allergy-like asthma and rhinitis. A cross-sectional survey of a respiratory cohort and a diagnostic approach using the autologous serum skin test. Int Arch Allergy Immunol 2004; 133:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/59\">",
"      Guttman-Yassky E, Bergman R, Maor C, et al. The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals. J Eur Acad Dermatol Venereol 2007; 21:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/60\">",
"      Taskapan O, Kutlu A, Karabudak O. Evaluation of autologous serum skin test results in patients with chronic idiopathic urticaria, allergic/non-allergic asthma or rhinitis and healthy people. Clin Exp Dermatol 2008; 33:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/61\">",
"      Fagiolo U, Kricek F, Ruf C, et al. Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 2000; 106:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/62\">",
"      Fusari A, Colangelo C, Bonifazi F, Antonicelli L. The autologous serum skin test in the follow-up of patients with chronic urticaria. Allergy 2005; 60:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/63\">",
"      Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/64\">",
"      Lapolla W, Desai N, English JC 3rd. Clinical utility of testing for autoimmunity in chronic idiopathic urticaria. J Am Acad Dermatol 2012; 66:e83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/65\">",
"      Gruber BL, Baeza ML, Marchese MJ, et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/66\">",
"      Sabroe RA, Greaves MW. Chronic idiopathic urticaria with functional autoantibodies: 12 years on. Br J Dermatol 2006; 154:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/67\">",
"      Tong LJ, Balakrishnan G, Kochan JP, et al. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/68\">",
"      Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/69\">",
"      Niimi N, Francis DM, Kermani F, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996; 106:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/70\">",
"      Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/71\">",
"      Brunetti L, Francavilla R, Miniello VL, et al. High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol 2004; 114:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/72\">",
"      Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998; 101:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/73\">",
"      Soundararajan S, Kikuchi Y, Joseph K, Kaplan AP. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 2005; 115:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/74\">",
"      Zweiman B, Valenzano M, Atkins PC, et al. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 1996; 98:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/75\">",
"      Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001; 107:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/76\">",
"      Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109:114.",
"     </a>",
"    </li>",
"    <li>",
"     The CU index test is available commercially. www.viracoribt.com (Accessed on April 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/78\">",
"      Eckman JA, Hamilton RG, Saini SS. Independent evaluation of a commercial test for \"autoimmune\" urticaria in normal and chronic urticaria subjects. J Invest Dermatol 2009; 129:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/79\">",
"      Horn MP, Pachlopnik JM, Vogel M, et al. Conditional autoimmunity mediated by human natural anti-Fc(epsilon)RIalpha autoantibodies? FASEB J 2001; 15:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/80\">",
"      Vasagar K, Vonakis BM, Gober LM, et al. Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 2006; 36:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/81\">",
"      Cho CB, Stutes SA, Altrich ML, et al. Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders. Ann Allergy Asthma Immunol 2013; 110:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/82\">",
"      Eckman JA, Hamilton RG, Gober LM, et al. Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008; 128:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/83\">",
"      Bossi F, Frossi B, Radillo O, et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy 2011; 66:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/84\">",
"      Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/85\">",
"      Asero R, Tedeschi A, Coppola R, et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007; 119:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/86\">",
"      Takahagi S, Mihara S, Iwamoto K, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010; 65:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/87\">",
"      Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984; 133:3282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/88\">",
"      Vliagoftis H. Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1. J Immunol 2002; 169:4551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/89\">",
"      Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/90\">",
"      Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011; 66:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/91\">",
"      Sajedi V, Movahedi M, Aghamohammadi A, et al. Comparison between sensitivity of autologous skin serum test and autologous plasma skin test in patients with Chronic Idiopathic Urticaria for detection of antibody against IgE or IgE receptor (Fc&epsilon;RI&alpha;). Iran J Allergy Asthma Immunol 2011; 10:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/92\">",
"      Kocat&uuml;rk E, Kavala M, Kural E, et al. Autologous serum skin test vs autologous plasma skin test in patients with chronic urticaria: evaluation of reproducibility, sensitivity and specificity and relationship with disease activity, quality of life and anti-thyroid antibodies. Eur J Dermatol 2011; 21:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/93\">",
"      Y��ld��z H, Karabudak O, Do��an B, Harmanyeri Y. Evaluation of autologous plasma skin test in patients with chronic idiopathic urticaria. Br J Dermatol 2011; 165:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/94\">",
"      Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/95\">",
"      Mahesh PA, Pudupakkam VK, Holla AD, Dande T. Effect of warfarin on chronic idiopathic urticaria. Indian J Dermatol Venereol Leprol 2009; 75:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/96\">",
"      Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2010; 5:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/97\">",
"      Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005; 153:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/98\">",
"      Asero R, Tedeschi A, Cugno M. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010; 152:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/99\">",
"      Jacques P, Lavoie A, B&eacute;dard PM, et al. Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission. J Allergy Clin Immunol 1992; 89:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/100\">",
"      Cohen RW, Rosenstreich DL. Discrimination between urticaria-prone and other allergic patients by intradermal skin testing with codeine. J Allergy Clin Immunol 1986; 77:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/101\">",
"      Grattan CE, Walpole D, Francis DM, et al. Flow cytometric analysis of basophil numbers in chronic urticaria: basopenia is related to serum histamine releasing activity. Clin Exp Allergy 1997; 27:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/102\">",
"      Grattan CE, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003; 33:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/103\">",
"      Caproni M, Giomi B, Volpi W, et al. Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005; 114:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/104\">",
"      Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/105\">",
"      Greaves MW, Plummer VM, McLaughlan P, Stanworth DR. Serum and cell bound IgE in chronic urticaria. Clin Allergy 1974; 4:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/106\">",
"      Kern F, Lichtenstein LM. Defective histamine release in chronic urticaria. J Clin Invest 1976; 57:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/107\">",
"      Vonakis BM, Vasagar K, Gibbons SP Jr, et al. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 2007; 119:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/108\">",
"      Sabroe RA, Francis DM, Barr RM, et al. Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 1998; 102:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/109\">",
"      Liutu M, Kalimo K, Uksila J, Kalimo H. Etiologic aspects of chronic urticaria. Int J Dermatol 1998; 37:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/110\">",
"      Di Campli C, Gasbarrini A, Nucera E, et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998; 43:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/111\">",
"      Ba��kan EB, T&uuml;rker T, G&uuml;lten M, Tunali S. Lack of correlation between Helicobacter pylori infection and autologous serum skin test in chronic idiopathic urticaria. Int J Dermatol 2005; 44:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/112\">",
"      Schnyder B, Helbling A, Pichler WJ. Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. Int Arch Allergy Immunol 1999; 119:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/113\">",
"      Wedi B, Raap U, Kapp A. Chronic urticaria and infections. Curr Opin Allergy Clin Immunol 2004; 4:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/114\">",
"      Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995; 70:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/115\">",
"      Shakouri A, Compalati E, Lang DM, Khan DA. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol 2010; 10:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/116\">",
"      Kobza Black A, Greaves MW, Champion RH, Pye RJ. The urticarias 1990. Br J Dermatol 1991; 124:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/117\">",
"      Nebiolo F, Bergia R, Bommarito L, et al. Effect of arterial hypertension on chronic urticaria duration. Ann Allergy Asthma Immunol 2009; 103:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/118\">",
"      Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001; 45:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/119\">",
"      Hiragun M, Hiragun T, Mihara S, et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy 2013; 68:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/120\">",
"      Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004; 59:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/19/30010/abstract/121\">",
"      van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol 2002; 146:110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8108 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30010=[""].join("\n");
var outline_f29_19_30010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1263694\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1183511\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1263753\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94602611\">",
"      Aggravating factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94601710\">",
"      ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94601717\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H557583\">",
"      - Thyroid disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94601739\">",
"      Unclear association with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1519355\">",
"      - Investigational tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Biopsy findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      THEORIES OF PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Autoimmune theory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10997853\">",
"      - The autologous serum skin test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1519631\">",
"      Problems with the ASST",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1180552\">",
"      Evidence against a pathogenic role of autoantibodies to IgE or FcEpsilonRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1180430\">",
"      Theories involving other serum or plasma factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cellular defects theory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1181729\">",
"      - Problems in basophil studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1519709\">",
"      Other theories",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Infectious agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Foods and food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1264349\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NATURAL HISTORY AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8108|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/2/29728\" title=\"picture 1\">",
"      Urticaria 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/55/24433\" title=\"picture 2\">",
"      Urticaria 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/2/11311\" title=\"picture 3\">",
"      Giant urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/12/22720\" title=\"picture 4\">",
"      Urticaria 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/25/36240\" title=\"picture 5\">",
"      UV lesions I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/53/39760\" title=\"picture 6\">",
"      UV lesions II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/45/9939\" title=\"picture 7\">",
"      UV lesions III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/11/12467\" title=\"picture 8\">",
"      Subacute cutaneous lupus - annular plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/49/41746\" title=\"picture 9\">",
"      Urticaria pigmentosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/25/37267\" title=\"picture 10\">",
"      PUPPP abd thighs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37465?source=related_link\">",
"      ACE inhibitor-induced angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=related_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30554?source=related_link\">",
"      Chronic urticaria: Treatment of refractory symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=related_link\">",
"      Cold urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=related_link\">",
"      Mast cells: Development, identification, and physiologic roles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=related_link\">",
"      Pathogenesis of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27833?source=related_link\">",
"      Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18706?source=related_link\">",
"      Patient information: Chronic hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=related_link\">",
"      Physical urticarias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=related_link\">",
"      Urticarial vasculitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_19_30011="Outcome of IVF by maternal age";
var content_f29_19_30011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcomes from in vitro fertilization using fresh embryos from non-donor oocytes (2009)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        &lt;35",
"       </td>",
"       <td class=\"subtitle1\">",
"        35-37",
"       </td>",
"       <td class=\"subtitle1\">",
"        38-40",
"       </td>",
"       <td class=\"subtitle1\">",
"        41-42",
"       </td>",
"       <td class=\"subtitle1\">",
"        43-44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of cycles",
"       </td>",
"       <td>",
"        56,843",
"       </td>",
"       <td>",
"        29,822",
"       </td>",
"       <td>",
"        29,907",
"       </td>",
"       <td>",
"        14,261",
"       </td>",
"       <td>",
"        8745",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percentage of cycles resulting in pregnancies",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percentage of cycles resulting in live births",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention (CDC). Society for Assisted Reproductive Technology, American Society for Reproductive Medicine. Assisted reproductive technology success rates. National summary and fertility clinic reports for 2009.&nbsp;",
"     <a href=\"file://www.cdc.gov/art/ART2009/\">",
"      file://www.cdc.gov/art/ART2009/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30011=[""].join("\n");
var outline_f29_19_30011=null;
var title_f29_19_30012="Hib conjugate vaccines US";
var content_f29_19_30012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of conjugate vaccines against",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b licensed in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"        <br/>",
"        (commercial name)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Carrier protein",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended age of administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Monovalent Hib vaccines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PRP-OMP*",
"        <br/>",
"        (PedVaxHIB)",
"       </td>",
"       <td>",
"        Outer membrane protein complex of",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"       </td>",
"       <td>",
"        2, 4, and 12 through 15 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PRP-T",
"        <br/>",
"        (ActHIB)",
"       </td>",
"       <td>",
"        Tetanus toxoid",
"       </td>",
"       <td>",
"        2, 4, 6, and 12 through 15 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PRP-T",
"        <br/>",
"        (Hiberix)",
"       </td>",
"       <td>",
"        Tetanus toxoid",
"       </td>",
"       <td>",
"        12 through 15 months (following primary series with PRP-OMP or ActHIB)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Combination Hib vaccines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PRP-OMP-Hepatitis B*",
"        <br/>",
"        (Comvax)",
"       </td>",
"       <td>",
"        Outer membrane protein complex of",
"        <em>",
"         N. meningitidis",
"        </em>",
"       </td>",
"       <td>",
"        2, 4, and 12 through 15 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DTaP-IPV/PRP-T",
"        <br/>",
"        (Pentacel)",
"       </td>",
"       <td>",
"        Tetanus toxoid",
"       </td>",
"       <td>",
"        2, 4, 6, and 15 through 18 months",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HibMenCY",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <br/>",
"        (Menhibrix)",
"       </td>",
"       <td>",
"        Tetanus toxoid",
"       </td>",
"       <td>",
"        2, 4, 6, and 12 through 15 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PRP-OMP: polyribosylribitol phosphate conjugated to outer membrane protein complex of",
"     <em>",
"      N. meningitidis",
"     </em>",
"     ; PRP-T: polyribosylribitol phosphate conjugated to tetanus toxoid; DTaP: diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine; IPV: inactivated polio vaccine; HibMenCY: combination",
"     <em>",
"      Haemophilus influenzae",
"     </em>",
"     type b and meningococcus serogroups C and Y conjugate vaccine.",
"     <br/>",
"     * Preferred for Native Americans and Alaskan natives.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     May be given as early as age 12 months of age, provided at least 6 months have elapsed since the third dose of DTaP.",
"     <br/>",
"     &Delta; Recommended for use in infants at increased risk for meningococcal disease (ie, those with persistent complement pathway deficiencies or anatomic or functional asplenia [including sickle cell disease]).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30012=[""].join("\n");
var outline_f29_19_30012=null;
var title_f29_19_30013="Cryos in chronic liver disease";
var content_f29_19_30013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Incidence of cryoglobulins in chronic liver disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 275px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of circulating cryoglobulins in 136 healthy controls and in 226 patients with chronic liver disease due to hepatitis C, hepatitis B, or other liver diseases (such as autoimmune hepatitis and primary biliary cirrhosis). Cryoglobulins were unusual in controls and most common in patients with hepatitis C virus infection, being detected in 54 percent of cases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lunel F, Musset L, Cacoub P, et al. Gastroenterology 1994; 106:1291.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30013=[""].join("\n");
var outline_f29_19_30013=null;
var title_f29_19_30014="Paclitaxel-cisplatin-paclitaxel for epithelial ovarian cancer";
var content_f29_19_30014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy regimens for epithelial ovarian cancer: Intravenous (IV) paclitaxel followed by intraperitoneal (IP) cisplatin and IP paclitaxel",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        <p>",
"         Cycle length: 21 days.",
"        </p>",
"        Total cycles: 6.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paclitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        135 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 mL normal saline (NS) or 5 percent dextrose in water (D5W) and administer over 24 hours*.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IP",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Dilute in 1 L of NS and infuse through the implantable peritoneal catheter via gravity drip as rapidly as possible. A second liter of saline is then administered IP as tolerated.",
"       </td>",
"       <td>",
"        Day 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paclitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IP",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Dilute in 1 L of NS and infuse IP via gravity drip as rapidly as possible. A second liter of saline is then administered IP as tolerated.",
"       </td>",
"       <td>",
"        Day 8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        The addition of 2 L of IP NS does not replace the need for adequate IV hydration before and after cisplatin, and the maintenance of excellent urine output. On day 2, IV prehydration with at least one liter of NS and a urine output of at least 100 mL/hour should be achieved before the administration of IP cisplatin to reduce the potential risk for nephrotoxicity",
"        <sup>",
"         [2]",
"        </sup>",
"        . Following the drug infusion, a second liter of IV NS should be given, and two hours of urine output of at least 100 mL/hour should be observed before sending the patient home. Some clinicians would add 12.5 g/L of mannitol in the pre and post hydration to enhance urinary output. Supplementation with magnesium and potassium may be required depending upon the serum electrolytes. A dose of furosemide may be required if urine output is insufficient. Refer to UpToDate topic on \"Management of intraperitoneal chemotherapy for treatment of ovarian cancer\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (greater than 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Paclitaxel may cause severe hypersensitivity reactions. Premedication regimen should include dexamethasone (either 20 mg orally twelve and six hours before, or 20 mg IV 30 minutes before drug administration) plus both an H1 (diphenhydramine 25 to 50 mg IV) and an H2 receptor antagonist (ranitidine 50 mg or famotidine 20 mg IV) 30 to 60 minutes prior to paclitaxel administration. Severe infusion reactions (eg, skin rash, flushing, dyspnea, urticaria, back pain, hypotension, chest pain, tachycardia) occur primarily during the first and second infusions, typically within the first hour after the start of the infusion. Routine prophylaxis is generally not indicated prior to cisplatin treatment",
"        <sup>",
"         [3]",
"        </sup>",
"        . Management of infusion reactions and issues related to rechallenge are discussed separately. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        IV paclitaxel can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Not applicable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Patients with abnormal renal function were excluded from the phase III clinical trial demonstrating the efficacy of this regimen",
"        <sup>",
"         [1]",
"        </sup>",
"        . Dose modifications are not required for paclitaxel in renal insufficiency, but the dose should be adjusted for preexisting hepatic impairment",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes, renal, and liver function each cycle during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Each cycle should not begin until the WBC count is greater than 1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , platelets are greater than 100,000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , and creatinine clearance is greater than 50 mL/min",
"        <sup>",
"         [1]",
"        </sup>",
"        . In the original trial, treatment modifications for hematologic toxic effects included cycle delay, dose reduction, and use of granulocyte colony-stimulating factor (in that sequence). Dose modification was not performed if the WBC nadir was not accompanied by fever. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        Both paclitaxel and cisplatin can cause neurotoxicity. In the original study, treatment was delayed in the case of grade 3 or 4 peripheral neuropathy until grade 1",
"        <sup>",
"         [1]",
"        </sup>",
"        . For severe neuropathy (grade 3 or 4) that persists for a week or longer, reduce the dose of paclitaxel by 20 percent for subsequent courses and substitute intravenous carboplatin for cisplatin",
"        <sup>",
"         [3]",
"        </sup>",
"        . Patients with mild neuropathy can continue to receive full cisplatin doses. If the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for renal dysfunction:",
"        </strong>",
"        Avoidance of cisplatin-related nephrotoxicity requires close attention to volume status and adequate antiemetic control. If renal insufficiency develops, treatment should be withheld until renal function improves. In the original trial, treatment was postponed for a creatinine level greater than 2.0 mg per deciliter or a creatinine clearance of less than 50 mL per minute",
"        <sup>",
"         [1]",
"        </sup>",
"        . Subsequent treatment was resumed only when it rose above 50 mL/min. Tolerability of the regimen may be improved by reducing the IP cisplatin dose to 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . Refer to UpToDate topic on \"Management of intraperitoneal chemotherapy for treatment of ovarian cancer\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Abdominal pain:",
"        </strong>",
"        Abdominal pain, which may be worse with IP paclitaxel than after cisplatin, is frequent. Peritonitis or gastrointestinal (GI) tract injury should be considered if there is guarding, rebound, nausea, vomiting, diarrhea, fever, or unexplained leucocytosis. If pain is encountered and there are no signs or symptoms to suggest peritonitis or GI tract injury, the second liter of NS can be reduced in volume or rate of flow, or withheld. In the original trial, the dose of IP chemotherapy was reduced for CTC grade 3 abdominal pain, recurrent CTC grade 2 abdominal pain, or complications involving the intraperitoneal catheter",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of IP chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; WBC: white blood cell; CTC: Common Toxicity Criteria.",
"     <br/>",
"     * Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less (both IV and IP administration).",
"     <br/>",
"     &Delta; Patients administered either paclitaxel or cisplatin by the intraperitoneal route should receive the same supportive care drugs as are indicated with intravenous administration of these agents.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Armstrong DK, et al. N Engl J Med 2006; 354:34.",
"      </li>",
"      <li>",
"       Platinol (cisplatin) injection, powder, lyophilized, for solution. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 8, 2011).",
"      </li>",
"      <li>",
"       Taxol (paclitaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online atdailymed.nlm.nih.gov, accessed on December 8, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30014=[""].join("\n");
var outline_f29_19_30014=null;
var title_f29_19_30015="Lateral RV angiogram tetralogy";
var content_f29_19_30015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right ventricular angiogram in tetralogy of Fallot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral projection of a right ventricular (RV) angiogram in tetralogy of Fallot shows an hypertrophied infundibulum (INF) with anterior and cephalad deviation of the septum, resulting in significant subpulmonary obstruction; the pulmonary valve annulus (*) is much larger than the subvalvar area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_19_30015=[""].join("\n");
var outline_f29_19_30015=null;
